(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number
WO 03/037931 A2

(51) International Patent Classification[7]: C07K 14/705

(21) International Application Number: PCT/US02/35129

(22) International Filing Date:
1 November 2002 (01.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/334,773 1 November 2001 (01.11.2001) US

(71) Applicant *(for all designated States except US)*: **AMERSHAM BIOSCIENCES (SV) CORP** [US/US]; 928 East Arques Avenue, Sunnyvale, CA 94085 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SHANNON, Mark** [US/US]; 3131-1 Arcadia Common, Livermore, CA 94550 (US). **PHAN, Thuymy** [VN/US]; 2512 Zachary Way, San Jose, CA 95121 (US).

(74) Agent: **RYAN, Stephen, G.**; Amersham Biosciences Corp, 800 Centennial Avenue, Piscataway, NJ 08855 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/037931 A2

(54) Title: HUMAN ANGIOMOTIN-LIKE PROTEIN 1

(57) Abstract: The invention provides isolated nucleic acids that encode human angiomotin-like protein (AMPL1), including two isoforms, and fragments thereof, vectors for propagating and expressing AMLP1 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel AMLP1 isoforms, and antibodies thereto. The innvention further provides transgenic cells and non-human organisms comprising AMLP2 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the AMLP1 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the AMLP1 nucleic acids, proteins, and antibodies of the present invention.

HUMAN ANGIOMOTIN-LIKE PROTEIN 1

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 120 to United States provisional application serial no. 60/334,773, filed November 1, 2001; the disclosure of which is incorporated herein by reference in its entireties.

REFERENCE TO SEQUENCE LISTING SUBMITTED ON COMPACT DISC

The present application includes a Sequence Listing filed on a single CD-R disc, provided in duplicate, containing a single file named pto_PB0184.txt, having 189 kilobytes, last modified on October 9, 2002 and recorded October 17, 2002. The Sequence Listing contained in said file on said disc is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to novel human angiomotin-like protein 1 (AMLP1), including two isoforms. More specifically, the invention provides isolated nucleic acid molecules of AMLP1, fragments thereof, vectors and host cells comprising isolated nucleic acid molecules encoding AMLP1, AMLP1 polypeptides, antibodies, transgenic cells and non-human organisms, and diagnostic, therapeutic, and investigational methods of using the same.

BACKGROUND OF THE INVENTION

The cytoskeleton plays a number of crucial roles in the life of a cell, from determining its shape

and polarity to directing its movements in response to external stimuli. The capacity for movement is a characteristic of virtually all animal cells and is pivotal for a variety of cellular activities such as T-cell mediated immune responses, developmental patterning during embryogenesis and tissue renewal processes as typified by wound healing. The cytoskeleton also participates in other vital cellular activities that include exocytosis, endocytosis, and membrane-bound vesicle trafficking within the cytoplasm. Evidence is emerging to suggest that the cytoskeleton may also play an important role as a platform or scaffold for assembling components of cellular signaling and response pathways.

Of these functions, the capacity of a cell to respond to external signals via movement is the one role with greatest potential impact on human cancer, as uncontrolled migration of cells is a hallmark of tumor invasiveness and is a precursor to tumor metastasis. For this reason, considerable effort has been given to identifying the components of the cell's signaling and response pathways that lead to changes in the actin cytoskeleton. Some of the components of these pathways that have been shown to be important for signaling changes in the actin cytoskeleton include members of the Rho family of small GTPases and their activators, inhibitors, and downstream targets.

Members of the Rho family of small GTPases (including Rho, Rac, and Cdc42) play central roles in the transduction of extracellular signals from the cell membrane to downstream effector molecules in the cytoplasm and nucleus and are highly conserved among eukaryotes. Reviewed by Takai Y. *et al, Physiol. Rev.* 18:153-208 (2001); Hall A., *Science* 279:509-514 (1998). This class of signaling molecules primarily affects

activities associated with the actin cytoskeleton, but can also influence gene expression.

Small GTPases of the Rho family exist in two states: an active GTP-bound form that is preferentially associated with membrane-bound structures and an inactive GDP-bound form that is largely found in the cytoplasm. Reviewed by Bishop A.L. and Hall A., *Biochem. J.* 348:241-255 (2000). The active form of Rho is capable of interacting with a diverse set of effector molecules that includes protein kinases and adaptor molecules that specifically result in changes in the actin cytoskeleton and/or activate kinase cascades that lead to changes in gene expression. Hydrolysis of GTP by members of the Rho family of GTPases converts the proteins into inactive molecules that no longer bind to their target effector proteins.

Although all members of the Rho family of GTPases exert effects on the actin cytoskeleton, the outcomes of activation of individual family members are variable. For instance, Rho activation results primarily in the formation of stress fibers and has been implicated in the processes of cell adhesion, determination of cell polarity, and cell migration in epithelia. Assoian R.K. and Zhu X., *Curr. Opin. Cell Biol.* 9:93 (1997); Braga V.M.M. *et al, J. Cell Biol.* 137:1421 (1997); Schmitz A.A. *et al., Exp. Cell Res.* 261:1-12 (2000). By contrast, Rac activation leads to the formation of lamellipodia or membrane ruffles (Ridley *et al., Cell* 70:401-410 (1992)) and appears to be associated with directed cell migration and axonal guidance (Van Aelst and D'Souza-Schorey, Genes Dev. 11:2295-2322 (1997)). It is therefore not surprising that overexpression of Rho family members has been associated with cell transformation and tumors in human patients (Ridley A.J. *Int. J. Biochem. Cell Biol.* 29:1225-12259 (1997); Aznar S. and Lacal. J.C., *Cancer*

Lett. 165:1-10 (2001)) and are likely to have an impact on tumor invasiveness and metastasis.

Proteins that interact directly with the actin cytoskeleton are likely to play important roles in signaling pathways upstream of small GTPases as well as in their downstream response pathways. Therefore it is of great value to identify cytoskeleton-associated proteins. Angiomotin is a recently identified protein that is expressed at high levels in endothelial cells of blood vessels and co-localizes with actin filaments at the leading edges of migrating cells (Troyanovsky *et al.*, *J. Cell Biol.* 152:1247-1254, (2001)). In addition, it has been found that angiomotin can bind to angiostatin, a known inhibitor of angiogenesis. This interaction was found to inhibit endothelial cell migration *in vitro*, suggesting that angiomotin plays an important role in controlling the migration of endothelial cells.

Recent reports suggest that at least one-third, and likely a higher percentage, of human genes are alternatively spliced. Hanke *et al.*, *Trends Genet.* 15(1):389 - 390 (1999); Mironov *et al.*, *Genome Res.* 9:1288-93 (1999); Brett *et al.*, *FEBS Lett.* 474(1):83-6 (2000). Alternative splicing has been proposed to account for at least part of the difference between the number of genes recently called from the completed human genome draft sequence – 30,000 to 40,000 (Genome International Sequencing Consortium, *Nature* 409:860-921 (2001)) – and earlier predictions of human gene number that routinely ranged as high as 120,000. Liang *et al.*, *Nature Genet.* 25(2):239-240 (2000). With the *Drosophila* homolog of one human gene reported to have 38,000 potential alternatively spliced variants, Schmucker *et al.*, *Cell* 101:671 (2000), it now appears that alternative splicing may permit the relatively small number of human coding regions to encode millions, perhaps tens of

millions, of structurally distinct proteins and protein isoforms.

Alternative splicing can introduce early stop codon and shortened open reading frame. For example, several alternatively spliced human growth hormone receptor transcripts have been identified and are associated with the introduction of early stop codon. It was found that one of the shorter isoform, although inactive by itself, could regulate the biological activity of the growth hormone receptor by forming heterodimers with the full-length counterpart and inhibit the function of the full-length receptor. *Ross et al, Molecular Endocrinology* 11:265-273 (1997).

Given a role for angiomotin as an adaptor protein that interacts with both angiostatin and components of the actin cytoskeleton and its demonstrated function as a mediator of angiostatin's anti-angiogenesis activity, there is a need to identify and to characterize additional human genes with structural and functional similarity to angiomotin.

SUMMARY OF THE INVENTION

The present invention solves these and other needs in the art by providing isolated nucleic acids that encode human angiomotin-like protein 1, including two isoforms (AMLP1a and AMLP1b), and fragments thereof.

In other aspects, the invention provides vectors for propagating and expressing the nucleic acids of the present invention, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the human AMLP1, and antibodies thereto.

The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention.

In other aspects, the invention provides transgenic cells and non-human organisms comprising human AMLP1 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human AMLP1.

The invention additionally provides diagnostic, investigational, and therapeutic methods based on the human AMLP1 nucleic acids, proteins, and antibodies of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects and advantages of the present invention will be apparent upon consideration of the following detailed description taken in conjunction with the accompanying drawings, in which like characters refer to like parts throughout, and in which:

FIG. 1 (A) schematizes the protein domain structure of human AMLP1a and AMLP1b, FIG. 1 (B) shows the alignment of the myosin-tail motif of AMLP1a with that of other proteins;

FIG. 2 is a map showing the genomic structure of human AMLP1 encoded at chromosome 11q21;

FIG. 3 presents the nucleotide and predicted amino acid sequences of human AMLP1a;

FIG. 4 presents the nucleotide and predicted amino acid sequences of human AMLP1b; and

FIG. 5 presents the expression profile of AMLP1 by RT-PCR analysis.

DETAILED DESCRIPTION OF THE INVENTION

Mining the sequence of the human genome for novel human genes, the present inventors have identified human AMLP1 (including two isoforms), an angiomotin-like protein, mutations of which could lead to cancer.

As schematized in FIG. 1, the newly isolated gene products share certain protein domains and an overall structural organization with human angiomotin. The shared structural features strongly imply that human AMLP1 plays a role similar to that of human angiomotin as an adaptor protein that interacts with both angiostatin-like protein and components of the actin cytoskeleton and has anti-angiogenesis activity.

Like human angiomotin, human AMLP1 contains a partial Myosin-tail domain. In AMLP1a, the partial Myosin-tail motif ocurrs at amino acids 351-733 (http://www.ncbi.nlm.gov/Structure/cdd/wrpsb.cgi). In the shorter AMLP1b protein, the partial Myosin-tail motif ends at amino acids sequence position 562 (which is the last amino acid for AMLP1b). The Myosin-tail motif is represented by the coiled-coil myosin heavy chain tail region. The coiled-coil is composed of the tail from two molecules of myosin. These can then assemble into the macromolecular thick filament. The coiled-coil region provides the structural backbone of the thick filament.

Other signatures of the newly isolated AMLP1 proteins were identified by searching the PROSITE database (http://www.expasy.ch/tools/scnpsit1.html). For AMLP1a, these signatures include four *N*-glycosylation sites (51 - 54, 57 - 60, 631 - 634 and 635 - 638), one cAMP- and cGMP-dependent protein kinase phosphorylation site (405 - 408), twelve protein kinase C phosphorylation sites, seventeen Casein kinase II phosphorylation sites, six *N*-myristoylation sites (3 - 8, 194 - 199, 244 - 249, 566 - 571, 743 - 748 and 784 - 789), as well as three tyrosine kinase phosphorylation sites (15 - 23, 453 - 459

and 659 - 666). For AMLP1b, these signatures include two *N*-glycosylation sites (51 - 54, 57 - 60), one cAMP- and cGMP-dependent protein kinase phosphorylation site (406 - 409), six protein kinase C phosphorylation sites, twelve Casein kinase II phosphorylation sites, three *N*-myristoylation sites (3 - 8, 195 - 200 and 245 - 250), as well as two tyrosine kinase phosphorylation sites (15 - 23 and 454 - 460).

FIG. 2 shows the genomic organization of human AMLP1.

At the top is shown the bacterial artificial chromosome (BAC), with GenBank accession numbers (AP001152.4), that spans the human AMLP1 locus.

As shown in FIG. 2, AMLP1a encodes a longer open reading frames compared to AMLP1b, and a protein of 869 amino acids. AMLP1a is comprised of exons 1 - 12. Insertion of a 66 base pair exon in AMLP1b (between exons 7 and 8 of AMLP1a) leads to frame shift and a shortened ORF with a protein of 563 amino acids. The predicted molecular weights for AMLP1a and AMLP1b, prior to any post-translational modifications, are 96.8 and 63.4 kD, respectively.

As further discussed in the examples herein, expression of AMLP1 was assessed using RT-PCR. RT-PCR detected high level expression of AMLP1 in brain, liver, kidney, and adrenal gland. AMLP1 expression is also detected in the other tissues tested, notably prostate, testis, lung, placenta, skeletal muscle, heart, bone marrow as well as colon tumor.

As more fully described below, the present invention provides isolated nucleic acids that encode human AMLP1 and fragments thereof. The invention further provides vectors for propagation and expression of the nucleic acids of the present invention, host cells

comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the present invention, and antibodies specific for all or any one of the isoforms. The invention provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention. The invention further provides transgenic cells and non-human organisms comprising human AMLP1 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human AMLP1. The invention additionally provides diagnostic, investigational, and therapeutic methods based on the human AMLP1 nucleic acids, proteins, and antibodies of the present invention.

DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs.

As used herein, **"nucleic acid"** (synonymously, **"polynucleotide"**) includes polynucleotides having natural nucleotides in native 5'-3' phosphodiester linkage – *e.g.*, DNA or RNA – as well as polynucleotides that have nonnatural nucleotide analogues, nonnative internucleoside bonds, or both, so long as the nonnatural polynucleotide is capable of sequence-discriminating basepairing under experimentally desired conditions. Unless otherwise specified, the term "nucleic acid" includes any topological conformation; the term thus explicitly comprehends single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular, and padlocked conformations.

As used herein, an **"isolated nucleic acid"** is a nucleic acid molecule that exists in a physical form that is nonidentical to any nucleic acid molecule of identical sequence as found in nature; "isolated" does not require, although it does not prohibit, that the nucleic acid so described has itself been physically removed from its native environment.

For example, a nucleic acid can be said to be "isolated" when it includes nucleotides and/or internucleoside bonds not found in nature. When instead composed of natural nucleosides in phosphodiester linkage, a nucleic acid can be said to be "isolated" when it exists at a purity not found in nature, where purity can be adjudged with respect to the presence of nucleic acids of other sequence, with respect to the presence of proteins, with respect to the presence of lipids, or with respect the presence of any other component of a biological cell, or when the nucleic acid lacks sequence that flanks an otherwise identical sequence in an organism's genome, or when the nucleic acid possesses sequence not identically present in nature.

As so defined, "isolated nucleic acid" includes nucleic acids integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.

As used herein, an isolated nucleic acid "encodes" a reference polypeptide when at least a portion of the nucleic acid, or its complement, can be directly translated to provide the amino acid sequence of the reference polypeptide, or when the isolated nucleic acid can be used, alone or as part of an expression vector, to express the reference polypeptide *in vitro*, in a prokaryotic host cell, or in a eukaryotic host cell.

As used herein, the term **"exon"** refers to a nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute contiguous sequence to a mature mRNA transcript.

As used herein, the phrase **"open reading frame"** and the equivalent acronym **"ORF"** refer to that portion of a transcript-derived nucleic acid that can be translated in its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

As used herein, the phrase **"ORF-encoded peptide"** refers to the predicted or actual translation of an ORF.

As used herein, the phrase **"degenerate variant"** of a reference nucleic acid sequence intends all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.

As used herein, the term **"microarray"** and the equivalent phrase **"nucleic acid microarray"** refer to a substrate-bound collection of plural nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed.

As so defined, the term "microarray" and phrase "nucleic acid microarray" include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999) (ISBN: 0199637768); *Nature Genet.* 21(1)(suppl):1 - 60 (1999); and Schena (ed.), Microarray

Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000) (ISBN: 1881299376), the disclosures of which are incorporated herein by reference in their entireties.

As so defined, the term "microarray" and phrase "nucleic acid microarray" also include substrate-bound collections of plural nucleic acids in which the plurality of nucleic acids are distributably disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):166501670 (2000), the disclosure of which is incorporated herein by reference in its entirety; in such case, the term "microarray" and phrase "nucleic acid microarray" refer to the plurality of beads in aggregate.

As used herein with respect to solution phase hybridization, the term **"probe"**, or equivalently, **"nucleic acid probe"** or **"hybridization probe"**, refers to an isolated nucleic acid of known sequence that is, or is intended to be, detectably labeled. As used herein with respect to a nucleic acid microarray, the term "probe" (or equivalently "nucleic acid probe" or "hybridization probe") refers to the isolated nucleic acid that is, or is intended to be, bound to the substrate. In either such context, the term "target" refers to nucleic acid intended to be bound to probe by sequence complementarity.

As used herein, the expression **"probe comprising SEQ ID NO:X"**, and variants thereof, intends a nucleic acid probe, at least a portion of which probe has either (i) the sequence directly as given in the referenced SEQ ID NO:X, or (ii) a sequence complementary to the sequence as given in the referenced SEQ ID NO:X, the choice as between sequence directly as given and

complement thereof dictated by the requirement that the probe be complementary to the desired target.

As used herein, the phrases **"expression of a probe"** and **"expression of an isolated nucleic acid"** and their linguistic equivalents intend that the probe or, (respectively, the isolated nucleic acid), or a probe (or, respectively, isolated nucleic acid) complementary in sequence thereto,can hybridize detectably under high stringency conditions to a sample of nucleic acids that derive from mRNA transcripts from a given source. For example, and by way of illustration only, expression of a probe in "liver" means that the probe can hybridize detectably under high stringency conditions to a sample of nucleic acids that derive from mRNA obtained from liver.

As used herein, **"a single exon probe"** comprises at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon. The single exon probe will not, however, hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon and that consist of one or more exons that are found adjacent to the reference exon in the genome.

For purposes herein, **"high stringency conditions"** are defined for solution phase hybridization as aqueous hybridization (*i.e.*, free of formamide) in 6X SSC (where 20X SSC contains 3.0 M NaCl and 0.3 M sodium citrate), 1% SDS at 65°C for at least 8 hours, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. **"Moderate stringency conditions"** are defined for solution phase hybridization as aqueous hybridization (i.e., free of formamide) in 6X SSC, 1% SDS at 65°C for at least 8

hours, followed by one or more washes in 2x SSC, 0.1% SDS at room temperature.

For microarray-based hybridization, standard "high stringency conditions" are defined as hybridization in 50% formamide, 5X SSC, 0.2 μg/μl poly(dA), 0.2 μg/μl human cot1 DNA, and 0.5% SDS, in a humid oven at 42°C overnight, followed by successive washes of the microarray in 1X SSC, 0.2% SDS at 55°C for 5 minutes, and then 0.1X SSC, 0.2% SDS, at 55°C for 20 minutes. For microarray-based hybridization, "moderate stringency conditions", suitable for cross-hybridization to mRNA encoding structurally- and functionally-related proteins, are defined to be the same as those for high stringency conditions but with reduction in temperature for hybridization and washing to room temperature (approximately 25°C).

As used herein, the terms **"protein"**, **"polypeptide"**, and **"peptide"** are used interchangeably to refer to a naturally-occurring or synthetic polymer of amino acid monomers (residues), irrespective of length, where amino acid monomer here includes naturally-occurring amino acids, naturally-occurring amino acid structural variants, and synthetic non-naturally occurring analogs that are capable of participating in peptide bonds. The terms "protein", "polypeptide", and "peptide" explicitly permits of post-translational and post-synthetic modifications, such as glycosylation.

The term **"oligopeptide"** herein denotes a protein, polypeptide, or peptide having 25 or fewer monomeric subunits.

The phrases **"isolated protein"**, **"isolated polypeptide"**, **"isolated peptide"** and **"isolated oligopeptide"** refer to a protein (or respectively to a polypeptide, peptide, or oligopeptide) that is

nonidentical to any protein molecule of identical amino acid sequence as found in nature; "isolated" does not require, although it does not prohibit, that the protein so described has itself been physically removed from its native environment.

For example, a protein can be said to be "isolated" when it includes amino acid analogues or derivatives not found in nature, or includes linkages other than standard peptide bonds.

When instead composed entirely of natural amino acids linked by peptide bonds, a protein can be said to be "isolated" when it exists at a purity not found in nature – where purity can be adjudged with respect to the presence of proteins of other sequence, with respect to the presence of non-protein compounds, such as nucleic acids, lipids, or other components of a biological cell, or when it exists in a composition not found in nature, such as in a host cell that does not naturally express that protein.

A **"purified protein"** (equally, a purified polypeptide, peptide, or oligopeptide) is an isolated protein, as above described, present at a concentration of at least 95%, as measured on a weight basis with respect to total protein in a composition. A **"substantially purified protein"** (equally, a substantially purified polypeptide, peptide, or oligopeptide) is an isolated protein, as above described, present at a concentration of at least 70%, as measured on a weight basis with respect to total protein in a composition.

As used herein, the phrase **"protein isoforms"** refers to a plurality of proteins having nonidentical primary amino acid sequence but that share amino acid sequence encoded by at least one common exon.

As used herein, the phrase **"alternative splicing"** and its linguistic equivalents includes all types of RNA processing that lead to expression of plural protein isoforms from a single gene; accordingly, the phrase **"splice variant(s)"** and its linguistic equivalents embraces mRNAs transcribed from a given gene that, however processed, collectively encode plural protein isoforms. For example, and by way of illustration only, splice variants can include exon insertions, exon extensions, exon truncations, exon deletions, alternatives in the 5' untranslated region ("5' UT") and alternatives in the 3' untranslated region ("3' UT"). Such 3' alternatives include, for example, differences in the site of RNA transcript cleavage and site of poly(A) addition. See, *e.g.*, Gautheret *et al.*, *Genome Res.* 8:524-530 (1998).

As used herein, **"orthologues"** are separate occurrences of the same gene in multiple species. The separate occurrences have similar, albeit nonidentical, amino acid sequences, the degree of sequence similarity depending, in part, upon the evolutionary distance of the species from a common ancestor having the same gene.

As used herein, the term **"paralogues"** indicates separate occurrences of a gene in one species. The separate occurrences have similar, albeit nonidentical, amino acid sequences, the degree of sequence similarity depending, in part, upon the evolutionary distance from the gene duplication event giving rise to the separate occurrences.

As used herein, the term **"homologues"** is generic to "orthologues" and "paralogues".

As used herein, the term **"antibody"** refers to a polypeptide, at least a portion of which is encoded by at least one immunoglobulin gene, or fragment thereof, and

that can bind specifically to a desired target molecule. The term includes naturally-occurring forms, as well as fragments and derivatives.

Fragments within the scope of the term "antibody" include those produced by digestion with various proteases, those produced by chemical cleavage and/or chemical dissociation, and those produced recombinantly, so long as the fragment remains capable of specific binding to a target molecule. Among such fragments are Fab, Fab', Fv, $F(ab)'_2$, and single chain Fv (scFv) fragments.

Derivatives within the scope of the term include antibodies (or fragments thereof) that have been modified in sequence, but remain capable of specific binding to a target molecule, including: interspecies chimeric and humanized antibodies; antibody fusions; heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies (see, *e.g.*, Marasco (ed.), Intracellular Antibodies: Research and Disease Applications, Springer-Verlag New York, Inc. (1998) (ISBN: 3540641513), the disclosure of which is incorporated herein by reference in its entirety).

As used herein, antibodies can be produced by any known technique, including harvest from cell culture of native B lymphocytes, harvest from culture of hybridomas, recombinant expression systems, and phage display.

As used herein, **"antigen"** refers to a ligand that can be bound by an antibody; an antigen need not itself be immunogenic. The portions of the antigen that make contact with the antibody are denominated **"epitopes"**.

"Specific binding" refers to the ability of two molecular species concurrently present in a heterogeneous

(inhomogeneous) sample to bind to one another in preference to binding to other molecular species in the sample. Typically, a specific binding interaction will discriminate over adventitious binding interactions in the reaction by at least two-fold, more typically by at least 10-fold, often at least 100-fold; when used to detect analyte, specific binding is sufficiently discriminatory when determinative of the presence of the analyte in a heterogeneous (inhomogeneous) sample. Typically, the affinity or avidity of a specific binding reaction is least about 10^{-7} M, with specific binding reactions of greater specificity typically having affinity or avidity of at least 10^{-8} M to at least about 10^{-9} M.

As used herein, **"molecular binding partners"** – and equivalently, **"specific binding partners"** – refer to pairs of molecules, typically pairs of biomolecules, that exhibit specific binding. Nonlimiting examples are receptor and ligand, antibody and antigen, and biotin to any of avidin, streptavidin, neutrAvidin and captAvidin.

The term **"antisense"**, as used herein, refers to a nucleic acid molecule sufficiently complementary in sequence, and sufficiently long in that complementary sequence, as to hybridize under intracellular conditions to (i) a target mRNA transcript or (ii) the genomic DNA strand complementary to that transcribed to produce the target mRNA transcript.

The term **"portion"**, as used with respect to nucleic acids, proteins, and antibodies, is synonymous with "fragment".

NUCLEIC ACID MOLECULES

In a first aspect, the invention provides isolated nucleic acids that encode human AMLP1, naturally

occurring allelic variants, variants having at least 65% sequence identity thereto, degenerate variants thereof, variants that encode human AMLP1 proteins having conservative or moderately conservative substitutions, cross-hybridizing nucleic acids, and fragments thereof.

FIG. 3 and FOG.4 presents the nucleotide sequence of the human AMLP1 cDNA clones, with predicted amino acid translation; the sequences are further presented in the Sequence Listing, incorporated herein by reference in its entirety, in SEQ ID NO: 1 (full length nucleotide sequence of human AMLP1a cDNA), SEQ ID NO: 3 (full length amino acid coding sequence of human AMLP1a), SEQ ID NO: 4 (full length nucleotide sequence of human AMLP1b cDNA) and SEQ ID NO: 6 (full length amino acid coding sequence of human AMLP1b).

Unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given sequence be interpreted as would be appropriate to the polynucleotide composition: for example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

Unless otherwise indicated, nucleotide sequences of the isolated nucleic acids of the present invention were determined by sequencing a DNA molecule that had resulted, directly or indirectly, from at least one enzymatic polymerization reaction (*e.g.*, reverse transcription and/or polymerase chain reaction) using an automated sequencer (such as the MegaBACE™ 1000, Amersham Biosciences, Sunnyvale, CA, USA), or by reliance upon such sequence or upon genomic sequence prior-accessioned into a public database. Unless otherwise indicated, all amino acid sequences of the polypeptides

of the present invention were predicted by translation from the nucleic acid sequences so determined.

As a consequence, any nucleic acid sequence presented herein may contain errors introduced by erroneous incorporation of nucleotides during polymerization, by erroneous base calling by the automated sequencer (although such sequencing errors have been minimized for the nucleic acids directly determined herein, unless otherwise indicated, by the sequencing of each of the complementary strands of a duplex DNA), or by similar errors accessioned into the public database. Such errors can readily be identified and corrected by resequencing of the genomic locus using standard techniques.

Single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes - more than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409:860 - 921 (2001) - and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Additionally, small deletions and insertions, rather than single nucleotide polymorphisms, are not uncommon in the general population, and often do not alter the function of the protein.

Accordingly, it is an aspect of the present invention to provide nucleic acids not only identical in sequence to those described with particularity herein, but also to provide isolated nucleic acids at least about 65% identical in sequence to those described with particularity herein, typically at least about 70%, 75%, 80%, 85%, or 90% identical in sequence to those described with particularity herein, usefully at least about 91%, 92%, 93%, 94%, or 95% identical in sequence to those described with particularity herein, usefully at least

about 96%, 97%, 98%, or 99% identical in sequence to those described with particularity herein, and, most conservatively, at least about 99.5%, 99.6%, 99.7%, 99.8% and 99.9% identical in sequence to those described with particularity herein. These sequence variants can be naturally occurring or can result from human intervention, as by random or directed mutagenesis.

For purposes herein, percent identity of two nucleic acid sequences is determined using the procedure of Tatiana *et al.*, "Blast 2 sequences - a new tool for comparing protein and nucleotide sequences", *FEMS Microbiol Lett.* 174:247-250 (1999), which procedure is effectuated by the computer program BLAST 2 SEQUENCES, available online at

http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html.

To assess percent identity of nucleic acids, the BLASTN module of BLAST 2 SEQUENCES is used with default values of (i) reward for a match: 1; (ii) penalty for a mismatch: -2; (iii) open gap 5 and extension gap 2 penalties; (iv) gap X_dropoff 50 expect 10 word size 11 filter, and both sequences are entered in their entireties.

As is well known, the genetic code is degenerate, with each amino acid except methionine translated from a plurality of codons, thus permitting a plurality of nucleic acids of disparate sequence to encode the identical protein. As is also well known, codon choice for optimal expression varies from species to species. The isolated nucleic acids of the present invention being useful for expression of human AMLP1 proteins and protein fragments, it is, therefore, another aspect of the present invention to provide isolated nucleic acids that encode human AMLP1 proteins and

portions thereof not only identical in sequence to those described with particularity herein, but degenerate variants thereof as well.

As is also well known, amino acid substitutions occur frequently among natural allelic variants, with conservative substitutions often occasioning only *de minimis* change in protein function.

Accordingly, it is an aspect of the present invention to provide nucleic acids not only identical in sequence to those described with particularity herein, but also to provide isolated nucleic acids that encode human AMLP1, and portions thereof, having conservative amino acid substitutions, and also to provide isolated nucleic acids that encode human AMLP1, and portions thereof, having moderately conservative amino acid substitutions.

Although there are a variety of metrics for calling conservative amino acid substitutions, based primarily on either observed changes among evolutionarily related proteins or on predicted chemical similarity, for purposes herein a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix reproduced herein below (*see* Gonnet *et al.*, *Science* 256(5062):1443-5 (1992)):

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
A	2	-1	0	0	0	0	0	0	-1	-1	-1	0	-1	-2	0	1	1	-4	-2	0
R	-1	5	0	0	-2	2	0	-1	1	-2	-2	3	-2	-3	-1	0	0	-2	-2	-2
N	0	0	4	2	-2	1	1	0	1	-3	-3	1	-2	-3	-1	1	0	-4	-1	-2
D	0	0	2	5	-3	1	3	0	0	-4	-4	0	-3	-4	-1	0	0	-5	-3	-3
C	0	-2	-2	-3	12	-2	-3	-2	-1	-1	-2	-3	-1	-1	-3	0	0	-1	0	0
Q	0	2	1	1	-2	3	2	-1	1	-2	-2	2	-1	-3	0	0	0	-3	-2	-2
E	0	0	1	3	-3	2	4	-1	0	-3	-3	1	-2	-4	0	0	0	-4	-3	-2
G	0	-1	0	0	-2	-1	-1	7	-1	-4	-4	-1	-4	-5	-2	0	-1	-4	-4	-3
H	-1	1	1	0	-1	1	0	-1	6	-2	-2	1	-1	0	-1	0	0	-1	2	-2
I	-1	-2	-3	-4	-1	-2	-3	-4	-2	4	3	-2	2	1	-3	-2	-1	-2	-1	3

L	-1	-2	-3	-4	-2	-2	-3	-4	-2	3	4	-2	3	2	-2	-2	-1	-1	0	2
K	0	3	1	0	-3	2	1	-1	1	-2	-2	3	-1	-3	-1	0	0	-4	-2	-2
M	-1	-2	-2	-3	-1	-1	-2	-4	-1	2	3	-1	4	2	-2	-1	-1	-1	0	2
F	-2	-3	-3	-4	-1	-3	-4	-5	0	1	2	-3	2	7	-4	-3	-2	4	5	0
P	0	-1	-1	-1	-3	0	0	-2	-1	-3	-2	-1	-2	-4	8	0	0	-5	-3	-2
S	1	0	1	0	0	0	0	0	0	-2	-2	0	-1	-3	0	2	2	-3	-2	-1
T	1	0	0	0	0	0	0	-1	0	-1	-1	0	-1	-2	0	2	2	-4	-2	0
W	-4	-2	-4	-5	-1	-3	-4	-4	-1	-2	-1	-4	-1	4	-5	-3	-4	14	4	-3
Y	-2	-2	-1	-3	0	-2	-3	-4	2	-1	0	-2	0	5	-3	-2	-2	4	8	-1
V	0	-2	-2	-3	0	-2	-2	-3	-2	3	2	-2	2	0	-2	-1	0	-3	-1	3

For purposes herein, a "moderately conservative" replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix reproduced herein above.

As is also well known in the art, relatedness of nucleic acids can also be characterized using a functional test, the ability of the two nucleic acids to base-pair to one another at defined hybridization stringencies.

It is, therefore, another aspect of the invention to provide isolated nucleic acids not only identical in sequence to those described with particularity herein, but also to provide isolated nucleic acids ("cross-hybridizing nucleic acids") that hybridize under high stringency conditions (as defined herein below) to all or to a portion of various of the isolated AMLP1 nucleic acids of the present invention ("reference nucleic acids"), as well as cross-hybridizing nucleic acids that hybridize under moderate stringency conditions to all or to a portion of various of the isolated AMLP1 nucleic acids of the present invention.

Such cross-hybridizing nucleic acids are useful, *inter alia*, as probes for, and to drive expression of, proteins related to the proteins of the present invention as alternative isoforms, homologues, paralogues, and orthologues. Particularly useful

orthologues are those from other primate species, such as chimpanzee, rhesus macaque, monkey, baboon, orangutan, and gorilla; from rodents, such as rats, mice, guinea pigs; from lagomorphs, such as rabbits; and from domestic livestock, such as cow, pig, sheep, horse, goat and chicken.

For purposes herein, high stringency conditions are defined as aqueous hybridization (*i.e.*, free of formamide) in 6X SSC (where 20X SSC contains 3.0 M NaCl and 0.3 M sodium citrate), 1% SDS at 65°C for at least 8 hours, followed by one or more washes in 0.2X SSC, 0.1% SDS at 65°C. For purposes herein, moderate stringency conditions are defined as aqueous hybridization (*i.e.*, free of formamide) in 6X SSC, 1% SDS at 65°C for at least 8 hours, followed by one or more washes in 2x SSC, 0.1% SDS at room temperature.

The hybridizing portion of the reference nucleic acid is typically at least 15 nucleotides in length, often at least 17 nucleotides in length. Often, however, the hybridizing portion of the reference nucleic acid is at least 20 nucleotides in length, 25 nucleotides in length, and even 30 nucleotides, 35 nucleotides, 40 nucleotides, and 50 nucleotides in length. Of course, cross-hybridizing nucleic acids that hybridize to a larger portion of the reference nucleic acid - for example, to a portion of at least 50 nt, at least 100 nt, at least 150 nt, 200 nt, 250 nt, 300 nt, 350 nt, 400 nt, 450 nt, or 500 nt or more - or even to the entire length of the reference nucleic acid, are also useful.

The hybridizing portion of the cross-hybridizing nucleic acid is at least 75% identical in sequence to at least a portion of the reference nucleic acid. Typically, the hybridizing portion of the cross-hybridizing nucleic acid is at least 80%, often at least 85%, 86%, 87%, 88%, 89% or even at least 90% identical in

sequence to at least a portion of the reference nucleic acid. Often, the hybridizing portion of the cross-hybridizing nucleic acid will be at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical in sequence to at least a portion of the reference nucleic acid sequence. At times, the hybridizing portion of the cross-hybridizing nucleic acid will be at least 99.5% identical in sequence to at least a portion of the reference nucleic acid.

The invention also provides fragments of various of the isolated nucleic acids of the present invention.

By "fragments" of a reference nucleic acid is here intended isolated nucleic acids, however obtained, that have a nucleotide sequence identical to a portion of the reference nucleic acid sequence, which portion is at least 17 nucleotides and less than the entirety of the reference nucleic acid. As so defined, "fragments" need not be obtained by physical fragmentation of the reference nucleic acid, although such provenance is not thereby precluded.

In theory, an oligonucleotide of 17 nucleotides is of sufficient length as to occur at random less frequently than once in the three gigabase human genome, and thus to provide a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. As is well known, further specificity can be obtained by probing nucleic acid samples of subgenomic complexity, and/or by using plural fragments as short as 17 nucleotides in length collectively to prime amplification of nucleic acids, as, *e.g.*, by polymerase chain reaction (PCR).

As further described herein below, nucleic acid fragments that encode at least 6 contiguous amino acids (*i.e.*, fragments of 18 nucleotides or more) are useful in

directing the expression or the synthesis of peptides that have utility in mapping the epitopes of the protein encoded by the reference nucleic acid. *See, e.g.*, Geysen *et al.*, "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984); and U.S. Pat. Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties.

As further described herein below, fragments that encode at least 8 contiguous amino acids (*i.e.*, fragments of 24 nucleotides or more) are useful in directing the expression or the synthesis of peptides that have utility as immunogens. *See, e.g.*, Lerner, "Tapping the immunological repertoire to produce antibodies of predetermined specificity," Nature 299:592-596 (1982); Shinnick *et al.*, "Synthetic peptide immunogens as vaccines," *Annu. Rev. Microbiol.* 37:425-46 (1983); Sutcliffe *et al.*, "Antibodies that react with predetermined sites on proteins," *Science* 219:660-6 (1983), the disclosures of which are incorporated herein by reference in their entireties.

The nucleic acid fragment of the present invention is thus at least 17 nucleotides in length, typically at least 18 nucleotides in length, and often at least 24 nucleotides in length. Often, the nucleic acid of the present invention is at least 25 nucleotides in length, and even 30 nucleotides, 35 nucleotides, 40 nucleotides, or 45 nucleotides in length. Of course, larger fragments having at least 50 nt, at least 100 nt, at least 150 nt, 200 nt, 250 nt, 300 nt, 350 nt, 400 nt, 450 nt, or 500 nt or more are also useful, and at times preferred.

Having been based upon the mining of genomic sequence, rather than upon surveillance of expressed

message, the present invention further provides isolated genome-derived nucleic acids that include portions of the AMLP1 gene.

The invention particularly provides genome-derived single exon probes.

As further described in commonly owned and copending U.S. patent application serial nos. 09/864,761, filed May 23, 2001; 09/774,203, filed January 29, 2001; and 09/632,366, filed August 3, 2000, the disclosures of which are incorporated herein by reference in their entireties, "a single exon probe" comprises at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon. The single exon probe will not, however, hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon and instead consist of one or more exons that are found adjacent to the reference exon in the genome.

Genome-derived single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. Often, the genome-derived single exon probe further comprises, contiguous to a second end of the exonic portion, a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome.

The minimum length of genome-derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids. Accordingly, the exon portion is at least 17 nucleotides, typically at least 18 nucleotides, 20 nucleotides, 24 nucleotides, 25 nucleotides or even 30, 35, 40, 45, or 50 nucleotides in length, and can usefully

include the entirety of the exon, up to 100 nt, 150 nt, 200 nt, 250 nt, 300 nt, 350 nt, 400 nt or even 500 nt or more in length.

The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one exon, that is, be unable to hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon but include one or more exons that are found adjacent to the reference exon the genome.

Given variable spacing of exons through eukaryotic genomes, the maximum length of single exon probes of the present invention is typically no more than 25 kb, often no more than 20 kb, 15 kb, 10 kb or 7.5 kb, or even no more than 5 kb, 4 kb, 3 kb, or even no more than about 2.5 kb in length.

The genome-derived single exon probes of the present invention can usefully include at least a first terminal priming sequence not found in contiguity with the rest of the probe sequence in the genome, and often will contain a second terminal priming sequence not found in contiguity with the rest of the probe sequence in the genome.

The present invention also provides isolated genome-derived nucleic acids that include nucleic acid sequence elements that control transcription of the AMLP1 gene.

With a complete draft of the human genome now available, genomic sequences that are within the vicinity of the AMLP1 coding region (and that are additional to those described with particularity herein) can readily be obtained by PCR amplification.

The isolated nucleic acids of the present invention can be composed of natural nucleotides in native 5'-3' phosphodiester internucleoside linkage –

e.g., DNA or RNA – or can contain any or all of nonnatural nucleotide analogues, nonnative internucleoside bonds, or post-synthesis modifications, either throughout the length of the nucleic acid or localized to one or more portions thereof.

As is well known in the art, when the isolated nucleic acid is used as a hybridization probe, the range of such nonnatural analogues, nonnative internucleoside bonds, or post-synthesis modifications will be limited to those that permit sequence-discriminating basepairing of the resulting nucleic acid. When used to direct expression or RNA or protein *in vitro* or *in vivo*, the range of such nonnatural analogues, nonnative internucleoside bonds, or post-synthesis modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent, the range of such changes will be limited to those that do not confer toxicity upon the isolated nucleic acid.

For example, when desired to be used as probes, the isolated nucleic acids of the present invention can usefully include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens.

Common radiolabeled analogues include those labeled with ^{33}P, ^{32}P, and ^{35}S, such as α-^{32}P-dATP, α-^{32}P-dCTP, α-^{32}P-dGTP, α-^{32}P-dTTP, α-^{32}P-3'dATP, α-^{32}P-ATP, α-^{32}P-CTP, α-^{32}P-GTP, α-^{32}P-UTP, α-^{35}S-dATP, γ-^{35}S-GTP, γ-^{33}P-dATP, and the like.

Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-

dCTP, Cy3-dUTP (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP, BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, OR, USA).

Protocols are available for custom synthesis of nucleotides having other fluorophores. Henegariu *et al.*, "Custom Fluorescent-Nucleotide Synthesis as an Alternative Method for Nucleic Acid Labeling," *Nature Biotechnol.* 18:345 - 348 (2000), the disclosure of which is incorporated herein by reference in its entirety.

Haptens that are commonly conjugated to nucleotides for subsequent labeling include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA; biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA).

As another example, when desired to be used for antisense inhibition of transcription or translation, the isolated nucleic acids of the present invention can usefully include altered, often nuclease-resistant,

internucleoside bonds. *See* Hartmann *et al.* (eds.), Manual of Antisense Methodology (Perspectives in Antisense Science), Kluwer Law International (1999) (ISBN:079238539X); Stein *et al.* (eds.), Applied Antisense Oligonucleotide Technology, Wiley-Liss (cover (1998) (ISBN: 0471172790); Chadwick *et al.* (eds.), Oligonucleotides as Therapeutic Agents - Symposium No. 209, John Wiley & Son Ltd (1997) (ISBN: 0471972797), the disclosures of which are incorporated herein by reference in their entireties. Such altered internucloside bonds are often desired also when the isolated nucleic acid of the present invention is to be used for targeted gene correction, Gamper *et al.*, *Nucl. Acids Res.* 28(21):4332-4339 (2000), the disclosures of which are incorporated herein by reference in its entirety.

Modified oligonucleotide backbones often preferred when the nucleic acid is to be used for antisense purposes are, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Representative U.S. patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925;

5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of which are incorporated herein by reference in their entireties.

Preferred modified oligonucleotide backbones for antisense use that do not include a phosphorus atom have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH_2 component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, the disclosures of which are incorporated herein by reference in their entireties.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA).

In PNA compounds, the phosphodiester backbone of the nucleic acid is replaced with an amide-containing

backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages.

The uncharged nature of the PNA backbone provides PNA/DNA and PNA/RNA duplexes with a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes, resulting from the lack of charge repulsion between the PNA and DNA or RNA strand. In general, the Tm of a PNA/DNA or PNA/RNA duplex is 1°C higher per base pair than the Tm of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl).

The neutral backbone also allows PNA to form stable DNA duplexes largely independent of salt concentration. At low ionic strength, PNA can be hybridized to a target sequence at temperatures that make DNA hybridization problematic or impossible. And unlike DNA/DNA duplex formation, PNA hybridization is possible in the absence of magnesium. Adjusting the ionic strength, therefore, is useful if competing DNA or RNA is present in the sample, or if the nucleic acid being probed contains a high level of secondary structure.

PNA also demonstrates greater specificity in binding to complementary DNA. A PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the Tm by 8-20°C (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the Tm by 4-16°C (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater.

Additionally, nucleases and proteases do not recognize the PNA polyamide backbone with nucleobase sidechains. As a result, PNA oligomers are resistant to

degradation by enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro*. In addition, PNA is stable over a wide pH range.

Because its backbone is formed from amide bonds, PNA can be synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference; automated PNA synthesis is readily achievable on commercial synthesizers (*see, e.g.*, "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA).

PNA chemistry and applications are reviewed, *inter alia*, in Ray *et al.*, *FASEB J.* 14(9):1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1):3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1):159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3):353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1):71-5 (1999), the disclosures of which are incorporated herein by reference in their entireties.

Differences from nucleic acid compositions found in nature — *e.g.*, nonnative bases, altered internucleoside linkages, post-synthesis modification — can be present throughout the length of the nucleic acid or can, instead, usefully be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and demonstrated utility for targeted gene repair, as further described in U.S. Pat. Nos. 5,760,012 and 5,731,181, the disclosures of which are incorporated herein by reference in their entireties. As another example, chimeric nucleic acids comprising both DNA and PNA have been demonstrated to have utility in

modified PCR reactions. *See* Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); *see also* Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), incorporated herein by reference.

Unless otherwise specified, nucleic acids of the present invention can include any topological conformation appropriate to the desired use; the term thus explicitly comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, branched, hairpinned, circular, and padlocked conformations. Padlock conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12:11-15 (2001); Escude *et al.*, Proc. Natl. Acad. Sci. USA 14;96(19):10603-7 (1999); Nilsson *et al.*, *Science* 265(5181):2085-8 (1994), the disclosures of which are incorporated herein by reference in their entireties. Triplex and quadruplex conformations, and their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1):181-206 (1999); Fox, *Curr. Med. Chem.* 7(1):17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130:189-201 (2000); Chan *et al.*, *J. Mol. Med.* 75(4):267-82 (1997), the disclosures of which are incorporated herein by reference in their entireties.

The nucleic acids of the present invention can be detectably labeled.

Commonly-used labels include radionuclides, such as ^{32}P, ^{33}P, ^{35}S, ^{3}H (and for NMR detection, ^{13}C and ^{15}N), haptens that can be detected by specific antibody or high affinity binding partner (such as avidin), and fluorophores.

As noted above, detectable labels can be incorporated by inclusion of labeled nucleotide analogues in the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation,

random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules, and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3, and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach.

Analogues can also be incorporated during automated solid phase chemical synthesis.

As is well known, labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3' hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

Various other post-synthetic approaches permit internal labeling of nucleic acids.

For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and PNA to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); *see* Alers *et al.*, *Genes, Chromosomes & Cancer*, Vol. 25, pp. 301 - 305 (1999); Jelsma *et al.*, *J. NIH Res.* 5:82 (1994); Van Belkum *et al.*, *BioTechniques* 16:148-153 (1994), incorporated herein by reference. As another example, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally coupled to the target nucleic acid using aryl azide chemistry; after reduction, a free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

Multiple independent or interacting labels can be incorporated into the nucleic acids of the present invention.

For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report specific hybridization through release of fluorescence quenching, Tyagi *et al.*, *Nature Biotechnol.* 14: 303-308 (1996); Tyagi *et al.*, *Nature Biotechnol.* 16, 49-53 (1998); Sokol *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); Kostrikis *et al.*, *Science* 279:1228-1229 (1998); Marras *et al.*, *Genet. Anal.* 14: 151-156 (1999); U.S. Pat. Nos. 5,846,726, 5,925,517, 5925517, or to report exonucleotidic excision, U.S. Pat. No. 5,538,848; Holland *et al.*, *Proc. Natl. Acad. Sci. USA* 88:7276-7280 (1991); Heid *et al.*, *Genome Res.* 6(10):986-94 (1996); Kuimelis *et al.*, *Nucleic Acids Symp Ser.* (37):255-6 (1997); U.S. Patent No. 5,723,591, the disclosures of which are incorporated herein by reference in their entireties.

So labeled, the isolated nucleic acids of the present invention can be used as probes, as further described below.

Nucleic acids of the present invention can also usefully be bound to a substrate. The substrate can porous or solid, planar or non-planar, unitary or distributed; the bond can be covalent or noncovalent. Bound to a substrate, nucleic acids of the present invention can be used as probes in their unlabeled state.

For example, the nucleic acids of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, nylon, or positively-charged derivatized nylon; so attached, the nucleic acids of the present invention can be used to detect AMLP1 nucleic acids present within a labeled nucleic acid sample, either a sample of genomic nucleic acids or a sample of transcript-derived nucleic acids, *e.g.* by reverse dot blot.

The nucleic acids of the present invention can also usefully be bound to a solid substrate, such as glass, although other solid materials, such as amorphous silicon, crystalline silicon, or plastics, can also be used. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof.

Typically, the solid substrate will be rectangular, although other shapes, particularly disks and even spheres, present certain advantages. Particularly advantageous alternatives to glass slides as support substrates for array of nucleic acids are optical discs, as described in Demers, "Spatially Addressable Combinatorial Chemical Arrays in CD-ROM Format," international patent publication WO 98/12559, incorporated herein by reference in its entirety.

The nucleic acids of the present invention can be attached covalently to a surface of the support substrate or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or some combination thereof.

The nucleic acids of the present invention can be bound to a substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of bound nucleic acids being separately detectable. At low density, *e.g.* on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such as glass, these substrate bound collections of plural nucleic acids are colloquially termed microarrays. As used herein, the term microarray

includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that include the nucleic acids of the present invention.

The isolated nucleic acids of the present invention can be used as hybridization probes to detect, characterize, and quantify AMLP1 nucleic acids in, and isolate AMLP1 nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably, detectably labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

For example, the isolated nucleic acids of the present invention can be used as probes to detect and characterize gross alterations in the AMLP1 genomic locus, such as deletions, insertions, translocations, and duplications of the AMLP1 genomic locus through fluorescence *in situ* hybridization (FISH) to chromosome spreads. *See, e.g.*, Andreeff *et al.* (eds.), Introduction to Fluorescence *In Situ* Hybridization: Principles and Clinical Applications, John Wiley & Sons (1999) (ISBN: 0471013455), the disclosure of which is incorporated herein by reference in its entirety. The isolated nucleic acids of the present invention can be used as probes to assess smaller genomic alterations using, *e.g.*, Southern blot detection of restriction fragment length polymorphisms. The isolated nucleic acids of the present invention can be used as probes to isolate genomic clones that include the nucleic acids of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

The isolated nucleic acids of the present invention can also be used as probes to detect,

characterize, and quantify AMLP1 nucleic acids in, and isolate AMLP1 nucleic acids from, transcript-derived nucleic acid samples.

For example, the isolated nucleic acids of the present invention can be used as hybridization probes to detect, characterize by length, and quantify AMLP1 mRNA by northern blot of total or poly-A^+- selected RNA samples. For example, the isolated nucleic acids of the present invention can be used as hybridization probes to detect, characterize by location, and quantify AMLP1 message by *in situ* hybridization to tissue sections (see, *e.g.*, Schwarchzacher *et al.*, In Situ Hybridization, Springer-Verlag New York (2000) (ISBN: 0387915966), the disclosure of which is incorporated herein by reference in its entirety). For example, the isolated nucleic acids of the present invention can be used as hybridization probes to measure the representation of AMLP1 clones in a cDNA library. For example, the isolated nucleic acids of the present invention can be used as hybridization probes to isolate AMLP1 nucleic acids from cDNA libraries, permitting sequence level characterization of AMLP1 messages, including identification of deletions, insertions, truncations – including deletions, insertions, and truncations of exons in alternatively spliced forms – and single nucleotide polymorphisms.

All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook *et al.*, Molecular Cloning: A Laboratory Manual (3^{rd} ed.), Cold Spring Harbor Laboratory Press (2001) (ISBN: 0879695773); Ausubel *et al.* (eds.), Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology (4^{th} ed.), John Wiley & Sons, 1999 (ISBN: 047132938X); and Walker *et al.* (eds.), The Nucleic

Acids Protocols Handbook, Humana Press (2000) (ISBN: 0896034593), the disclosures of which are incorporated herein by reference in their entirety.

As described in the Examples herein below, the nucleic acids of the present invention can also be used to detect and quantify AMLP1 nucleic acids in transcript-derived samples – that is, to measure expression of the AMLP1 gene – when included in a microarray. Measurement of AMLP1 expression has particular utility in diagnosis and treatment of cancer, as further described in the Examples herein below.

As would be readily apparent to one of skill in the art, each AMLP1 nucleic acid probe – whether labeled, substrate-bound, or both – is thus currently available for use as a tool for measuring the level of AMLP1 expression in each of the tissues in which expression has already been confirmed, notably brain, liver, kidney, and adrenal gland, as well as prostate, testis, lung, placenta, skeletal muscle, heart, bone marrow and colon tumor. The utility is specific to the probe: under high stringency conditions, the probe reports the level of expression of message specifically containing that portion of the human AMLP1 gene included within the probe.

Measuring tools are well known in many arts, not just in molecular biology, and are known to possess credible, specific, and substantial utility. For example, U.S. Patent No. 6,016,191 describes and claims a tool for measuring characteristics of fluid flow in a hydrocarbon well; U.S. Patent No. 6,042,549 describes and claims a device for measuring exercise intensity; U.S. Patent No. 5,889,351 describes and claims a device for measuring viscosity and for measuring characteristics of a fluid; U.S. Patent No. 5,570,694 describes and claims a device for measuring blood pressure; U.S. Patent No.

5,930,143 describes and claims a device for measuring the dimensions of machine tools; U.S. Patent No. 5,279,044 describes and claims a measuring device for determining an absolute position of a movable element; U.S. Patent No. 5,186,042 describes and claims a device for measuring action force of a wheel; and U.S. Patent No. 4,246,774 describes and claims a device for measuring the draft of smoking articles such as cigarettes.

As for tissues not yet demonstrated to express AMLP1, the AMLP1 nucleic acid probes of the present invention are currently available as tools for surveying such tissues to detect the presence of AMLP1 nucleic acids.

Survey tools – *i.e.*, tools for determining the presence and/or location of a desired object by search of an area – are well known in many arts, not just in molecular biology, and are known to possess credible, specific, and substantial utility. For example, U.S. Patent No. 6,046,800 describes and claims a device for surveying an area for objects that move; U.S. Patent No. 6,025,201 describes and claims an apparatus for locating and discriminating platelets from non-platelet particles or cells on a cell-by-cell basis in a whole blood sample; U.S. Patent No. 5,990,689 describes and claims a device for detecting and locating anomalies in the electromagnetic protection of a system; U.S. Patent No. 5,984,175 describes and claims a device for detecting and identifying wearable user identification units; U.S. Patent No. 3,980,986 ("Oil well survey tool"), describes and claims a tool for finding the position of a drill bit working at the bottom of a borehole.

As noted above, the nucleic acid probes of the present invention are useful in constructing microarrays; the microarrays, in turn, are products of manufacture

that are useful for measuring and for surveying gene expression.

When included on a microarray, each AMLP1 nucleic acid probe makes the microarray specifically useful for detecting that portion of the AMLP1 gene included within the probe, thus imparting upon the microarray device the ability to detect a signal where, absent such probe, it would have reported no signal. This utility makes each individual probe on such microarray akin to an antenna, circuit, firmware or software element included in an electronic apparatus, where the antenna, circuit, firmware or software element imparts upon the apparatus the ability newly and additionally to detect signal in a portion of the radio-frequency spectrum where previously it could not; such devices are known to have specific, substantial, and credible utility.

Changes in the level of expression need not be observed for the measurement of expression to have utility.

For example, where gene expression analysis is used to assess toxicity of chemical agents on cells, the failure of the agent to change a gene's expression level is evidence that the drug likely does not affect the pathway of which the gene's expressed protein is a part. Analogously, where gene expression analysis is used to assess side effects of pharmacologic agents – whether in lead compound discovery or in subsequent screening of lead compound derivatives – the inability of the agent to alter a gene's expression level is evidence that the drug does not affect the pathway of which the gene's expressed protein is a part.

WO 99/58720, incorporated herein by reference in its entirety, provides methods for quantifying the relatedness of a first and second gene expression profile

and for ordering the relatedness of a plurality of gene expression profiles, without regard to the identity or function of the genes whose expression is used in the calculation.

Gene expression analysis, including gene expression analysis by microarray hybridization, is, of course, principally a laboratory-based art. Devices and apparatus used principally in laboratories to facilitate laboratory research are well-established to possess specific, substantial, and credible utility. For example, U.S. Patent No. 6,001,233 describes and claims a gel electrophoresis apparatus having a cam-activated clamp; for example, U.S. Patent No. 6,051,831 describes and claims a high mass detector for use in time-of-flight mass spectrometers; for example, U.S. Patent NO. 5,824,269 describes and claims a flow cytometer—as is well known, few gel electrophoresis apparatuses, TOF-MS devices, or flow cytometers are sold for consumer use.

Indeed, and in particular, nucleic acid microarrays, as devices intended for laboratory use in measuring gene expression, are well-established to have specific, substantial and credible utility. Thus, the microarrays of the present invention have at least the specific, substantial and credible utilities of the microarrays claimed as devices and articles of manufacture in the following U.S. patents, the disclosures of each of which is incorporated herein by reference: U.S. Patent Nos. 5,445,934 ("Array of oligonucleotides on a solid substrate"); 5,744,305 ("Arrays of materials attached to a substrate"); and 6,004,752 ("Solid support with attached molecules").

Genome-derived single exon probes and genome-derived single exon probe microarrays have the additional utility, *inter alia*, of permitting high-throughput detection of splice variants of the nucleic acids of the

present invention, as further described in copending and commonly owned U.S. Patent application no. 09/632,366, filed August 3, 2000, the disclosure of which is incorporated herein by reference in its entirety.

The isolated nucleic acids of the present invention can also be used to prime synthesis of nucleic acid, for purpose of either analysis or isolation, using mRNA, cDNA, or genomic DNA as template.

For use as primers, at least 17 contiguous nucleotides of the isolated nucleic acids of the present invention will be used. Often, at least 18, 19, or 20 contiguous nucleotides of the nucleic acids of the present invention will be used, and on occasion at least 20, 22, 24, or 25 contiguous nucleotides of the nucleic acids of the present invention will be used, and even 30 nucleotides or more of the nucleic acids of the present invention can be used to prime specific synthesis.

The nucleic acid primers of the present invention can be used, for example, to prime first strand cDNA synthesis on an mRNA template.

Such primer extension can be done directly to analyze the message. Alternatively, synthesis on an mRNA template can be done to produce first strand cDNA. The first strand cDNA can thereafter be used, *inter alia*, directly as a single-stranded probe, as above-described, as a template for sequencing – permitting identification of alterations, including deletions, insertions, and substitutions, both normal allelic variants and mutations associated with abnormal phenotypes– or as a template, either for second strand cDNA synthesis (*e.g.*, as an antecedent to insertion into a cloning or expression vector), or for amplification.

The nucleic acid primers of the present invention can also be used, for example, to prime single base extension (SBE) for SNP detection (*see, e.g.*, U.S.

Pat. No. 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

As another example, the nucleic acid primers of the present invention can be used to prime amplification of AMLP1 nucleic acids, using transcript-derived or genomic DNA as template.

Primer-directed amplification methods are now well-established in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR (Basics: From Background to Bench), Springer Verlag (2000) (ISBN: 0387916008); Innis *et al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic Press (1999) (ISBN: 0123721857); Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998) (ISBN: 0123721822); Newton *et al.*, PCR, Springer-Verlag New York (1997) (ISBN: 0387915060); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996) (ISBN: 047195697X); White (ed.), PCR Cloning Protocols: From Molecular Cloning to Genetic Engineering, Vol. 67, Humana Press (1996) (ISBN: 0896033430); McPherson et al. (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995) (ISBN: 0199634254), the disclosures of which are incorporated herein by reference in their entireties. Methods for performing RT-PCR are collected, *e.g.*, in Siebert *et al.* (eds.), Gene Cloning and Analysis by RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998 (ISBN: 1881299147); Siebert (ed.), PCR Technique:RT-PCR, Eaton Publishing Company/BioTechniques Books (1995) (ISBN:1881299139), the disclosure of which is incorporated herein by reference in its entirety.

Isothermal amplification approaches, such as rolling circle amplification, are also now well-described. *See, e.g.*, Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1):21-7 (2001); U.S. Patent Nos.

6,235,502, 6,221,603, 6,210,884, 6,183,960, 5,854,033, 5,714,320, 5,648,245, and international patent publications WO 97/19193 and WO 00/15779, the disclosures of which are incorporated herein by reference in their entireties. Rolling circle amplification can be combined with other techniques to facilitate SNP detection. See, *e.g.*, Lizardi *et al.*, *Nature Genet.* 19(3):225-32 (1998).

As further described below, nucleic acids of the present invention, inserted into vectors that flank the nucleic acid insert with a phage promoter, such as T7, T3, or SP6 promoter, can be used to drive *in vitro* expression of RNA complementary to either strand of the nucleic acid of the present invention. The RNA can be used, *inter alia*, as a single-stranded probe, in cDNA-mRNA subtraction, or for *in vitro* translation.

As will be further discussed herein below, nucleic acids of the present invention that encode AMLP1 protein or portions thereof can be used, *inter alia*, to express the AMLP1 proteins or protein fragments, either alone, or as part of fusion proteins.

Expression can be from genomic nucleic acids of the present invention, or from transcript-derived nucleic acids of the present invention.

Where protein expression is effected from genomic DNA, expression will typically be effected in eukaryotic, typically mammalian, cells capable of splicing introns from the initial RNA transcript. Expression can be driven from episomal vectors, such as EBV-based vectors, or can be effected from genomic DNA integrated into a host cell chromosome. As will be more fully described below, where expression is from transcript-derived (or otherwise intron-less) nucleic acids of the present invention, expression can be effected in wide variety of prokaryotic or eukaryotic cells.

Expressed *in vitro*, the protein, protein fragment, or protein fusion can thereafter be isolated, to be used, *inter alia*, as a standard in immunoassays specific for the proteins, or protein isoforms, of the present invention; to be used as a therapeutic agent, *e.g.*, to be administered as passive replacement therapy in individuals deficient in the proteins of the present invention, or to be administered as a vaccine; to be used for *in vitro* production of specific antibody, the antibody thereafter to be used, *e.g.*, as an analytical reagent for detection and quantitation of the proteins of the present invention or to be used as an immunotherapeutic agent.

The isolated nucleic acids of the present invention can also be used to drive *in vivo* expression of the proteins of the present invention. *In vivo* expression can be driven from a vector – typically a viral vector, often a vector based upon a replication incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV) – for purpose of gene therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad CA, USA), for purpose of "naked" nucleic acid vaccination, as further described in U.S. Pat. Nos. 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; 6,204,250, the disclosures of which are incorporated herein by reference in their entireties.

The nucleic acids of the present invention can also be used for antisense inhibition of transcription or translation. *See* Phillips (ed.), Antisense Technology, Part B, Methods in Enzymology Vol. 314, Academic Press, Inc. (1999) (ISBN: 012182215X); Phillips (ed.), Antisense Technology, Part A, Methods in Enzymology Vol. 313,

Academic Press, Inc. (1999) (ISBN: 0121822141); Hartmann *et al.* (eds.), Manual of Antisense Methodology (Perspectives in Antisense Science), Kluwer Law International (1999) (ISBN:079238539X); Stein *et al.* (eds.), Applied Antisense Oligonucleotide Technology, Wiley-Liss (cover (1998) (ISBN: 0471172790); Agrawal *et al.* (eds.), Antisense Research and Application, Springer-Verlag New York, Inc. (1998) (ISBN: 3540638334); Lichtenstein *et al.* (eds.), Antisense Technology: A Practical Approach, Vol. 185, Oxford University Press, INC. (1998) (ISBN: 0199635838); Gibson (ed.), Antisense and Ribozyme Methodology: Laboratory Companion, Chapman & Hall (1997) (ISBN: 3826100794); Chadwick *et al.* (eds.), Oligonucleotides as Therapeutic Agents - Symposium No. 209, John Wiley & Son Ltd (1997) (ISBN: 0471972797), the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acids of the present invention, particularly cDNAs of the present invention, that encode full-length AMLP1 protein isoforms, have additional, well-recognized, immediate, real world utility as commercial products of manufacture suitable for sale.

For example, Invitrogen Corp. (Carlsbad, CA, USA), through its Research Genetics subsidiary, sells full length human cDNAs cloned into one of a selection of expression vectors as GeneStorm® expression-ready clones; utility is specific for the gene, since each gene is capable of being ordered separately and has a distinct catalogue number, and utility is substantial, each clone selling for $650.00 US. Similarly, Incyte Genomics (Palo Alto, CA, USA) sells clones from public and proprietary sources in multi-well plates or individual tubes.

Nucleic acids of the present invention that include genomic regions encoding the AMLP1 protein, or portions thereof, have yet further utilities.

For example, genomic nucleic acids of the present invention can be used as amplification substrates, *e.g.* for preparation of genome-derived single exon probes of the present invention, as described above and in copending and commonly-owned U.S. patent application nos. 09/864,761, filed May 23, 2001, 09/774,203, filed January 29, 2001, and 09/632,366, filed August 3, 2000, the disclosures of which are incorporated herein by reference in their entireties.

As another example, genomic nucleic acids of the present invention can be integrated non-homologously into the genome of somatic cells, *e.g.* CHO cells, COS cells, or 293 cells, with or without amplification of the insertional locus, in order, *e.g.*, to create stable cell lines capable of producing the proteins of the present invention.

As another example, more fully described herein below, genomic nucleic acids of the present invention can be integrated nonhomologously into embryonic stem (ES) cells to create transgenic non-human animals capable of producing the proteins of the present invention.

Genomic nucleic acids of the present invention can also be used to target homologous recombination to the AMLP1 locus. *See, e.g.*, U.S. Patent Nos. 6,187,305; 6,204,061; 5,631,153; 5,627,059; 5,487,992; 5,464,764; 5,614,396; 5,527,695 and 6,063,630; and Kmiec *et al.* (eds.), Gene Targeting Protocols, Vol. 133, Humana Press (2000) (ISBN: 0896033600); Joyner (ed.), Gene Targeting: A Practical Approach, Oxford University Press, Inc. (2000) (ISBN: 0199637938); Sedivy *et al.*, Gene Targeting, Oxford University Press (1998) (ISBN: 071677013X); Tymms *et al.* (eds.), Gene Knockout Protocols, Humana Press (2000) (ISBN: 0896035727); Mak *et al.* (eds.), The Gene Knockout FactsBook, Vol. 2, Academic Press, Inc. (1998) (ISBN: 0124660444); Torres *et al.*, Laboratory Protocols

for Conditional Gene Targeting, Oxford University Press (1997) (ISBN: 019963677X); Vega (ed.), Gene Targeting, CRC Press, LLC (1994) (ISBN: 084938950X), the disclosures of which are incorporated herein by reference in their entireties.

Where the genomic region includes transcription regulatory elements, homologous recombination can be used to alter the expression of AMLP1, both for purpose of *in vitro* production of AMLP1 protein from human cells, and for purpose of gene therapy. *See, e.g.*, U.S. Pat. Nos. 5,981,214, 6,048,524; 5,272,071.

Fragments of the nucleic acids of the present invention smaller than those typically used for homologous recombination can also be used for targeted gene correction or alteration, possibly by cellular mechanisms different from those engaged during homologous recombination.

For example, partially duplexed RNA/DNA chimeras have been shown to have utility in targeted gene correction, U.S. Pat. Nos. 5,945,339, 5,888,983, 5,871,984, 5,795,972, 5,780,296, 5,760,012, 5,756,325, 5,731,181, the disclosures of which are incorporated herein by reference in their entireties. So too have small oligonucleotides fused to triplexing domains have been shown to have utility in targeted gene correction, Culver *et al.*, "Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides," *Nature Biotechnol.* 17(10):989-93 (1999), as have oligonucleotides having modified terminal bases or modified terminal internucleoside bonds, Gamper *et al.*, *Nucl. Acids Res.* 28(21):4332-9 (2000), the disclosures of which are incorporated herein by reference.

The isolated nucleic acids of the present invention can also be used to provide the initial substrate for recombinant engineering of AMLP1 protein

variants having desired phenotypic improvements. Such engineering includes, for example, site-directed mutagenesis, random mutagenesis with subsequent functional screening, and more elegant schemes for recombinant evolution of proteins, as are described, *inter alia*, in U.S. Pat. Nos. 6,180,406; 6,165,793; 6,117,679; and 6,096,548, the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acids of the present invention can be obtained by using the labeled probes of the present invention to probe nucleic acid samples, such as genomic libraries, cDNA libraries, and mRNA samples, by standard techniques. Nucleic acids of the present invention can also be obtained by amplification, using the nucleic acid primers of the present invention, as further demonstrated in Example 1, herein below. Nucleic acids of the present invention of fewer than about 100 nt can also be synthesized chemically, typically by solid phase synthesis using commercially available automated synthesizers.

"Full Length" AMLP1 Nucleic Acids

In a first series of nucleic acid embodiments, the invention provides isolated nucleic acids that encode the entirety of the human AMLP1 protein. As discussed above, the "full-length" nucleic acids of the present invention can be used, *inter alia*, to express full length human AMLP1 protein. The full-length nucleic acids can also be used as nucleic acid probes; used as probes, the isolated nucleic acids of these embodiments will hybridize to human AMLP1.

In a first such embodiment, the invention provides an isolated nucleic acid comprising (i) the nucleotide sequence of SEQ ID NO: 1, or (ii) the

complement of (i). SEQ ID NO: 1 presents the entire cDNA of human AMLP1a, including the 5' untranslated (UT) region and 3' UT.

In a second embodiment, the invention provides an isolated nucleic acid comprising (i) the nucleotide sequence of SEQ ID NO: 2, (ii) a degenerate variant of the nucleotide sequence of SEQ ID NO: 2, or (iii) the complement of (i) or (ii). SEQ ID NO: 2 presents the open reading frame (ORF) from SEQ ID NO: 2.

In a third embodiment, the invention provides an isolated nucleic acid comprising (i) a nucleotide sequence that encodes a polypeptide with the amino acid sequence of SEQ ID NO: 3 or (ii) the complement of a nucleotide sequence that encodes a polypeptide with the amino acid sequence of SEQ ID NO: 3. SEQ ID NO: 3 provides the amino acid sequence of human AMLP1a.

In a fourth embodiment, the invention provides an isolated nucleic acid having a nucleotide sequence that (i) encodes a polypeptide having the sequence of SEQ ID NO: 3, (ii) encodes a polypeptide having the sequence of SEQ ID NO: 3 with conservative amino acid substitutions, or (iii) that is the complement of (i) or (ii), where SEQ ID NO: 3 provides the amino acid sequence of human AMLP1a.

In another such embodiment, the invention provides an isolated nucleic acid comprising (i) the nucleotide sequence of SEQ ID NO: 4, or (ii) the complement of (i). SEQ ID NO: 4 presents the entire cDNA of human AMLP1b, including the 5' untranslated (UT) region and 3' UT.

In another embodiment, the invention provides an isolated nucleic acid comprising (i) the nucleotide sequence of SEQ ID NO: 5, (ii) a degenerate variant of the nucleotide sequence of SEQ ID NO: 5, or (iii) the

complement of (i) or (ii). SEQ ID NO: 5 presents the open reading frame (ORF) from SEQ ID NO: 5.

In another embodiment, the invention provides an isolated nucleic acid comprising (i) a nucleotide sequence that encodes a polypeptide with the amino acid sequence of SEQ ID NO: 6 or (ii) the complement of a nucleotide sequence that encodes a polypeptide with the amino acid sequence of SEQ ID NO: 6. SEQ ID NO: 6 provides the amino acid sequence of human AMLP1a.

In another embodiment, the invention provides an isolated nucleic acid having a nucleotide sequence that (i) encodes a polypeptide having the sequence of SEQ ID NO: 6, (ii) encodes a polypeptide having the sequence of SEQ ID NO: 6 with conservative amino acid substitutions, or (iii) that is the complement of (i) or (ii), where SEQ ID NO: 6 provides the amino acid sequence of human AMLP1a.

Selected Partial Nucleic Acids

In a second series of nucleic acid embodiments, the invention provides isolated nucleic acids that encode select portions of human AMLP1. As will be further discussed herein below, these "partial" nucleic acids can be used, *inter alia*, to express specific portions of the human AMLP1. These "partial" nucleic acids can also be used, *inter alia*, as nucleic probes.

In a first such embodiment, the invention provides an isolated nucleic acid comprising (i) the nucleotide sequence of SEQ ID NO: 7, (ii) a degenerate variant of SEQ ID NO: 7, or (iii) the complement of (i) or (ii), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb length. SEQ ID NO: 7 encodes a novel portion of AMLP1.

Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

In another embodiment, the invention provides an isolated nucleic acid comprising (i) a nucleotide sequence that encodes SEQ ID NO: 8 or (ii) the complement of a nucleotide sequence that encodes SEQ ID NO: 8, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, frequently no more than about 50 kb in length. SEQ ID NO: 8 is the amino acid sequence encoded by the portion of AMLP1 not found in any EST fragments. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

In another embodiment, the invention provides an isolated nucleic acid comprising (i) a nucleotide sequence that encodes SEQ ID NO: 8, (ii) a nucleotide sequence that encodes SEQ ID NO: 8 with conservative substitititions, or (iii) the complement of (i) or (ii), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

In another such embodiment, the invention provides an isolated nucleic acid comprising (i) the nucleotide sequence of SEQ ID NO: 33, (ii) or the complement of (i), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than

about 50 kb length. SEQ ID NO: 33 encodes the novel exon of AMLP1b not found in AMLP1a or any EST sequences. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

Cross-Hybridizing Nucleic Acids

In another series of nucleic acid embodiments, the invention provides isolated nucleic acids that hybridize to various of the human AMLP1 nucleic acids of the present invention. These cross-hybridizing nucleic acids can be used, *inter alia*, as probes for, and to drive expression of, proteins that are related to human AMLP1 of the present invention as further isoforms, homologues, paralogues, or orthologues.

In a first such embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under high stringency conditions to a probe the nucleotide sequence of which consists of at least 17 nt, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, or 50 nt of SEQ ID NO: 7 or the complement of SEQ ID NO: 7, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

In a further embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under moderate stringency conditions to a probe the nucleotide sequence of which consists of at least 17 nt, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, or

50 nt of SEQ ID NO: 7 or the complement of SEQ ID NO: 7, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

In a further embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under high stringency conditions to a hybridization probe the nucleotide sequence of which (i) encodes a polypeptide having the sequence of SEQ ID NO: 8, (ii) encodes a polypeptide having the sequence of SEQ ID NO: 8 with conservative amino acid substitutions, or (iii) is the complement of (i) or (ii), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

In a first such embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under high stringency conditions to a probe the nucleotide sequence of which consists of at least 17 nt, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, or 50 nt of SEQ ID NO: 33 or the complement of SEQ ID NO: 33, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often

no more than about 15 kb in length, and frequently no more than about 10 kb in length.

In a further embodiment, the invention provides an isolated nucleic acid comprising a sequence that hybridizes under moderate stringency conditions to a probe the nucleotide sequence of which consists of at least 17 nt, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, or 50 nt of SEQ ID NO: 33 or the complement of SEQ ID NO: 33, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, and often no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

Particularly Useful Nucleic Acids

Particularly useful among the above-described nucleic acids are those that are expressed, or the complement of which are expressed, in brain, liver, kidney, and adrenal gland, as well as prostate, testis, lung, placenta, skeletal muscle, heart, bone marrow and colon tumor.

Also particularly useful among the above-described nucleic acids are those that encode, or the complement of which encode, a polypeptide as an adaptor protein that interacts with both angiostatin-like protein and components of the actin cytoskeleton and has anti-angiogenesis activity.

Other particularly useful embodiments of the nucleic acids above-described are those that encode, or the complement of which encode, a polypeptide having a partial Myosin-tail motif.

Nucleic Acid Fragments

In another series of nucleic acid embodiments, the invention provides fragments of various of the isolated nucleic acids of the present invention which prove useful, *inter alia*, as nucleic acid probes, as amplification primers, and to direct expression or synthesis of epitopic or immunogenic protein fragments.

In a first such embodiment, the invention provides an isolated nucleic acid comprising at least 17 nucleotides, 18 nucleotides, 20 nucleotides, 24 nucleotides, or 25 nucleotides of (i) SEQ ID NO: 7, (ii) a degenerate variant of SEQ ID NO: 7, or (iii) the complement of (i) or (ii), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

The invention also provides an isolated nucleic acid comprising (i) a nucleotide sequence that encodes a peptide of at least 8 contiguous amino acids of SEQ ID NO: 8, (ii) a nucleotide sequence that encodes a peptide of at least 15 contiguous amino acids of SEQ ID NO: 8, or (iii) the complement of (i) or (ii), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

The invention also provides an isolated nucleic acid comprising a nucleotide sequence that encodes (i) a

polypeptide having the sequence of at least 8 contiguous amino acids of SEQ ID NO: 8 with conservative amino acid substitutions, (ii) a polypeptide having the sequence of at least 15 contiguous amino acids of SEQ ID NO: 8 with nservative amino acid substitutions, (iii) a polypeptide having the sequence of at least 8 contiguous amino acids of SEQ ID NO: 8 with moderately conservative substitutions, (iv) a polypeptide having the sequence of at last 15 congiuous amino acids of SEQ ID NO: 8 with moderately conservative substitutions, or (v) the complement of any of (i) - (iv), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

In another such embodiment, the invention provides an isolated nucleic acid comprising at least 17 nucleotides, 18 nucleotides, 20 nucleotides, 24 nucleotides, or 25 nucleotides of (i) SEQ ID NO: 33, (ii) a degenerate variant of SEQ ID NO: 33, or (iii) the complement of (i) or (ii), wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

Single Exon Probes

The invention further provides genome-derived single exon probes having portions of no more than one

exon of the AMLP1 gene. As further described in commonly owned and copending U.S. patent application serial no. 09/632,366, filed August 3, 2000 ("Methods and Apparatus for High Throughput Detection and Characterization of alternatively Spliced Genes"), the disclosure of which is incorporated herein by reference in its entirety, such single exon probes have particular utility in identifying and characterizing splice variants. In particular, such single exon probes are useful for identifying and discriminating the expression of distinct isoforms of AMLP1.

In a first embodiment, the invention provides an isolated nucleic acid comprising a nucleotide sequence of no more than one portion of SEQ ID NOs: 9 - 20 and SEQ ID NO: 33 or the complement of SEQ ID NOs: 9 - 20 and SEQ ID NO: 33, wherein the portion comprises at least 17 contiguous nucleotides, 18 contiguous nucleotides, 20 contiguous nucleotides, 24 contiguous nucleotides, 25 contiguous nucleotides, or 50 contiguous nucleotides of any one of SEQ ID NOs: 9 - 22 and SEQ ID NO: 33, or their complement. In a further embodiment, the exonic portion comprises the entirety of the referenced SEQ ID NO: or its complement.

In other embodiments, the invention provides isolated single exon probes having the nucleotide sequence of any one of SEQ ID NOs: 21 - 32 and SEQ ID NO: 34.

Transcription Control Nucleic Acids

In another aspect, the present invention provides genome-derived isolated nucleic acids that include nucleic acid sequence elements that control transcription of the AMLP1 gene. These nucleic acids can be used, *inter alia*, to drive expression of heterologous

coding regions in recombinant constructs, thus conferring upon such heterologous coding regions the expression pattern of the native AMLP1 gene. These nucleic acids can also be used, conversely, to target heterologous transcription control elements to the AMLP1 genomic locus, altering the expression pattern of the AMLP1 gene itself.

In a first such embodiment, the invention provides an isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO: 35 or its complement, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

In another embodiment, the invention provides an isolated nucleic acid comprising at least 17, 18, 20, 24, or 25 nucleotides of the sequence of SEQ ID NO: 35 or its complement, wherein the isolated nucleic acid is no more than about 100 kb in length, typically no more than about 75 kb in length, more typically no more than about 50 kb in length. Often, the isolated nucleic acids of this embodiment are no more than about 25 kb in length, often no more than about 15 kb in length, and frequently no more than about 10 kb in length.

VECTORS AND HOST CELLS

In another aspect, the present invention provides vectors that comprise one or more of the isolated nucleic acids of the present invention, and host cells in which such vectors have been introduced.

The vectors can be used, *inter alia*, for propagating the nucleic acids of the present invention in host cells (cloning vectors), for shuttling the nucleic acids of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acids of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of the nucleic acids of the present invention *in vitro* or within a host cell, and for expressing polypeptides encoded by the nucleic acids of the present invention, alone or as fusions to heterologous polypeptides. Vectors of the present invention will often be suitable for several such uses.

Vectors are by now well-known in the art, and are described, *inter alia*, in Jones *et al.* (eds.), Vectors: Cloning Applications : Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd 1998 (ISBN: 047196266X); Jones *et al.* (eds.), Vectors: Expression Systems : Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd, 1998 (ISBN:0471962678); Gacesa *et al.*, Vectors: Essential Data, John Wiley & Sons, 1995 (ISBN: 0471948411); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co., 2000 (ISBN: 188129935X); Sambrook *et al.*, Molecular Cloning: A Laboratory Manual (3rd ed.), Cold Spring Harbor Laboratory Press, 2001 (ISBN: 0879695773); Ausubel *et al.* (eds.), Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology (4th ed.), John Wiley & Sons, 1999 (ISBN: 047132938X), the disclosures of which are incorporated herein by reference in their entireties. Furthermore, an enormous variety of vectors are available commercially. Use of existing vectors and modifications thereof being well within the

skill in the art, only basic features need be described here.

Typically, vectors are derived from virus, plasmid, prokaryotic or eukaryotic chromosomal elements, or some combination thereof, and include at least one origin of replication, at least one site for insertion of heterologous nucleic acid, typically in the form of a polylinker with multiple, tightly clustered, single cutting restriction sites, and at least one selectable marker, although some integrative vectors will lack an origin that is functional in the host to be chromosomally modified, and some vectors will lack selectable markers. Vectors of the present invention will further include at least one nucleic acid of the present invention inserted into the vector in at least one location.

Where present, the origin of replication and selectable markers are chosen based upon the desired host cell or host cells; the host cells, in turn, are selected based upon the desired application.

For example, prokaryotic cells, typically *E. coli*, are typically chosen for cloning. In such case, vector replication is predicated on the replication strategies of coliform-infecting phage – such as phage lambda, M13, T7, T3 and P1 – or on the replication origin of autonomously replicating episomes, notably the ColE1 plasmid and later derivatives, including pBR322 and the pUC series plasmids. Where *E. coli* is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: *e.g.*, typical markers confer resistance to antibiotics, such as ampicillin, tetracycline, chloramphenicol, kanamycin, streptomycin, zeocin; auxotrophic markers can also be used.

As another example, yeast cells, typically *S. cerevisiae*, are chosen, *inter alia*, for eukaryotic

genetic studies, due to the ease of targeting genetic changes by homologous recombination and to the ready ability to complement genetic defects using recombinantly expressed proteins, for identification of interacting protein components, *e.g.* through use of a two-hybrid system, and for protein expression. Vectors of the present invention for use in yeast will typically, but not invariably, contain an origin of replication suitable for use in yeast and a selectable marker that is functional in yeast.

Integrative YIp vectors do not replicate autonomously, but integrate, typically in single copy, into the yeast genome at low frequencies and thus replicate as part of the host cell chromosome; these vectors lack an origin of replication that is functional in yeast, although they typically have at least one origin of replication suitable for propagation of the vector in bacterial cells. YEp vectors, in contrast, replicate episomally and autonomously due to presence of the yeast 2 micron plasmid origin (2 μm ori). The YCp yeast centromere plasmid vectors are autonomously replicating vectors containing centromere sequences, CEN, and autonomously replicating sequences, ARS; the ARS sequences are believed to correspond to the natural replication origins of yeast chromosomes. YACs are based on yeast linear plasmids, denoted YLp, containing homologous or heterologous DNA sequences that function as telomeres (TEL) *in vivo*, as well as containing yeast ARS (origins of replication) and CEN (centromeres) segments.

Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific auxotrophic mutations, such as ura3-52, his3-D1, leu2-D1, trp1-D1 and lys2-201. The URA3 and LYS2 yeast genes further permit

negative selection based on specific inhibitors, 5-fluoro-orotic acid (FOA) and α-aminoadipic acid (αAA), respectively, that prevent growth of the prototrophic strains but allows growth of the ura3 and lys2 mutants, respectively. Other selectable markers confer resistance to, *e.g.*, zeocin.

As yet another example, insect cells are often chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda* – *e.g.*, Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA) – the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors are used to replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following cotransfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10 promoter. Selection can be based upon visual screening for lacZ fusion activity.

As yet another example, mammalian cells are often chosen for expression of proteins intended as pharmaceutical agents, and are also chosen as host cells for screening of potential agonist and antagonists of a protein or a physiological pathway.

Where mammalian cells are chosen as host cells, vectors intended for autonomous extrachromosomal replication will typically include a viral origin, such as the SV40 origin (for replication in cell lines expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for

long term episomal replication (for use, *e.g.*, in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A). Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an origin of replication functional in mammalian cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy.

Selectable markers for use in mammalian cells include resistance to neomycin (G418), blasticidin, hygromycin and to zeocin, and selection based upon the purine salvage pathway using HAT medium.

Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

For propagation of nucleic acids of the present invention that are larger than can readily be accomodated in vectors derived from plasmids or virus, the invention further provides artificial chromosomes – BACs, YACs, PACs, and HACs – that comprise AMLP1 nucleic acids, often genomic nucleic acids.

The BAC system is based on the well-characterized *E. coli* F-factor, a low copy plasmid that exists in a supercoiled circular form in host cells. The structural features of the F-factor allow stable maintenance of individual human DNA clones as well as easy manipulation of the cloned DNA. *See* Shizuya *et al.*, *Keio J. Med.* 50(1):26-30 (2001); Shizuya *et al.*, *Proc. Natl. Acad. Sci. USA* 89(18):8794-7 (1992).

YACs are based on yeast linear plasmids, denoted YLp, containing homologous or heterologous DNA

sequences that function as telomeres (TEL) *in vivo*, as well as containing yeast ARS (origins of replication) and CEN (centromeres) segments.

HACs are human artifical chromosomes. Kuroiwa *et al.*, *Nature Biotechnol.* 18(10):1086-90 (2000); Henning *et al.*, *Proc. Natl. Acad. Sci. USA* 96(2):592-7 (1999); Harrington *et al.*, *Nature Genet.* 15(4):345-55 (1997). In one version, long synthetic arrays of alpha satellite DNA are combined with telomeric DNA and genomic DNA to generate linear microchromosomes that are mitotically and cytogenetically stable in the absence of selection.

PACs are P1-derived artificial chromosomes. Sternberg, *Proc. Natl. Acad. Sci. USA* 87(1):103-7 (1990); Sternberg *et al.*, *New Biol.* 2(2):151-62 (1990); Pierce *et al.*, *Proc. Natl Acad. Sci. USA* 89(6):2056-60 (1992).

Vectors of the present invention will also often include elements that permit *in vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

Expression vectors of the present invention – that is, those vectors that will drive expression of polypeptides from the inserted heterologous nucleic acid – will often include a variety of other genetic elements operatively linked to the protein-encoding heterologous nucleic acid insert, typically genetic elements that drive transcription, such as promoters and enhancer elements, those that facilitate RNA processing, such as transcription termination and/or polyadenylation signals, and those that facilitate translation, such as ribosomal consensus sequences.

For example, vectors for expressing proteins of the present invention in prokaryotic cells, typically *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the trc promoter, a hybrid derived from the trp and lac promoters, the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), or the araBAD operon. Often, such prokaryotic expression vectors will further include transcription terminators, such as the aspA terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon, Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83:8506-8510 (1986).

As another example, vectors for expressing proteins of the present invention in yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the CYC1 promoter, the GAL1 promoter, ADH1 promoter, or the GPD promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the CYC1 or ADH1 gene.

As another example, vectors for expressing proteins of the present invention in mammalian cells will include a promoter active in mammalian cells. Such promoters are often drawn from mammalian viruses – such as the enhancer-promoter sequences from the immediate early gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), and the enhancer-promoter from SV40. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include introns, such as intron

II of rabbit β-globin gene and the SV40 splice elements.

Vector-drive protein expression can be constitutive or inducible.

Inducible vectors include either naturally inducible promoters, such as the trc promoter, which is regulated by the lac operon, and the pL promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid Plac/ara-1 promoter and the PLtetO-1 promoter. The PltetO-1 promoter takes advantage of the high expression levels from the PL promoter of phage lambda, but replaces the lambda repressor sites with two copies of operator 2 of the Tn10 tetracycline resistance operon, causing this promoter to be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline.

As another example of inducible elements, hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), can confer hormone inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

Expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or visualization.

For example, proteins of the present invention can be expressed with a polyhistidine tag that facilitates purification of the fusion protein by

immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography medium, Clontech Labs, Palo Alto, CA, USA). As another example, the fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverley, MA, USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically excisable fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, WI, USA). As another useful alternative, the proteins of the present invention can be expressed as a fusion to glutathione-S-transferase, the affinity and specificity of binding to glutathione permitting purification using glutathione affinity resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione.

Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, CA, USA), and the HA epitope.

For secretion of expressed proteins, vectors can include appropriate sequences that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2

kb mammalian expression vectors that carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

Expression vectors can also be designed to fuse proteins encoded by the heterologous nucleic acid insert to polypeptides larger than purification and/or identification tags. Useful protein fusions include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusions for use in two hybrid systems.

Vectors for phage display fuse the encoded polypeptide to, *e.g.*, the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. *See* Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001) (ISBN 0-87969-546-3); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, San Diego: Academic Press, Inc., 1996; Abelson *et al.* (eds.), Combinatorial Chemistry, Methods in Enzymology vol. 267, Academic Press (May 1996).

Vectors for yeast display, *e.g.* the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the α-agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S. cerevisiae*. Vectors for mammalian display, *e.g.*, the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface targeting signal and a C-terminal transmembrane anchoring domain of platelet derived growth factor receptor.

A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. These proteins are intrinsically fluorescent: the GFP-like chromophore is entirely encoded by its amino acid sequence and can fluoresce without requirement for cofactor or substrate.

Structurally, the GFP-like chromophore comprises an 11-stranded β-barrel (β-can) with a central α-helix, the central α-helix having a conjugated π-resonance system that includes two aromatic ring systems and the bridge between them. The π-resonance system is created by autocatalytic cyclization among amino acids; cyclization proceeds through an imidazolinone intermediate, with subsequent dehydrogenation by molecular oxygen at the Cα-Cβ bond of a participating tyrosine.

The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. Li *et al.*,"Deletions of the *Aequorea victoria* Green Fluorescent Protein Define the Minimal Domain Required for Fluorescence," *J. Biol. Chem.* 272:28545-28549 (1997).

Alternatively, the GFP-like chromophore can be selected from GFP-like chromophores modified from those

found in nature. Typically, such modifications are made to improve recombinant production in heterologous expression systems (with or without change in protein sequence), to alter the excitation and/or emission spectra of the native protein, to facilitate purification, to facilitate or as a consequence of cloning, or are a fortuitous consequence of research investigation.

The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of protein fusions, are well-known in the art. Early results of these efforts are reviewed in Heim *et al.*, *Curr. Biol.* 6:178-182 (1996), incorporated herein by reference in its entirety; a more recent review, with tabulation of useful mutations, is found in Palm *et al.*, "Spectral Variants of Green Fluorescent Protein," in Green Fluorescent Proteins, Conn (ed.), *Methods Enzymol.* vol. 302, pp. 378 - 394 (1999), incorporated herein by reference in its entirety. A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention.

For example, EGFP ("enhanced GFP"), Cormack *et al.*, *Gene* 173:33-38 (1996); U.S. Pat. Nos. 6,090,919 and 5,804,387, is a red-shifted, human codon-optimized variant of GFP that has been engineered for brighter fluorescence, higher expression in mammalian cells, and for an excitation spectrum optimized for use in flow cytometers. EGFP can usefully contribute a GFP-like chromophore to the fusion proteins of the present invention. A variety of EGFP vectors, both plasmid and viral, are available commercially (Clontech Labs, Palo Alto, CA, USA), including vectors for bacterial expression, vectors for N-terminal protein fusion

expression, vectors for expression of C-terminal protein fusions, and for bicistronic expression.

Toward the other end of the emission spectrum, EBFP ("enhanced blue fluorescent protein") and BFP2 contain four amino acid substitutions that shift the emission from green to blue, enhance the brightness of fluorescence and improve solubility of the protein, Heim *et al.*, *Curr. Biol.* 6:178-182 (1996); Cormack *et al.*, *Gene* 173:33-38 (1996). EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria; as is further discussed below, the host cell of production does not affect the utility of the resulting fusion protein. The GFP-like chromophores from EBFP and BFP2 can usefully be included in the fusion proteins of the present invention, and vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, CA, USA).

Analogously, EYFP ("enhanced yellow fluorescent protein"), also available from Clontech Labs, contains four amino acid substitutions, different from EBFP, Ormö *et al.*, *Science* 273:1392-1395 (1996), that shift the emission from green to yellowish-green. Citrine, an improved yellow fluorescent protein mutant, is described in Heikal *et al.*, *Proc. Natl. Acad. Sci. USA* 97:11996-12001 (2000). ECFP ("enhanced cyan fluorescent protein") (Clontech Labs, Palo Alto, CA, USA) contains six amino acid substitutions, one of which shifts the emission spectrum from green to cyan. Heim *et al.*, *Curr. Biol.* 6:178-182 (1996); Miyawaki *et al.*, *Nature* 388:882-887 (1997). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

The GFP-like chromophore can also be drawn from other modified GFPs, including those described in U.S.

Pat. Nos. 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. See also Conn (ed.), Green Fluorescent Protein, *Methods in Enzymol*. Vol. 302, pp 378-394 (1999), incorporated herein by reference in its entirety. A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention.

Fusions to the IgG Fc region increase serum half life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in international patent application nos. WO 97/43316, WO 97/34631, WO 96/32478, WO 96/18412.

For long-term, high-yield recombinant production of the proteins, protein fusions, and protein fragments of the present invention, stable expression is particularly useful.

Stable expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection for integrants.

For example, the pUB6/V5-His A, B, and C vectors (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and cell lines. pUB6/V5-His uses the promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The bsd gene permits rapid selection of stably transfected mammalian cells with the potent antibiotic blasticidin.

Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, prove particularly useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines – such as RetroPack™ PT 67, EcoPack2™-293, AmphoPack-293, GP2-293 cell lines (all available from Clontech Laboratories, Palo Alto, CA, USA) – allow a wide host range to be infected with high efficiency; varying the multiplicity of infection readily adjusts the copy number of the integrated provirus. Retroviral vectors are available with a variety of selectable markers, such as resistance to neomycin, hygromycin, and puromycin, permitting ready selection of stable integrants.

The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into the host cell chromosome.

Among other considerations, some of which are described above, a host cell strain may be chosen for its ability to process the expressed protein in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation, and it is an aspect of the present invention to provide AMLP1 proteins with such post-translational modifications.

As noted earlier, host cells can be prokaryotic or eukaryotic. Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast

cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from *Spodoptera frugiperda* – *e.g.*, Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA) – *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include COS1 and COS7 cells, chinese hamster ovary (CHO) cells, NIH 3T3 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, murine ES cell lines (*e.g.*, from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562, Jurkat cells, and BW5147. Other mammalian cell lines are well known and readily available from the American Type Culture Collection (Manassas, VA, USA) and the National Institute of General medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA).

Methods for introducing the vectors and nucleic acids of the present invention into the host cells are well known in the art; the choice of technique will depend primarily upon the specific vector to be introduced and the host cell chosen.

For example, phage lambda vectors will typically be packaged using a packaging extract (*e.g.*, Gigapack® packaging extract, Stratagene, La Jolla, CA, USA), and the packaged virus used to infect *E. coli*. Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells.

E. coli cells can be rendered chemically competent by treatment, *e.g.*, with $CaCl_2$, or a solution of Mg^{2+}, Mn^{2+}, Ca^{2+}, Rb^{+} or K^{+}, dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced

by heat shock. A wide variety of chemically competent strains are also available commercially (*e.g.*, Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5α competent cells (Clontech Laboratories, Palo Alto, CA, USA); TOP10 Chemically Competent E. coli Kit (Invitrogen, Carlsbad, CA, USA)).

Bacterial cells can be rendered electrocompetent – that is, competent to take up exogenous DNA by electroporation – by various pre-pulse treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided online in Electroprotocols (BioRad, Richmond, CA, USA) (http://www.bio-rad.com/LifeScience/pdf/New_Gene_Pulser.pdf).

Vectors can be introduced into yeast cells by spheroplasting, treatment with lithium salts, electroporation, or protoplast fusion.

Spheroplasts are prepared by the action of hydrolytic enzymes – a snail-gut extract, usually denoted Glusulase, or Zymolyase, an enzyme from *Arthrobacter luteus* – to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol (PEG) and Ca^{2+}. Subsequently, the cells are resuspended in a solution of sorbitol, mixed with molten agar and then layered on the surface of a selective plate containing sorbitol. For lithium-mediated transformation, yeast cells are treated with lithium acetate, which apparently permeabilizes the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of PEG and lithium acetate, and subsequently spread on plates containing ordinary selective medium. Increased

frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6):339-46 (1989). For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194:182-7 (1991). The efficiency of transformation by electroporation can be increased over 100-fold by using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means.

For chemical transfection, DNA can be coprecipitated with $CaPO_4$ or introduced using liposomal and nonliposomal lipid-based agents. Commercial kits are available for $CaPO_4$ transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN® Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent, FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA). Protocols for electroporating mammalian cells can be found online in Electroprotocols (Bio-Rad, Richmond, CA, USA)

(http://www.bio-rad.com/LifeScience/pdf/New_Gene_Pulser.pdf). *See also*, Norton *et al.* (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000) (ISBN 1-881299-34-1), incorporated herein by reference in its entirety.

Other transfection techniques include transfection by particle embardment. *See, e.g.*, Cheng *et al.*, *Proc. Natl. Acad. Sci. USA* 90(10):4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA* 87(24):9568-72 (1990).

PROTEINS

In another aspect, the present invention provides AMLP1 proteins, various fragments thereof suitable for use as antigens (*e.g.*, for epitope mapping) and for use as immunogens (e.g., for raising antibodies or as vaccines), fusions of AMLP1 polypeptides and fragments to heterologous polypeptides, and conjugates of the proteins, fragments, and fusions of the present invention to other moieties (*e.g.*, to carrier proteins, to fluorophores).

FIG. 3 and FIG. 4 presents the predicted amino acid sequences encoded by the AMLP1a and AMLP1b cDNA clones, respectively. The amino acid sequences are further presented, respectively, in SEQ ID NO: 3 and SEQ ID NO: 6.

Unless otherwise indicated, amino acid sequences of the proteins of the present invention were determined as a predicted translation from a nucleic acid sequence. Accordingly, any amino acid sequence presented herein may contain errors due to errors in the nucleic acid sequence, as described in detail above.

Furthermore, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes - more than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409:860 - 921 (2001) - and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Small deletions and insertions can often be found that do not alter the function of the protein.

Accordingly, it is an aspect of the present invention to provide proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins at least about 65% identical in sequence to those described with particularity herein, typically at least about 70%, 75%, 80%, 85%, or 90% identical in sequence to those described with particularity herein, usefully at least about 91%, 92%, 93%, 94%, or 95% identical in sequence to those described with particularity herein, usefully at least about 96%, 97%, 98%, or 99% identical in sequence to those described with particularity herein, and, most conservatively, at least about 99.5%, 99.6%, 99.7%, 99.8% and 99.9% identical in sequence to those described with particularity herein. These sequence variants can be naturally occurring or can result from human intervention by way of random or directed mutagenesis.

For purposes herein, percent identity of two amino acid sequences is determined using the procedure of Tatiana *et al.*, "Blast 2 sequences - a new tool for comparing protein and nucleotide sequences", *FEMS Microbiol Lett.* 174:247-250 (1999), which procedure is effectuated by the computer program BLAST 2 SEQUENCES, available online at

http://www.ncbi.nlm.nih.gov/blast/bl2seq/bl2.html,

To assess percent identity of amino acid sequences, the BLASTP module of BLAST 2 SEQUENCES is used with default values of (i) BLOSUM62 matrix, Henikoff *et al.*, *Proc. Natl. Acad. Sci USA* 89(22):10915-9 (1992); (ii) open gap 11 and extension gap 1 penalties; and (iii) gap x_dropoff 50 expect 10 word size 3 filter, and both sequences are entered in their entireties.

As is well known, amino acid substitutions occur frequently among natural allelic variants, with conservative substitutions often occasioning only *de minimis* change in protein function.

Accordingly, it is an aspect of the present invention to provide proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins having the sequence of AMLP1 proteins, or portions thereof, with conservative amino acid substitutions. It is a further aspect to provide isolated proteins having the sequence of AMLP1 proteins, and portions thereof, with moderately conservative amino acid substitutions. These conservatively-substituted and moderately conservatively-substituted variants can be naturally occurring or can result from human intervention.

Although there are a variety of metrics for calling conservative amino acid substitutions, based primarily on either observed changes among evolutionarily related proteins or on predicted chemical similarity, for purposes herein a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix reproduced herein below (*see* Gonnet *et al.*, *Science* 256(5062):1443-5 (1992)):

	A	R	N	D	C	Q	E	G	H	I	L	K	M	F	P	S	T	W	Y	V
A	2	-1	0	0	0	0	0	0	-1	-1	-1	0	-1	-2	0	1	1	-4	-2	0

R	-1	5	0	0	-2	2	0	-1	1	-2	-2	3	-2	-3	-1	0	0	-2	-2	-2
N	0	0	4	2	-2	1	1	0	1	-3	-3	1	-2	-3	-1	1	0	-4	-1	-2
D	0	0	2	5	-3	1	3	0	0	-4	-4	0	-3	-4	-1	0	0	-5	-3	-3
C	0	-2	-2	-3	12	-2	-3	-2	-1	-1	-2	-3	-1	-1	-3	0	0	-1	0	0
Q	0	2	1	1	-2	3	2	-1	1	-2	-2	2	-1	-3	0	0	0	-3	-2	-2
E	0	0	1	3	-3	2	4	-1	0	-3	-3	1	-2	-4	0	0	0	-4	-3	-2
G	0	-1	0	0	-2	-1	-1	7	-1	-4	-4	-1	-4	-5	-2	0	-1	-4	-4	-3
H	-1	1	1	0	-1	1	0	-1	6	-2	-2	1	-1	0	-1	0	0	-1	2	-2
I	-1	-2	-3	-4	-1	-2	-3	-4	-2	4	3	-2	2	1	-3	-2	-1	-2	-1	3
L	-1	-2	-3	-4	-2	-2	-3	-4	-2	3	4	-2	3	2	-2	-2	-1	-1	0	2
K	0	3	1	0	-3	2	1	-1	1	-2	-2	3	-1	-3	-1	0	0	-4	-2	-2
M	-1	-2	-2	-3	-1	-1	-2	-4	-1	2	3	-1	4	2	-2	-1	-1	-1	0	2
F	-2	-3	-3	-4	-1	-3	-4	-5	0	1	2	-3	2	7	-4	-3	-2	4	5	0
P	0	-1	-1	-1	-3	0	0	-2	-1	-3	-2	-1	-2	-4	8	0	0	-5	-3	-2
S	1	0	1	0	0	0	0	0	0	-2	-2	0	-1	-3	0	2	2	-3	-2	-1
T	1	0	0	0	0	0	0	-1	0	-1	-1	0	-1	-2	0	2	2	-4	-2	0
W	-4	-2	-4	-5	-1	-3	-4	-4	-1	-2	-1	-4	-1	4	-5	-3	-4	14	4	-3
Y	-2	-2	-1	-3	0	-2	-3	-4	2	-1	0	-2	0	5	-3	-2	-2	4	8	-1
V	0	-2	-2	-3	0	-2	-2	-3	-2	3	2	-2	2	0	-2	-1	0	-3	-1	3

For purposes herein, a "moderately conservative" replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix reproduced herein above.

As is also well known in the art, relatedness of proteins can also be characterized using a functional test, the ability of the encoding nucleic acids to base-pair to one another at defined hybridization stringencies.

It is, therefore, another aspect of the invention to provide isolated proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins ("hybridization related proteins") that are encoded by nucleic acids that hybridize under high stringency conditions (as defined herein above) to all or to a portion of various of the isolated nucleic acids of the present invention ("reference nucleic acids"). It is a further aspect of the invention to provide isolated proteins

("hybridization related proteins") that are encoded by nucleic acids that hybridize under moderate stringency conditions (as defined herein above) to all or to a portion of various of the isolated nucleic acids of the present invention ("reference nucleic acids").

The hybridization related proteins can be alternative isoforms, homologues, paralogues, and orthologues of the AMLP1 protein of the present invention. Particularly useful orthologues are those from other primate species, such as chimpanzee, rhesus macaque monkey, baboon, orangutan, and gorilla, from rodents, such as rats, mice, guinea pigs; from lagomorphs, such as rabbits, and from domestic livestock, such as cow, pig, sheep, horse, and goat.

Relatedness of proteins can also be characterized using a second functional test, the ability of a first protein competitively to inhibit the binding of a second protein to an antibody.

It is, therefore, another aspect of the present invention to provide isolated proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins ("cross-reactive proteins") that competitively inhibit the binding of antibodies to all or to a portion of various of the isolated AMLP1 proteins of the present invention ("reference proteins"). Such competitive inhibition can readily be determined using immunoassays well known in the art.

Among the proteins of the present invention that differ in amino acid sequence from those described with particularity herein – including those that have deletions and insertions causing up to 10% non-identity, those having conservative or moderately conservative substitutions, hybridization related proteins, and cross-reactive proteins – those that substantially retain one

or more AMLP1 activities are particularly useful. As described above, AMLP1 plays a role similar to that of angiomotin as an adaptor protein that interacts with both angiostatin-like protein and components of the actin cytoskeleton and has anti-angiogenesis activity.

Residues that are tolerant of change while retaining function can be identified by altering the protein at known residues using methods known in the art, such as alanine scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908):1081-5 (1989); transposon linker scanning mutagenesis, Chen *et al.*, *Gene* 263(1-2):39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin *et al.*, J. Mol. Biol. 226(3):851-65 (1992); combinatorial alanine scanning, Weiss *et al.*, Proc. Natl. Acad. Sci USA 97(16):8950-4 (2000), followed by functional assay. Transposon linker scanning kits are available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-102S; EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, Epicentre Technologies Corporation, Madison, WI, USA).

As further described below, the isolated proteins of the present invention can readily be used as specific immunogens to raise antibodies that specifically recognize AMLP1 proteins, their isoforms, homologues, paralogues, and/or orthologues. The antibodies, in turn, can be used, *inter alia*, specifically to assay for the AMLP1 proteins of the present invention – *e.g.* by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning cytometry, for detection of protein in tissue samples, or by flow cytometry, for detection of intracellular protein in cell suspensions – for specific antibody-mediated isolation and/or purification of AMLP1 proteins, as for example by

immunoprecipitation, and for use as specific agonists or antagonists of AMLP1 action.

The isolated proteins of the present invention are also immediately available for use as specific standards in assays used to determine the concentration and/or amount specifically of the AMLP1 proteins of the present invention. As is well known, ELISA kits for detection and quantitation of protein analytes typically include isolated and purified protein of known concentration for use as a measurement standard (*e.g.*, the human interferon-γ OptEIA kit, catalog no. 555142, Pharmingen, San Diego, CA, USA includes human recombinant gamma interferon, baculovirus produced).

The isolated proteins of the present invention are also immediately available for use as specific biomolecule capture probes for surface-enhanced laser desorption ionization (SELDI) detection of protein-protein interactions, WO 98/59362; WO 98/59360; WO 98/59361; and Merchant *et al.*, *Electrophoresis* 21(6):1164-77 (2000), the disclosures of which are incorporated herein by reference in their entireties. Analogously, the isolated proteins of the present invention are also immediately available for use as specific biomolecule capture probes on BIACORE surface plasmon resonance probes. . *See* Weinberger *et al.*, *Pharmacogenomics* 1(4):395-416 (2000); Malmqvist, *Biochem. Soc. Trans.* 27(2):335-40 (1999).

The isolated proteins of the present invention are also useful as a therapeutic supplement in patients having a specific deficiency in AMLP1 production.

In another aspect, the invention also provides fragments of various of the proteins of the present invention. The protein fragments are useful, *inter alia*, as antigenic and immunogenic fragments of AMLP1.

By "fragments" of a protein is here intended isolated proteins (equally, polypeptides, peptides, oligopeptides), however obtained, that have an amino acid sequence identical to a portion of the reference amino acid sequence, which portion is at least 6 amino acids and less than the entirety of the reference nucleic acid. As so defined, "fragments" need not be obtained by physical fragmentation of the reference protein, although such provenance is not thereby precluded.

Fragments of at least 6 contiguous amino acids are useful in mapping B cell and T cell epitopes of the reference protein. *See, e.g.*, Geysen *et al.*, "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid," *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984) and U.S. Pat. Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of the proteins of the present invention have utility in such a study.

Fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, have utility as immunogens for raising antibodies that recognize the proteins of the present invention. *See, e.g.*, Lerner, "Tapping the immunological repertoire to produce antibodies of predetermined specificity," Nature 299:592-596 (1982); Shinnick *et al.*, "Synthetic peptide immunogens as vaccines," *Annu. Rev. Microbiol.* 37:425-46 (1983); Sutcliffe *et al.*, "Antibodies that react with predetermined sites on proteins," *Science* 219:660-6 (1983), the disclosures of which are incorporated herein by reference in their entireties. As further described in the above-cited references, virtually all 8-mers,

conjugated to a carrier, such as a protein, prove immunogenic – that is, prove capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the proteins of the present invention have utility as immunogens.

Fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as competitive inhibitors of binding of the entire protein, or a portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein; this competitive inhibition permits identification and separation of molecules that bind specifically to the protein of interest, U.S. Pat. Nos. 5,539,084 and 5,783,674, incorporated herein by reference in their entireties.

The protein, or protein fragment, of the present invention is thus at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15 amino acids in length. Often, the protein or the present invention, or fragment thereof, is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids, or 50 amino acids or more in length. Of course, larger fragments having at least 75 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

The present invention further provides fusions of each of the proteins and protein fragments of the present invention to heterologous polypeptides.

By fusion is here intended that the protein or protein fragment of the present invention is linearly contiguous to the heterologous polypeptide in a peptide-bonded polymer of amino acids or amino acid analogues; by "heterologous polypeptide" is here intended a polypeptide that does not naturally occur in contiguity with the

protein or protein fragment of the present invention. As so defined, the fusion can consist entirely of a plurality of fragments of the AMLP1 protein in altered arrangement; in such case, any of the AMLP1 fragments can be considered heterologous to the other AMLP1 fragments in the fusion protein. More typically, however, the heterologous polypeptide is not drawn from the AMLP1 protein itself.

The fusion proteins of the present invention will include at least one fragment of the protein of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the protein of the present to be included in the fusion can usefully be at least 25 amino acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of the proteins of the present invention have particular utility.

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and usefully at least 15, 20, and 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP chromophore-containing proteins), have particular utility.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated herein by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of recombinantly-expressed proteins. Although purification tags can also be incorporated into

fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so included render the fusion proteins of the present invention useful as directly detectable markers of AMLP1 presence.

As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins – into the periplasmic space or extracellular milieu for prokaryotic hosts, into the culture medium for eukaryotic cells – through incorporation of secretion signals and/or leader sequences.

Other useful protein fusions of the present invention include those that permit use of the protein of the present invention as bait in a yeast two-hybrid system. *See* Bartel *et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997) (ISBN: 0195109384); Zhu *et al.*, Yeast Hybrid Technologies, Eaton Publishing, (2000) (ISBN 1-881299-15-5); Fields *et al.*, *Trends Genet.* 10(8):286-92 (1994); Mendelsohn *et al.*, *Curr. Opin. Biotechnol.* 5(5):482-6 (1994); Luban *et al.*, *Curr. Opin. Biotechnol.* 6(1):59-64 (1995); Allen *et al.*, Trends Biochem. Sci. 20(12):511-6 (1995); Drees, *Curr. Opin. Chem. Biol.* 3(1):64-70 (1999); Topcu *et al.*, *Pharm. Res.* 17(9):1049-55 (2000); Fashena et al., Gene 250(1-2):1-14 (2000), the disclosures of which are incorporated herein by reference in their entireties. Typically, such fusion is to either *E. coli* LexA or yeast GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful protein fusions include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above, which discussion is incorporated here by reference in its entirety.

The proteins and protein fragments of the present invention can also usefully be fused to protein toxins, such as Pseudomonas exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

The isolated proteins, protein fragments, and protein fusions of the present invention can be composed of natural amino acids linked by native peptide bonds, or can contain any or all of nonnatural amino acid analogues, nonnative bonds, and post-synthetic (post translational) modifications, either throughout the length of the protein or localized to one or more portions thereof.

As is well known in the art, when the isolated protein is used, *e.g.*, for epitope mapping, the range of such nonnatural analogues, nonnative inter-residue bonds, or post-synthesis modifications will be limited to those that permit binding of the peptide to antibodies. When used as an immunogen for the preparation of antibodies in a non-human host, such as a mouse, the range of such nonnatural analogues, nonnative inter-residue bonds, or post-synthesis modifications will be limited to those that do not interfere with the immunogenicity of the protein. When the isolated protein is used as a therapeutic agent, such as a vaccine or for replacement therapy, the range of such changes will be limited to

those that do not confer toxicity upon the isolated protein.

Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common.

Solid phase chemical synthesis of peptides is well established in the art. Procedures are described, inter alia, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000) (ISBN: 0199637245); Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (August 1992) (ISBN: 0198556683); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (December 1993) (ISBN: 0387564314), the disclosures of which are incorporated herein by reference in their entireties.

For example, D-enantiomers of natural amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-enantiomers can also be used to confer specific three dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (Kole *et al.*, *Biochem. Biophys. Res. Com.* 209:817-821 (1995)), and various halogenated phenylalanine derivatives.

Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide a labeled polypeptide.

Biotin, for example (indirectly detectable through interaction with avidin, streptavidin,

neutravidin, captavidin, or anti-biotin antibody), can be added using biotinoyl--(9-fluorenylmethoxycarbonyl)-L-lysine (FMOC biocytin) (Molecular Probes, Eugene, OR, USA). (Biotin can also be added enzymatically by incorporation into a fusion protein of a *E. coli* BirA substrate peptide.)

The FMOC and *t*BOC derivatives of dabcyl-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate the dabcyl chromophore at selected sites in the peptide sequence during synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyl quencher in fluorescence resonance energy transfer (FRET) systems, can be introduced during automated synthesis of peptides by using EDANS--FMOC-L-glutamic acid or the corresponding *t*BOC derivative (both from Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be incorporated during automated FMOC synthesis of peptides using (FMOC)--TMR-L-lysine (Molecular Probes, Inc. Eugene, OR, USA).

Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.

A large number of other FMOC-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially, including, *e.g.*, Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-bicyclo[2.2.1]hept-5-ene-2-endo-carboxylic

acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-aminobenzoyl)-b-alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmoc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-?-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid, all available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by

chemical aminoacylation with the desired unnatural amino acid and. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9):4780-5 (1999); Wang *et al.*, *Science* 292(5516):498-500 (2001).

The isolated proteins, protein fragments and fusion proteins of the present invention can also include nonnative inter-residue bonds, including bonds that lead to circular and branched forms.

The isolated proteins and protein fragments of the present invention can also include post-translational and post-synthetic modifications, either throughout the length of the protein or localized to one or more portions thereof.

For example, when produced by recombinant expression in eukaryotic cells, the isolated proteins, fragments, and fusion proteins of the present invention will typically include N-linked and/or O-linked glycosylation, the pattern of which will reflect both the availability of glycosylation sites on the protein sequence and the identity of the host cell. Further modification of glycosylation pattern can be performed enzymatically.

As another example, recombinant polypeptides of the invention may also include an initial modified methionine residue, in some cases resulting from host-mediated processes.

When the proteins, protein fragments, and protein fusions of the present invention are produced by

chemical synthesis, post-synthetic modification can be performed before deprotection and cleavage from the resin or after deprotection and cleavage. Modification before deprotection and cleavage of the synthesized protein often allows greater control, *e.g.* by allowing targeting of the modifying moiety to the N-terminus of a resin-bound synthetic peptide.

Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores.

A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA), *e.g.*, offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue,

Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA).

The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents.

Common homobifunctional reagents include, *e.g.*, APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA); common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMPA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available Pierce, Rockford, IL, USA).

The proteins, protein fragments, and protein fusions of the present invention can be conjugated, using such cross-linking reagents, to fluorophores that are not amine- or thiol-reactive.

Other labels that usefully can be conjugated to the proteins, protein fragments, and fusion proteins of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

The proteins, protein fragments, and protein fusions of the present invention can also usefully be conjugated using cross-linking agents to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-AMLP1 antibodies.

The proteins, protein fragments, and protein fusions of the present invention can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum half life of proteins administered intravenously for replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4):249-304 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6):423-38 (1998); DeSantis *et al.*, *Curr. Opin. Biotechnol.* 10(4):324-30 (1999), incorporated herein by reference in their entireties. PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild conditions.

The isolated proteins of the present invention, including fusions thereof, can be produced by recombinant expression, typically using the expression vectors of the present invention as above-described or, if fewer than about 100 amino acids, by chemical synthesis (typically, solid phase synthesis), and, on occasion, by *in vitro* translation.

Production of the isolated proteins of the present invention can optionally be followed by purification.

Purification of recombinantly expressed proteins is now well within the skill in the art. *See, e.g.*, Thorner *et al.* (eds.), Applications of Chimeric Genes and Hybrid Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Volume 326),

Academic Press (2000), (ISBN: 0121822273); Harbin (ed.), Cloning, Gene Expression and Protein Purification : Experimental Procedures and Process Rationale, Oxford Univ. Press (2001) (ISBN: 0195132947); Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996) (ISBN: 0-87969-385-1); and Roe (ed.), Protein Purification Applications, Oxford University Press (2001), the disclosures of which are incorporated herein by reference in their entireties, and thus need not be detailed here.

Briefly, however, if purification tags have been fused through use of an expression vector that appends such tag, purification can be effected, at least in part, by means appropriate to the tag, such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high performance liquid chromatography (HPLC), and preparative gel electrophoresis.

Purification of chemically-synthesized peptides can readily be effected, *e.g.*, by HPLC.

Accordingly, it is an aspect of the present invention to provide the isolated proteins of the present invention in pure or substantially pure form.

A purified protein of the present invention is an isolated protein, as above described, that is present at a concentration of at least 95%, as measured on a weight basis (w/w) with respect to total protein in a composition. Such purities can often be obtained during chemical synthesis without further purification, as, *e.g.*, by HPLC. Purified proteins of the present invention can be present at a concentration (measured on a weight basis with respect to total protein in a

composition) of 96%, 97%, 98%, and even 99%. The proteins of the present invention can even be present at levels of 99.5%, 99.6%, and even 99.7%, 99.8%, or even 99.9% following purification, as by HPLC.

Although high levels of purity are particularly useful when the isolated proteins of the present invention are used as therapeutic agents – such as vaccines, or for replacement therapy – the isolated proteins of the present invention are also useful at lower purity. For example, partially purified proteins of the present invention can be used as immunogens to raise antibodies in laboratory animals.

Thus, in another aspect, the present invention provides the isolated proteins of the present invention in substantially purified form. A "substantially purified protein" of the present invention is an isolated protein, as above described, present at a concentration of at least 70%, measured on a weight basis with respect to total protein in a composition. Usefully, the substantially purified protein is present at a concentration, measured on a weight basis with respect to total protein in a composition, of at least 75%, 80%, or even at least 85%, 90%, 91%, 92%, 93%, 94%, 94.5% or even at least 94.9%.

In preferred embodiments, the purified and substantially purified proteins of the present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

The proteins, fragments, and fusions of the present invention can usefully be attached to a substrate. The substrate can porous or solid, planar or non-planar; the bond can be covalent or noncovalent.

For example, the proteins, fragments, and fusions of the present invention can usefully be bound to

a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically derivatized, hydrophilic PVDF; so bound, the proteins, fragments, and fusions of the present invention can be used to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention.

As another example, the proteins, fragments, and fusions of the present invention can usefully be bound to a substantially nonporous substrate, such as plastic, to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when the assay is performed in standard microtiter dish, the plastic is typically polystyrene.

The proteins, fragments, and fusions of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound protein to indicate biologic interaction therebetween. The proteins, fragments, and fusions of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or

avidity to the surface-bound protein to indicate biological interaction therebetween.

Human AMLP1 Proteins

In a first series of protein embodiments, the invention provides an isolated AMLP1 polypeptide having the amino acid sequence in SEQ ID NO: 3 and SEQ ID NO: 6, which are full length human AMLP1a and AMLP1b proteins, respectively. When used as immunogens, the full length proteins of the present invention can be used, *inter alia*, to elicit antibodies that bind to a variety of epitopes of the AMLP1 protein.

The invention further provides fragments of the above-described polypeptides, particularly fragments having at least 6 amino acids, typically at least 8 amino acids, often at least 15 amino acids, and even the entirety of the sequence given in SEQ ID NO: 3 and SEQ ID NO: 6.

The invention further provides fragments of at least 6 amino acids, typically at least 8 amino acids, often at least 15 amino acids, and even the entirety of the sequence given in SEQ ID NO: 8.

As described above, the invention further provides proteins that differ in sequence from those described with particularity in the above-referenced SEQ ID NOs., whether by way of insertion or deletion, by way of conservative or moderately conservative substitutions, as hybridization related proteins, or as cross-hybridizing proteins, with those that substantially retain an AMLP1 activity particularly useful.

The invention further provides fusions of the proteins and protein fragments herein described to heterologous polypeptides.

ANTIBODIES AND ANTIBODY-PRODUCING CELLS

In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to AMLP1 proteins and protein fragments of the present invention or to one or more of the proteins and protein fragments encoded by the isolated AMLP1 nucleic acids of the present invention. The antibodies of the present invention can be specific for all of linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, *e.g.*, by solubilization in SDS.

In other embodiments, the invention provides antibodies, including fragments and derivatives thereof, the binding of which can be competitively inhibited by one or more of the AMLP1 proteins and protein fragments of the present invention, or by one or more of the proteins and protein fragments encoded by the isolated AMLP1 nucleic acids of the present invention.

As used herein, the term "antibody" refers to a polypeptide, at least a portion of which is encoded by at least one immunoglobulin gene, which can bind specifically to a first molecular species, and to fragments or derivatives thereof that remain capable of such specific binding.

By "bind specifically" and "specific binding" is here intended the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said specifically to "recognize" a first molecular species

when it can bind specifically to that first molecular species.

As is well known in the art, the degree to which an antibody can discriminate as among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention will discriminate over adventitious binding to non-AMLP1 proteins by at least two-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine the presence of the protein of the present invention in samples derived from human brain, liver, kidney, and adrenal gland as well as prostate, testis, lung, placenta, skeletal muscle, heart, bone marrow and colon tumor.

Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the present invention will be at least about 1×10^{-6} molar (M), typically at least about 5×10^{-7} M, usefully at least about 1×10^{-7} M, with affinities and avidities of at least 1×10^{-8} M, 5×10^{-9} M, and 1×10^{-10} M proving especially useful.

The antibodies of the present invention can be naturally-occurring forms, such as IgG, IgM, IgD, IgE, and IgA, from any mammalian species.

Human antibodies can, but will infrequently, be drawn directly from human donors or human cells. In such case, antibodies to the proteins of the present invention will typically have resulted from fortuitous

immunization, such as autoimmune immunization, with the protein or protein fragments of the present invention. Such antibodies will typically, but will not invariably, be polyclonal.

Human antibodies are more frequently obtained using transgenic animals that express human immunoglobulin genes, which transgenic animals can be affirmatively immunized with the protein immunogen of the present invention. Human Ig-transgenic mice capable of producing human antibodies and methods of producing human antibodies therefrom upon specific immunization are described, *inter alia*, in U.S. Patent Nos. 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318; 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically produced using techniques developed for production of murine antibodies.

Human antibodies are particularly useful, and often preferred, when the antibodies of the present invention are to be administered to human beings as *in vivo* diagnostic or therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by administration of an antibody derived from another species, such as mouse.

IgG, IgM, IgD, IgE and IgA antibodies of the present invention are also usefully obtained from other mammalian species, including rodents – typically mouse, but also rat, guinea pig, and hamster – lagomorphs, typically rabbits, and also larger mammals, such as sheep, goats, cows, and horses. In such cases, as with the transgenic human-antibody-producing non-human

mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the protein or protein fragment of the present invention.

As discussed above, virtually all fragments of 8 or more contiguous amino acids of the proteins of the present invention can be used effectively as immunogens when conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

Immunogenicity can also be conferred by fusion of the proteins and protein fragments of the present invention to other moieties.

For example, peptides of the present invention can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical definition and improved safety in vaccine development. Tam *et al.*, Proc. Natl. Acad. Sci. USA 85:5409-5413 (1988); Posnett et al., *J. Biol. Chem.* 263, 1719-1725 (1988).

Protocols for immunizing non-human mammals are well-established in the art, Harlow *et al.* (eds.), Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998) (ISBN: 0879693142); Coligan *et al.* (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001) (ISBN: 0-471-52276-7); Zola, Monoclonal Antibodies : Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000) (ISBN: 0387915907), the disclosures of which are incorporated herein by reference, and often include multiple immunizations, either with or without adjuvants such as

Freund's complete adjuvant and Freund's incomplete adjuvant.

Antibodies from nonhuman mammals can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the proteins of the present invention and monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the proteins of the present invention.

Following immunization, the antibodies of the present invention can be produced using any art-accepted technique. Such techniques are well known in the art, Coligan *et al.* (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001) (ISBN: 0-471-52276-7); Zola, Monoclonal Antibodies : Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000) (ISBN: 0387915907); Howard *et al.* (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000) (ISBN: 0849394457); Harlow *et al.* (eds.), Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998) (ISBN: 0879693142); Davis (ed.), Monoclonal Antibody Protocols, Vol. 45, Humana Press (1995) (ISBN: 0896033082); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997) (ISBN: 0471970107); Kenney, Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997) (ISBN: 0412141914), incorporated herein by reference in their entireties, and thus need not be detailed here.

Briefly, however, such techniques include, *inter alia*, production of monoclonal antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two methods of production are not mutually exclusive: genes

encoding antibodies specific for the proteins or protein fragments of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two necessarily be performed together: *e.g.*, genes encoding antibodies specific for the proteins and protein fragments of the present invention can be cloned directly from B cells known to be specific for the desired protein, as further described in U.S. Pat. No. 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

Host cells for recombinant antibody production – either whole antibodies, antibody fragments, or antibody derivatives – can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies of the present invention.

The technology of phage-displayed antibodies, in which antibody variable region fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established, Sidhu, *Curr. Opin. Biotechnol.* 11(6):610-6 (2000); Griffiths *et al.*, *Curr. Opin. Biotechnol.* 9(1):102-8 (1998); Hoogenboom *et al.*, *Immunotechnology*, 4(1):1-20 (1998); Rader *et al.*, *Current Opinion in Biotechnology* 8:503-508 (1997); Aujame *et al.*, *Human Antibodies* 8:155-168 (1997); Hoogenboom, *Trends in Biotechnol.* 15:62-70 (1997); de Kruif *et al.*, 17:453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14:230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994), and techniques and protocols

required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled, Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001) (ISBN 0-87969-546-3); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc. (1996); Abelson *et al.* (eds.), Combinatorial Chemistry, Methods in Enzymology vol. 267, Academic Press (May 1996), the disclosures of which are incorporated herein by reference in their entireties.

Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length antibody in a further prokaryotic or a eukaryotic host cell.

Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the present invention.

For example, antibody fragments of the present invention can be produced in *Pichia pastoris*, Takahashi *et al.*, *Biosci. Biotechnol. Biochem.* 64(10):2138-44 (2000); Freyre *et al.*, J. Biotechnol. 76(2-3):157-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2):117-20 (1999); Pennell *et al.*, *Res. Immunol.* 149(6):599-603 (1998); Eldin *et al.*, *J. Immunol. Methods.* 201(1):67-75 (1997); and in *Saccharomyces cerevisiae*, Frenken *et al.*, *Res. Immunol.* 149(6):589-99 (1998); Shusta et al., *Nature Biotechnol.* 16(8):773-7 (1998), the disclosures of which are incorporated herein by reference in their entireties.

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in insect cells, Li *et al.*, *Protein Expr. Purif.*

21(1):121-8 (2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3):196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1):96-104 (1997); Edelman *et al.*, *Immunology* 91(1):13-9 (1997); and Nesbit *et al.*, *J. Immunol. Methods*. 151(1-2):201-8 (1992), the disclosures of which are incorporated herein by reference in their entireties.

Antibodies and fragments and derivatives thereof of the present invention can also be produced in plant cells, Giddings *et al.*, *Nature Biotechnol.* 18(11):1151-5 (2000); Gavilondo *et al.*, *Biotechniques* 29(1):128-38 (2000); Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2):83-92 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2):113-6 (1999); Fischer *et al.*, *Biol. Chem.* 380(7-8):825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240:119-38 (1999); and Ma *et al.*, *Plant Physiol.* 109(2):341-6 (1995), the disclosures of which are incorporated herein by reference in their entireties.

Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS cells, 293 cells, and myeloma cells.

Verma *et al.*, *J. Immunol. Methods* 216(1-2):165-81 (1998), review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies.

Antibodies of the present invention can also be prepared by cell free translation, as further described in Merk *et al.*, J. Biochem. (Tokyo). 125(2):328-33 (1999) and Ryabova *et al.*, *Nature Biotechnol.* 15(1):79-84 (1997), and in the milk of transgenic animals, as further described in Pollock *et al.*, *J. Immunol. Methods* 231(1-2):147-57 (1999), the disclosures of which are incorporated herein by reference in their entireties.

The invention further provides antibody fragments that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

Among such useful fragments are Fab, Fab', Fv, $F(ab)'_2$, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4):395-402 (1998).

It is also an aspect of the present invention to provide antibody derivatives that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

Among such useful derivatives are chimeric, primatized, and humanized antibodies; such derivatives are less immunogenic in human beings, and thus more suitable for in vivo administration, than are unmodified antibodies from non-human mammalian species.

Chimeric antibodies typically include heavy and/or light chain variable regions (including both CDR and framework residues) of immunoglobulins of one species, typically mouse, fused to constant regions of another species, typically human. *See, e.g.*, U.S. Pat. No. 5,807,715; Morrison *et al.*, *Proc. Natl. Acad. Sci*

USA.81(21):6851-5 (1984); Sharon *et al.*, *Nature* 309(5966):364-7 (1984); Takeda *et al.*, *Nature* 314(6010):452-4 (1985), the disclosures of which are incorporated herein by reference in their entireties. Primatized and humanized antibodies typically include heavy and/or light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al.*, *Nature* 332(6162):323-7 (1988); Co *et al.*, *Nature* 351(6326):501-2 (1991); U.S. Pat. Nos. 6,054,297; 5,821,337; 5,770,196; 5,766,886; 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of which are incorporated herein by reference in their entireties.

Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to provide labeled antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

The choice of label depends, in part, upon the desired use.

For example, when the antibodies of the present invention are used for immunohistochemical staining of

tissue samples, the label can usefully be an enzyme that catalyzes production and local deposition of a detectable product.

Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well known, and include alkaline phosphatase, β-galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG); o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl phosphate (PNPP); p-nitrophenyl-beta-D-galactopryanoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN); 5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BluoGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS); phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide (H_2O_2), horseradish peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic compounds. Advantages include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. *See, e.g.*, Thorpe *et al.*, *Methods Enzymol.* 133:331-53 (1986); Kricka *et al.*, *J. Immunoassay* 17(1):67-83 (1996); and Lundqvist *et al.*, *J. Biolumin.*

Chemilumin. 10(6):353-9 (1995), the disclosures of which are incorporated herein by reference in their entireties. Kits for such enhanced chemiluminescent detection (ECL) are available commercially.

The antibodies can also be labeled using colloidal gold.

As another example, when the antibodies of the present invention are used, *e.g.*, for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent immunoassay, they can usefully be labeled with fluorophores.

There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention.

For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular

Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, all of which are also useful for fluorescently labeling the antibodies of the present invention.

For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.

When the antibodies of the present invention are used, *e.g.*, for western blotting applications, they can usefully be labeled with radioisotopes, such as ^{33}P, ^{32}P, ^{35}S, ^{3}H, and ^{125}I.

As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be ^{228}Th, ^{227}Ac, ^{225}Ac, ^{223}Ra, ^{213}Bi, ^{212}Pb, ^{212}Bi, ^{211}At, ^{203}Pb, ^{194}Os, ^{188}Re, ^{186}Re, ^{153}Sm, ^{149}Tb, ^{131}I, ^{125}I, ^{111}In, ^{105}Rh, ^{99m}Tc, ^{97}Ru, ^{90}Y, ^{90}Sr, ^{88}Y, ^{72}Se, ^{67}Cu, or ^{47}Sc.

As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*, *Radiology* 207(2):529-38 (1998), or by radioisotopic labeling

As would be understood, use of the labels described above is not restricted to the application as for which they were mentioned.

The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to cells that display and/or express the proteins of the present invention. Commonly, the antibody in such immunotoxins is conjugated to Pseudomonas exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. *See* Hall (ed.),

Immunotoxin Methods and Protocols (Methods in Molecular Biology, Vol 166), Humana Press (2000) (ISBN:0896037754); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag New York, Incorporated (1998) (ISBN:3540640975), the disclosures of which are incorporated herein by reference in their entireties, for review.

The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, attached to a substrate.

Substrates can be porous or nonporous, planar or nonplanar.

For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography.

For example, the antibodies of the present invention can usefully be attached to paramagnetic microspheres, typically by biotin-streptavidin interaction, which microsphere can then be used for isolation of cells that express or display the proteins of the present invention. As another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

As noted above, the antibodies of the present invention can be produced in prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

Human AMLP1 Antibodies

In a first series of antibody embodiments, the invention provides antibodies, both polyclonal and monoclonal, and fragments and derivatives thereof, that bind specifically to a polypeptide having an amino acid sequence encoded by the cDNA, or that have the amino acid sequence in SEQ ID NO: 3, which are full length human AMLP1a proteins.

In another series of antibody embodiments, the invention provides antibodies, both polyclonal and monoclonal, and fragments and derivatives thereof, that bind specifically to a polypeptide having an amino acid sequence encoded by the cDNA, or that have the amino acid sequence in SEQ ID NO: 6, which are full length human AMLP1b proteins.

Such antibodies are useful in *in vitro* immunoassays, such as ELISA, western blot or immunohistochemical assay of disease tissue or cells. Such antibodies are also useful in isolating and purifying human AMLP1 proteins, including related cross-reactive proteins, by immunoprecipitation, immunoaffinity chromatography, or magnetic bead-mediated purification.

In another series of antibody embodiments, the invention provides antibodies, both polyclonal and monoclonal, and fragments and derivatives thereof, the specific binding of which can be competitively inhibited by the isolated proteins and polypeptides of the present invention.

In other embodiments, the invention further provides the above-described antibodies detectably labeled, and in yet other embodiments, provides the above-described antibodies attached to a substrate.

PHARMACEUTICAL COMPOSITIONS

Human AMLP1 plays an important role within the cell as an adaptor protein that interacts with both angiostatin-like protein and components of the actin cytoskeleton, and has anti-angiogenesis activity. Defects in human AMLP1 expression, activity, distribution, localization, and/or solubility are a cause of human disease, which disease can manifest as a disorder of brain, liver, kidney, adrenal gland, prostate, testis, lung, placenta, skeletal muscle, heart or bone marrow function.

Accordingly, pharmaceutical compositions comprising nucleic acids, proteins, and antibodies of the present invention, as well as mimetics, agonists, antagonists, or inhibitors of AMLP1 activity, can be

administered as therapeutics for treatment of AMLP1 defects.

Thus, in another aspect, the invention provides pharmaceutical compositions comprising the nucleic acids, nucleic acid fragments, proteins, protein fusions, protein fragments, antibodies, antibody derivatives, antibody fragments, mimetics, agonists, antagonists, and inhibitors of the present invention.

Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable carrier or excipient.

Pharmaceutical formulation is a well-established art, and is further described in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20th ed., Lippincott, Williams & Wilkins (2000) (ISBN: 0683306472); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippincott Williams & Wilkins Publishers (1999) (ISBN: 0683305727); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3rd ed. (2000) (ISBN: 091733096X), the disclosures of which are incorporated herein by reference in their entireties, and thus need not be described in detail herein.

Briefly, however, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation, topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Solid formulations of the compositions for oral administration can contain suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and alginic acid.

Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, corn starch, sodium starch glycolate, and alginic acid.

Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone™), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

Solid oral dosage forms need not be uniform throughout.

For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Liquid formulations of the pharmaceutical compositions for oral (enteral) administration are prepared in water or other aqueous vehicles and can contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.

The pharmaceutical compositions of the present invention can also be formulated for parenteral administration.

For intravenous injection, water soluble versions of the compounds of the present invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline, 0.9% saline, Hanks' solution, or Ringer's solution.

Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.

Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).

Aqueous injection suspensions can also contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition.

The pharmaceutical compositions of the present invention can be administered topically.

A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, *e.g.*, 5 to 10%, in a carrier such as a pharmaceutical cream base. Various formulations for topical use include drops, tinctures, lotions, creams, solutions, and ointments containing the active ingredient and various supports and vehicles. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone.

Inhalation formulations can also readily be formulated. For inhalation, various powder and liquid formulations can be prepared.

The pharmaceutically active compound in the pharmaceutical compositions of the present inention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

The active compound will be present in an amount effective to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

A "therapeutically effective dose" refers to that amount of active ingredient – for example AMLP1 protein, fusion protein, or fragments thereof, antibodies specific for AMLP1, agonists, antagonists or inhibitors of AMLP1 – which ameliorates the signs or symptoms of the

disease or prevents progression thereof; as would be understood in the medical arts, cure, although desired, is not required.

The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine an initial useful concentration range and route of administration.

For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in one or more cell culture of animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are particularly useful.

The data obtained from cell culture assays and animal studies is used in formulating an initial dosage range for human use, and preferably provides a range of circulating concentrations that includes the ED50 with little or no toxicity. After administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age, weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction

sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (e.g., 1mg/kg to 5 mg/kg). The pharmaceutical formulation can be administered in multiple doses per day, if desired, to achieve the total desired daily dose.

Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to the patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

THERAPEUTIC METHODS

The present invention further provides methods of treating subjects having defects in AMLP1 – *e.g.*, in

expression, activity, distribution, localization, and/or solubility of AMLP1 – which can manifest as a disorder of brain, liver, kidney, adrenal gland, prostate, testis, lung, placenta, skeletal muscle, heart or bone marrow function. As used herein, "treating" includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease.

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising AMLP1 protein, fusion, fragment or derivative thereof is administered to a subject with a clinically-significant AMLP1 defect.

Protein compositions are administered, for example, to complement a deficiency in native AMLP1. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to AMLP1. The immune response can be used to modulate activity of AMLP1 or, depending on the immunogen, to immunize against aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate AMLP1.

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising nucleic acid of the present invention is administered. The nucleic acid can be delivered in a vector that drives expression of AMLP1 protein, fusion, or fragment thereof, or without such vector.

Nucleic acid compositions that can drive expression of AMLP1 are administered, for example, to complement a deficiency in native AMLP1, or as DNA vaccines. Expression vectors derived from virus,

replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used – *see, e.g.*, Cid-Arregui (ed.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co., 2000 (ISBN: 188129935X) – as can plasmids.

Antisense nucleic acid compositions, or vectors that drive expression of AMLP1 antisense nucleic acids, are administered to downregulate transcription and/or translation of AMLP1 in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

Antisense compositions useful in therapy can have sequence that is complementary to coding or to noncoding regions of the AMLP1 gene. For example, oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are particularly useful.

Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to AMLP1 transcripts, are also useful in therapy. *See, e.g.*, Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3):97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10):1649-53 (1998); Rossi, *Ciba Found. Symp.* 209:195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8):286-9 (1995), the disclosures of which are incorporated herein by reference in their entireties.

Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the AMLP1 genomic locus. Such triplexing oligonucleotides are able to inhibit transcription, Intody *et al.*, Nucleic Acids Res. 28(21):4283-90 (2000); McGuffie *et al.*, *Cancer Res.* 60(14):3790-9 (2000), the disclosures of which are incorporated herein by reference, and pharmaceutical compositions comprising such triplex forming oligos

(TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is administered. As is well known, antibody compositions are administered, for example, to antagonize activity of AMLP1, or to target therapeutic agents to sites of AMLP1 presence and/or accumulation.

In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of AMLP1 is administered. Antagonists of AMLP1 can be produced using methods generally known in the art. In particular, purified AMLP1 can be used to screen libraries of pharmaceutical agents, often combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of AMLP1.

In other embodiments a pharmaceutical composition comprising an agonist of AMLP1 is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express AMLP1, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement defects in AMLP1 production or activity.

In other embodiments, pharmaceutical compositions comprising the AMLP1 proteins, nucleic acids, antibodies, antagonists, and agonists of the

present invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art according to conventional pharmaceutical principles. The combination of therapeutic agents or approaches can act additively or synergistically to effect the treatment or prevention of the various disorders described above, providing greater therapeutic efficacy and/or permitting use of the pharmaceutical compositions of the present invention using lower dosages, reducing the potential for adverse side effects.

TRANSGENIC ANIMALS AND CELLS

In another aspect, the invention provides transgenic cells and non-human organisms comprising AMLP1 isoform nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the AMLP1 gene.

The cells can be embryonic stem cells or somatic cells. The transgenic non-human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes.

DIAGNOSTIC METHODS

The nucleic acids of the present invention can be used as nucleic acid probes to assess the levels of AMLP1 mRNA in disease tissue or cells, and antibodies of the present invention can be used to assess the expression levels of AMLP1 proteins in disease tissue or cells to diagnose cancer.

The following examples are offered for purpose of illustration, not limitation.

EXAMPLE 1

Identification and Characterization of cDNAs Encoding Human AMLP1 Proteins

Bioinformatic algorithms were applied to human genomic sequence data to identify putative exons. Based on sequence information of one such exon, we identified a possible open reading frame. The predicted protein sequence from this potential ORF shares significant homology with GTPase activating proteins.

Marathon-Ready™ adult testis cDNA (Clontech Laboratories, Palo Alto, CA, USA) was used as a substrate for standard RT-PCR to obtain cDNA clones that correspond to alternatively spliced forms of AMLP1 along with the forward primer (5'-AGCCCCAGTAGTCCTGTCCAGGTTCT-3'; SEQ ID NO: 862) and the reverse primer (5'-TAGATGAGGACTTCCATCATCTCTCC-3'; SEQ ID NO: 863). In addition, the same cDNA was used as a substrate for standard RACE (rapid amplification of cDNA ends) to obtain cDNA clones that correspond to the 3' end of the AMLP1 gene. Alternatively spliced forms of the gene span 3.1 and 3.2 kilobases and appear to contain the entire coding region of the gene to which the exon contributes; for reasons described below, we termed these cDNAs AMLP1a and AMLP1b, respectively.

The AMLP1 isoform cDNAs were sequenced on both strands using a MegaBACE™ 1000 sequencer (Amersham Biosciences, Sunnyvale, CA, USA). Sequencing both strands provided us with the exact chemical structure of the cDNAs, which are shown in FIG. 3 and FIG. 4 and further presented in the SEQUENCE LISTING as SEQ ID NO: 1 and SEQ ID NO: 4, and placed us in actual physical possession of the entire set of single-base incremented

fragments of the sequenced clone, starting at the 5' and 3' termini.

Two overlapping cDNA products were cloned that together contained the complete sequence of AMLP1a. Another two overlapping cDNA products were cloned that together contained the complete sequence of AMLP1b. These experiments placed us in possession of a complete set of fragments of the template.

As shown in FIG. 3, the human AMLP1a cDNA spans 3173 nucleotides and contains an open reading frame from nucleotide 190 through and including nt 2799 (inclusive of termination codon), predicting a protein of 869 amino acids with a (posttranslationally unmodified) molecular weight of 96.8 kD. The clone appears full length, with the reading frame opening starting with a methionine and terminating with a stop codon.

As shown in FIG. 4, the human AMLP1b cDNA spans 3248 nucleotides and contains an open reading frame from nucleotide 190 through and including nt 1878 (inclusive of termination codon), predicting a protein of 562 amino acids with a (posttranslationally unmodified) molecular weight of 63.4 kD. The clone appears full length, with the reading frame opening starting with a methionine and terminating with a stop codon.

BLAST query of genomic sequence identified one BACS, spanning 76 kb, that constitute the minimum set of clones encompassing the cDNA sequence. Based upon the known origin of the BACs (GenBank accession numbers AP001152.4, the human AMLP1 gene can be mapped to human chromosome 11q21.

Comparison of the cDNA and genomic sequences identified 12 exons for AMLP1a, and an additional exon (exon 8) for AMLP1b. Exon organizations of AMLP1a and AMLP1b are listed in Table 1 and Table 2, respectively.

Table 1
AML1a Exon Structure

Exon no.	cDNA range	genomic range	BAC accession
1	1-130	7552-7681	AP001152.4
2	131-1049	11911-12832	
3	1050-1341	34051-34342	
4	1342-1486	42571-42715	
5	1487-1576	43973-44062	
6	1577-1722	62634-62779	
7	1723-1872	66453-66602	
8	1873-2063	72045-72235	
9	2064-2189	77255-77380	
10	2190-2416	78462-78688	
11	2417-2692	81718-81993	
12	2693-3141	83209-83657	

Table 2
AML1b Exon Structure

Exon no.	cDNA range	genomic range	BAC accession
1	1-130	7552-7681	AP001152.4
2	131-1052	11911-12832	
3	1053-1344	34051-34342	
4	1345-1489	42571-42715	
5	1490-1579	43973-44062	
6	1580-1725	62634-62779	
7	1726-1875	66453-66602	
8	1876-1941	70184-70249	

Table 2
AMLP1b Exon Structure

9	1942-2132	72045-72235	
10	2133-2258	77255-77380	
11	2259-2485	78462-78688	
12	2486-2761	81718-81993	
13	2762-3214	83209-83661	

Sequence comparison of AMLP1a, AMLP1b cDNA as well as the AP001152.4 genomic clone revealed ten allelic variations between the three. The frequency of allelic variations for the AMLP1 gene observed here is similar to those reported in earlier studies that surveyed rates of SNP occurrence in a variety of genes. Cargill et al., *Nature Genet.* 22:231-238 (1999). Most of the variations we observed are single nucleotide polymorphisms (SNPs), with only one being a three base pair insertion in the AMLP1b cDNA. This insertion occurred within a trinucleotide (CAG) repeat, of which AMLP1a contains seven copies. Table 3 lists the position, nucleotide sequence, as well as the amino acid sequence for the ten allelic variations. Analysis of such allelic variantions in a population can be used for association studies to establish gene-disease relationship.

Table 3
Allelic variations among AMLP1a, AMLP1b and AP001152.4.

AMPL1a Position	AMPL1b Position	AMPL1a Allele	AMLP1a amino acid	AMPL1b Allele	AMLP1b amino acid	AP001152
222	222	G	T	A	T	A
339	339	T	N	C	N	C

Table 3
Allelic variations among AMLP1a, AMLP1b and AP001152.4.

AMPL1a Position	AMPL1b Position	AMPL1a Allele	AMLP1a amino acid	AMPL1b Allele	AMLP1b amino acid	AP001152
550	550-552			CAG	Q	
700	703	A	I	G	V	G
713	716	G	S	C	T	G
788	791	A	D	G	G	G
811	814	C	P	T	S	T
1541	1544	G	G	A	E	A
1603	1606	A	K	G	E	A
2126	2195	A	H	G	Non-coding	A

FIG. 2 schematizes the exon organization of the human AMLP1 clones.

At the top is shown the bacterial artificial chromosome (BAC), with GenBank accession numbers, that spans the human AMLP1 locus.

As shown in FIG. 2, AMLP1a encodes a longer open reading frames compared to AMLP1b, and a protein of 869 amino acids. AMLP1a is comprised of exons 1 - 12. Insertion of a 66 base pair exon in AMLP1b (exon 8 of AMLP1b) leads to frame shift and a shortened ORF with a protein of 563 amino acids. The predicted molecular weights for AMLP1a and AMLP1b, prior to any post-translational modifications, are 96.8 and 63.4 kD, respectively.

As further discussed in the examples herein, expression of AMLP1 was assessed using RT-PCR. RT-PCR detected high level expression of AMLP1 in brain, liver, kidney, and adrenal gland. AMLP1 expression is also detected in the other tissues tested, notably prostate,

testis, lung, placenta, skeletal muscle, heart, bone marrow as well as colon tumor.

The sequences of the human AMLP1 cDNAs were used as a BLAST query into the GenBank nr and dbEst databases. The nr database includes all non-redundant GenBank coding sequence translations, sequences derived from the 3-dimensional structures in the Brookhaven Protein Data Bank (PDB), sequences from SwissProt, sequences from the protein information resource (PIR), and sequences from protein research foundation (PRF). The dbEst (database of expressed sequence tags) includes ESTs, short, single pass read cDNA (mRNA) sequences, and cDNA sequences from differential display experiments and RACE experiments.

BLAST search identified multiple human ESTs, and four mouse ESTs as having sequence closely related to AMLP1.

Globally, the human AMLP1 proteins resembles the human angiomotin protein (GenBank accession: AAG01851.1, the AMLP1a protein with 61 % amino acid identity and 78 % amino acid similarity over 471 amino acids). AMLP1 also resembles a putative mouse transcript (GenBank accession: BAB30287.1, the AMLP1a protein with 88 % amino acid identity and 91 % amino acid similarity over the entire open reading frame). AMLP1 aslo resembles a human putative transcript (GenBank accession: BAA76833.1, the AMLP1a protein with 43 % amino acid identity and 56 % amino acid similarity over 807 amino acids).

Motif searches using Pfam (http://pfam.wustl.edu), SMART (http://smart.embl-heidelberg.de), and PROSITE pattern and profile databases (http://www.expasy.ch/prosite), identified several known domains shared with human angiomotin.

FIG. 1 schematizes the protein domain structure of human AMLP1a and AMLP1b, and the alignment of the myosin-tail motif of AMLP1a with that of other proteins.

As schematized in FIG. 1, the newly isolated gene products share certain protein domains and an overall structural organization with human angiomotin. The shared structural features strongly imply that human AMLP1 plays a role similar to that of human angiomotin as an adaptor protein that interacts with both angiostatin-like protein and components of the actin cytoskeleton and has anti-angiogenesis activity.

Like human angiomotin, human AMLP1 contains a partial Myosin-tail domain. In AMLP1a, the partial Myosin-tail motif ocurrs at amino acids 351-733 (http://www.ncbi.nlm.gov/Structure/cdd/wrpsb.cgi). In the shorter AMLP1b protein, the partial Myosin-tail motif ends at amino acids sequence position 562 (which is the last amino acid for AMLP1b). The Myosin-tail motif is represented by the coiled-coil myosin heavy chain tail region. The coiled-coil is composed of the tail from two molecules of myosin. These can then assemble into the macromolecular thick filament. The coiled-coil region provides the structural backbone of the thick filament.

Other signatures of the newly isolated AMLP1 proteins were identified by searching the PROSITE database (http://www.expasy.ch/tools/scnpsit1.html). For AMLP1a, these signatures include four *N*-glycosylation sites (51 - 54, 57 - 60, 631 - 634 and 635 - 638), one cAMP- and cGMP-dependent protein kinase phosphorylation site (405 - 408), twelve protein kinase C phosphorylation sites, seventeen Casein kinase II phosphorylation sites, six *N*-myristoylation sites (3 - 8, 194 - 199, 244 - 249, 566 - 571, 743 - 748 and 784 - 789), as well as three tyrosine kinase phosphorylation sites (15 - 23, 453 - 459 and 659 - 666). For AMLP1b, these signatures include two

N-glycosylation sites (51 - 54, 57 - 60), one cAMP- and cGMP-dependent protein kinase phosphorylation site (406 - 409), six protein kinase C phosphorylation sites, twelve Casein kinase II phosphorylation sites, three *N*-myristoylation sites (3 - 8, 195 - 200 and 245 - 250), as well as two tyrosine kinase phosphorylation sites (15 - 23 and 454 - 460).

Possession of the genomic sequence permitted search for promoter and other control sequences for the human AMLP1 gene.

A putative transcriptional control region, inclusive of promoter and downstream elements, was defined as 1 kb around the transcription start site, itself defined as the first nucleotide of the human AMLP1 cDNA clone. The region, drawn from sequence of BAC AP001152.4, has the sequence given in SEQ ID NO: 35, which lists 1000 nucleotides before the transcription start site.

Transcription factor binding sites were identified using a web based program (http://motif.genome.ad.jp/), including a binding site for TCF11 (789 - 801), for Pbx-1 (846 - 854 bp) and for AP-1 (914 - 922, with numbering according to SEQ ID NO: 35), amongst others.

We have thus identified a newly described human gene, human AMLP1 (including two isoforms), which shares certain protein domains and an overall structural organization with human angiomotin; the shared structural features strongly imply that the human AMLP1 protein plays a role similar to human angiomotin, as an adaptor protein that interacts with both angiostatin-like protein and components of the actin cytoskeleton and has anti-angiogenesis activity, making the human AMLP1 proteins and nucleic acids clinically useful diagnostic markers and potential therapeutic agents for cancer.

EXAMPLE 2
Preparation and Labeling of
Useful Fragments of Human AMLP1

Useful fragments of AMLP1 are produced by PCR, using standard techniques, or solid phase chemical synthesis using an automated nucleic acid synthesizer. Each fragment is sequenced, confirming the exact chemical structure thereof.

The exact chemical structure of preferred fragments is provided in the attached SEQUENCE LISTING, the disclosure of which is incorporated herein by reference in its entirety. The following summary identifies the fragments whose structures are more fully described in the SEQUENCE LISTING:

SEQ ID NO: 1	(nt,	full length AMLP1a cDNA)
SEQ ID NO: 2	(nt,	cDNA ORF of AMLP1a)
SEQ ID NO: 3	(aa,	full length AMLP1a protein)
SEQ ID NO: 4	(nt,	full length AMLP1b cDNA)
SEQ ID NO: 5	(nt,	cDNA ORF of AMLP1b)
SEQ ID NO: 6	(aa,	full length AMLP1b protein)
SEQ ID NO: 7	(nt,	(nt 409 - 795) portion of AMLP1a)
SEQ ID NO: 8	(aa,	(aa 74 - 202) CDS entirely within SEQ ID NO: 7)
SEQ ID NO: 9 - 20	(nt,	exons 1 - 12 of AMLP1a (from genomic sequence))
SEQ ID NO: 21 - 32	(nt,	500 bp genomic amplicon centered about exons 1 - 12 of AMLP1a)
SEQ ID NO: 33	(nt,	novel exon of AMLP1b)
SEQ ID NO: 34	(nt,	500 bp genomic amplicon centered about novel exon of AMLP1b)
SEQ ID NO: 35	(nt,	1000 bp putative promoter)

SEQ ID NOs: 36 - 406 (nt, 17-mers scanning (nt 409 - 795) portion of AMLP1a)

SEQ ID NOs: 407 - 769 (nt, 25-mers scanning (nt 409 - 795) portion of AMLP1a)

SEQ ID NOs: 770 - 819 (nt, 17-mers scanning novel exon of AMLP1b)

SEQ ID NOs: 820 - 861 (nt, 25-mers scanning novel exon of AMLP1b)

SEQ ID NO: 862 (nt, forward primer for cloning of AMLP1 cDNA)

SEQ ID NO: 863 (nt, reverse primer for cloning of AMLP1 cDNA)

SEQ ID NO: 864 (nt, forward primer for expression analysis of AMLP1 by RT-PCR)

SEQ ID NO: 865 (nt, reverse primer for expression analysis of AMLP1 by RT-PCR)

SEQ ID NO: 866 (aa, consensus sequence of the Myosin-tail motif)

SEQ ID NO: 867 (aa, sequence of the AMLP1a Myosin-tail motif)

SEQ ID NO: 868 (aa, sequence of the Myosin-tail motif of protein MHC A)

SEQ ID NO: 869 (aa, sequence of the Myosin-tail motif of Myosin_HC)

SEQ ID NO: 870 (aa, sequence of the Myosin-tail motif of protein MHC B)

Upon confirmation of the exact structure, each of the above-described nucleic acids of confirmed structure is recognized to be immediately useful as an AMLP1-specific probe.

For use as labeled nucleic acid probes, the above-described AMLP1 nucleic acids are separately labeled by random priming. As is well known in the art of molecular biology, random priming places the investigator in possession of a near-complete set of labeled fragments of the template of varying length and varying starting nucleotide.

The labeled probes are used to identify the AMLP1 gene on a Southern blot, and are used to measure expression of AMLP1 mRNA on a northern blot and by RT-PCR, using standard techniques.

EXAMPLE 3

RT-PCR Analysis of AMLP1 Expression

The expression pattern of AMLP1 in human tissues was analyzed using RT-PCR. A forward primer (5'-TCAGAGGTGGAAATGAGAGGTTGG-3'; SEQ ID NO: 864) and a reverse primer (5'-ACCGTATTGTCCACCTGGTGTTCT-3'; SEQ ID NO: 865) - both derived from the open reading frame of AMLP1 - were used in standard RT-PCR. Sambrook et al., Molecular cloning: 3rd edition, 2001. The cDNA emplates were obtained from brain, kidney, liver, testis, skeletal muscle, heart, bone marrow, lung, placenta, and prostate. The PCR reactions were carried out according to the following schedule: 94C, 20 seconds; 65C 20 seconds; 72C, 60 seconds, for 35 cycles. PCR products were separated on an agarose gel and visualized with a Typhoon™ fluorimager and Imagequant software (Amersham Biosciences, Sunnyvale, CA, USA). RT-PCR product for AMLP1 was found to be present most highly in brain, liver, kidney, and adrenal gland, but was also found at lower levels in the other tissues tested, notably

prostate, testis, lung, placenta, skeletal muscle, heart, bone marrow as well as colon tumor (FIG. 5).

EXAMPLE 4

Production of Human AMLP1 Protein

The full length AMLP1 cDNA clone is cloned into the mammalian expression vector pcDNA3.1/HISA (Invitrogen, Carlsbad, CA, USA), transfected into COS7 cells, transfectants selected with G418, and protein expression in transfectants confirmed by detection of the anti-Xpress™ epitope according to manufacturer's instructions. Protein is purified using immobilized metal affinity chromatography and vector-encoded protein sequence is then removed with enterokinase, per manufacturer's instructions, followed by gel filtration and/or HPLC.

Following epitope tag removal, AMLP1 protein is present at a concentration of at least 70%, measured on a weight basis with respect to total protein (i.e., w/w), and is free of acrylamide monomers, bis acrylamide monomers, polyacrylamide and ampholytes. Further HPLC purification provides AMLP1 protein at a concentration of at least 95%, measured on a weight basis with respect to total protein (i.e., w/w).

EXAMPLE 5

Production of Anti-Human AMLP1 Antibody

Purified proteins prepared as in Example 4 are conjugated to carrier proteins and used to prepare murine monoclonal antibodies by standard techniques. Initial screening with the unconjugated purified proteins, followed by competitive inhibition screening using

peptide fragments of the AMLP1, identifies monoclonal antibodies with specificity for AMLP1.

EXAMPLE 6

Use of Human AMLP1 Probes and Antibodies for Diagnosis of cancer

After informed consent is obtained, samples are drawn from disease tissue or cells and tested for AMLP1 mRNA levels by standard techniques and tested additionally for AMLP1 protein levels using anti- AMLP1 antibodies in a standard ELISA.

EXAMPLE 7

Use of Human AMLP1 Nucleic Acids, Proteins, and Antibodies in Therapy

Once over-expression of AMLP1 is detected in patients, AMLP1 antisense RNA or AMLP1-specific antibody is introduced into disease cells to reduce the amount of the protein.

Once mutations of AMLP1 have been detected in patients, normal AMLP1 is reintroduced into the patient's disease cells by introduction of expression vectors that drive AMLP1 expression or by introducing AMLP1 proteins into cells. Antibodies for the mutated forms of AMLP1 are used to block the function of the abnormal forms of the protein.

EXAMPLE 8

Human AMLP1 Disease Associations

Diseases that map to the AMLP1 chromosomal region are shown in Table 4. Mutations of AMLP1 might

lead to the disease(s) listed below. Alternatively, mutations of AMLP1 might lead to some other human disorder(s) as well.

Table 4:
Diseases mapped to human chromosome 11q21 (AMLP1 region).

OMIM No	disease	chromosomal location
133780	EXUDATIVE VITREORETINOPATHY 1	11q13-q23
213200	CEREBELLAR ATAXIA 1	11q14-q21
603342	SCHIZOPHRENIA 2	11q14-q21
603965	FOCAL SEGMENTAL GLOMERULOSCLEROSIS 2	11q21-q22
165720	OSTEOARTHRITIS	11q

All patents, patent publications, and other published references mentioned herein are hereby incorporated by reference in their entireties as if each had been individually and specifically incorporated by reference herein. While preferred illustrative embodiments of the present invention are described, one skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments, which are presented for purposes of illustration only and not by way of limitation. The present invention is limited only by the claims that follow.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid that encodes a human angiomotin-like protein, comprising:

(a) a nucleotide sequence selected from the group consisting of:

(i) SEQ ID NO: 1, SEQ ID NO: 4;

(ii) the complement of the sequences set forth in (i);

(iii) the nucleotide sequence of SEQ ID NO: 2, SEQ ID NO: 5;

(iv) a degenerate variant of the sequences set forth in (iii); and

(v) the complement of the sequences set forth in (iii) and (iv); or

(b) a nucleotide sequence selected from the group consisting of:

(i) a nucleotide sequence that encodes a polypeptide having the sequence of SEQ ID NO: 3, SEQ ID NO: 6;

(ii) a nucleotide sequence that encodes a polypeptide having the sequence of SEQ ID NO: 3, SEQ ID NO: 6, with conservative amino acid substitutions; and

(iii) the complement of the sequences set forth in (i) and (ii),

wherein said isolated nucleic acid comprising a nucleotide sequence selected from group (b) is no more than about 100 kb in length.

2. The isolated nucleic acid of claim 1 wherein said nucleic acid, or the complement of said nucleic acid, encodes a polypeptide as an adaptor protein that interacts with both angiostatin-like protein

and components of the actin cytoskeleton and has anti-angiogenesis activity.

3. The isolated nucleic acid of claim 1, wherein said nucleic acid, or the complement of said nucleic acid, is expressed in brain, liver, kidney, adrenal gland, prostate, testis, lung, placenta, skeletal muscle, heart, bone marrow or colon tumor.

4. A nucleic acid probe, comprising:
(a) the nucleic acid of claim 1; or
(b) at least 17 contiguous nucleotides of SEQ ID NO: 7, SEQ ID NO: 33;
wherein said probe according to (b) is no longer than about 100 kb in length.

5. The probe of claim 4, wherein said probe is detectably labeled.

6. The probe of claim 4, attached to a substrate.

7. A microarray, wherein at least one probe of said array is a probe according to claim 4.

8. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule is operably linked to one or more expression control elements.

9. A replicable vector comprising a nucleic acid molecule of claim 1.

10. A replicable vector comprising an isolated nucleic acid molecule of claim 8.

11. A host cell transformed to contain the nucleic acid

molecule of any one of claims 1 or 8 - 10, or the progeny thereof.

12. A method for producing a polypeptide, the method comprising: culturing the host cell of claim 11 under conditions in which the protein encoded by said nucleic acid molecule is expressed.

13. An isolated polypeptide produced by the method of claim 12.

14. An isolated polypeptide, comprising:
(a) an amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 6;
(b) an amino acid sequence having at least 65% amino acid sequence identity to that of (a);
(c) an amino acid sequence according to (a) in which at least 95% of deviations from the sequence of (a) are conservative substitutions; or
(d) a fragment of at least 8 contiguous amino acids of any of (a) - (c).

15. A fusion protein, said fusion protein comprising a polypeptide of claim 14 fused to a heterologous amino acid sequence.

16. The fusion protein of claim 15, wherein said heterologous amino acid sequence is a detectable moiety.

17. The fusion protein of claim 16, wherein said detectable moiety is fluorescent.

18. The fusion protein of claim 15, wherein said

heterologous amino acid sequence is an Ig Fc region.

19. An isolated antibody, or antigen-binding fragment or derivative thereof, the binding of which can be competitively inhibited by a polypeptide of claim 14.

20. A transgenic non-human animal modified to contain the nucleic acid molecule of any one of claims 1 or 8 - 10.

21. A transgenic non-human animal unable to express the endogenous orthologue of the nucleic acid molecule of claim 1.

22. A method of identifying agents that modulate the expression of AMLP1, the method comprising:

contacting a cell or tissue sample believed to express AMLP1 with a chemical or biological agent, and then

comparing the amount of AMLP1 expression in said cell or tissue sample with that of a control, changes in the amount relative to control identifying an agent that modulates expression of AMLP1.

23. A method of identifying agonists and antagonists of AMLP1, the method comprising:

contacting a cell or tissue sample believed to express AMLP1 with a chemical or biological agent, and then

comparing the activity of AMLP1 with that of a control, increased activity relative to a control identifying an agonist, decreased activity relative to a control identifying an antagonist.

24. A purified agonist of the polypeptide of claim 14.

25. A purified antagonist of the polypeptide of claim 14.

26. A method of identifying a specific binding partner for a polypeptide according to claim 14, the method comprising:

contacting said polypeptide to a potential binding partner; and

determining if the potential binding partner binds to said polypeptide.

27. The method of claim 26, wherein said contacting is performed *in vivo*.

28. A purified binding partner of the polypeptide of claim 14.

29. A method for detecting a target nucleic acid in a sample, said target being a nucleic acid according to claim 1, the method comprising:

(a) hybridizing the sample with a probe comprising at least 17 contiguous nucleotides of a sequence complementary to said target nucleic acid in said sample under high stringency hybridization conditions, and

(b) detecting the presence or absence, and optionally the amount, of said binding.

30. A method of diagnosing a disease caused by mutation in AMLP1, comprising:

detecting said mutation in a sample of nucleic acids that derives from a subject suspected to have said disease.

31. A method of diagnosing or monitoring a disease caused by altered expression of AMLP1, comprising:

determining the level of expression of AMLP1 in a sample of nucleic acids or proteins that derives from a subject suspected to have said disease, alterations from a normal level of expression providing diagnostic and/or monitoring information.

32. A diagnostic composition comprising the nucleic acid of claim 1, said nucleic acid being detectably labeled.

33. The diagnostic composition of claim 32, wherein said composition is further suitable for *in vivo* administration.

34. A diagnostic composition comprising the polypeptide of claim 14, said polypeptide being detectably labeled.

35. The diagnostic composition of claim 34, wherein said composition is further suitable for *in vivo* administration.

36. A diagnostic composition comprising the antibody, or antigen-binding fragment or derivative thereof, of claim 19.

37. The diagnostic composition of claim 36, wherein said antibody or antigen-binding fragment or derivative thereof is detectably labeled.

38. The diagnostic composition of claim 37, wherein said composition is further suitable for *in vivo* administration.

39. A pharmaceutical composition comprising the nucleic acid of claim 1 and a pharmaceutically acceptable excipient.

40. A pharmaceutical composition comprising the polypeptide of claim 14 and a pharmaceutically acceptable excipient.

41. A pharmaceutical composition comprising the antibody or antigen-binding fragment or derivative thereof of claim 19 and a pharmaceutically acceptable excipient.

42. A pharmaceutical composition comprising the agonist of claim 24 and a pharmaceutically acceptable excipient.

43. A pharmaceutical composition comprising the antagonist of claim 25 and a pharmaceutically acceptable excipient.

44. A method for treating or preventing a disorder associated with decreased expression or activity of AMLP1, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of any of claims 39, 40 or 42.

45. A method for treating or preventing a disorder associated with increased expression or activity of

AMLP1, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 41 or 43.

46. A method of modulating the expression of a nucleic acid according to claim 1, the method comprising:

administering an effective amount of an agent which modulates the expression of a nucleic acid according to claim 1.

47. A method of modulating at least one activity of a polypeptide according to claim 14, the method comprising:

administering an effective amount of an agent which modulates at least one activity of a polypeptide according to claim 14.

Structure of AMLP1 and Alignment of Myosin-tail Motifs.

A



B

Myosin-tail motif

```
                          10        20        30        40        50        60
                     ....*....|....*....|....*....|....*....|....*....|....*....|
consensus      1 ELERQKRELENQLYRKESELSQLSSKLEDEQALVAQLQKKIKELEARIRELEEELEAERA 60
AMLP1a           ------------------------------------------------------------
MHC A       1067 DLERVKRDLEDAGRKKDMEINGLNSKLEDEQNLVAQLQKKIKELQARIEELEEELEAERQ 1126
Myosin_HC   1054 DLERVKRDLEEQLRRKEAEIGGLSGKFEDEQGLVAQLQRKIKELQTRIQELEEDLEAERA 1113
MHC B       1080 ESGRQRHDLENNLKKKESELHSVSSRLEDEQALVSKLQRQIKDGQSRISELEEELENERQ 1139

                          70        80        90       100       110       120
                     ....*....|....*....|....*....|....*....|....*....|....*....|
consensus     61 ARAKAEKARADLSRELEELSERLEEAGGATAAQIELNKKREAELAKLRKDLEEANLQHEE  120
AMLP1a         1 ----------mrgsedaaagtvlqrliqeqlrygtptenmnllaiqhqatgsagpahptn 50
MHC A       1127 ARTKVEKQRTELSRELEELGERLDEAGGATAAQMELNKKREQELLRLRRDLEEATMQHES 1186
Myosin_HC   1114 ARSKAEKSRQQLESELEEVVDRLEEQDGATAAQSDLTKKREAELMKLKRDLEDTRLQNEQ 1173
MHC B       1140 SRSKADRAKSDLQRELEELGEKLDEQGGATAAQVEVNKKREAELAKLRRDLEEANMNHEN 1199
```

FIG. 1

B

Myosin-tail motif

(Continued)

```
                    130       140       150       160       170       180
                ....*....|....*....|....*....|....*....|....*....|....*....|
consensus   121 ALATLRKKHQDAINELSEQIEQLQKQKAKAEKEKSQLQAEVDDLLAQLDSITKAKLNAEK  180
AMLP1a       51 nfsstenltqedpqmvyqsarqepqgqehqvdntvmekqvrstqpqqnneelptyeeaka 110
MHC A      1187 QIATLRKKNQEATNELGDQIDQLQKVKSRLEKEKTQLRAEMDDVQSQVEHAGKNRGCSEK 1246
Myosin_HC  1174 AIATMRKKQSDAINELADQLDQANKAKAKAEKERSQFKAELDDAHNQVDSIMKAKLNSEK 1233
MHC B      1200 QLGGLRKKHTDAVAELTDQLDQLNKAKAKVEKDKAQAVRDAEDLAAQLDQETSGKLNNEK 1259

                    190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|
consensus   181 KAKQLESQLSELQVKLDELQRQLNDLTSQKSRLQSENSDLTRQLEEAEAQVSNLSKLKSQ  240
AMLP1a      111 qsqffrgqqqqqqqqgavghgyymaggtsqksrtegrptvnransgqahkdealkelkqgh 170
MHC A      1247 MSKQMEAQLSELNAKIDDQARSVSELTSQKSRLQTEAADLTRQLEEAEHNVGQLTKLKSS 1306
Myosin_HC  1234 TVKALESQLQEVSVKLDEATRNLNEQASTKARSSQEVSELQRQLEEAESQLSQLNKIKQQ 1293
MHC B      1260 LAKQFELQLTELQSKADEQSRQLQDFTSLKGRLHSENGDLVRQLEDAESQVNQLTRLKSQ 1319

                    250       260       270       280       290       300
                ....*....|....*....|....*....|....*....|....*....|....*....|
consensus   241 LESQLEEAKRSLEEESRERANLQAQLRQLEHDLDSLREQLEEESEAKAELERQLSKANAE  300
AMLP1a      171 irslserimqlslerngakqhlpgsgngkdfkvgggpppaqpagkvldprgpppeypfkt 230
MHC A      1307 LGASLEDAKRSLEDEGRLRAKLQAEVRNLNSDIDGIRESLEEEAESKSDLQRALSRANAE 1366
Myosin_HC  1294 LSAQLEEARHSLEDESRMKAKLNGEVRNLTSDLDSLRETLEEEQSAKGDLQRQLQKLQGE 1353
MHC B      1320 LTSQLEEARRTADEEARERQTVAAQAKNYQHEAEQLQESLEEEIEGKNEILRQLSKANAD 1379
```

FIG. 1

B

Myosin-tail motif

(Continued)

```
                    310       320       330       340       350       360
                ....*....|....*....|....*....|....*....|....*....|....*....|
consensus   301 IQQWRSKFESEGALRAEELEELKKKLNQKISELEEAAEAANAKCDSLEKTKSRLQSELED  360
AMLP1a      231 kqmmspvsktqehglfygdqhpgmlhemvkpypapqpvrtdvavlryqpppeygvtsrpc 290
MHC A      1367 VQQWRSKFESEGAARADELEDAKRKLQAKLSEAEQTADTLHSKCAGLEKAKSRLQGELED 1426
Myosin_HC  1354 LQQLRSRGGGGGDVRSEEVEELKRKMNAKIPALESEAESAKSKCGQLEKTKARLQGELED 1413
MHC B      1380 IQQWKARFEGEGLLKADELEDAKRRQAQKINELQEALDAANSKNASLEKTKSRLVGDLDD 1439

                    370       380       390       400       410       420
                ....*....|....*....|....*....|....*....|....*....|....*....|
consensus   361 LQIELERANAAASELEKKQKNFDKILAEWKRKVDELQAELDTAQREARNLSTELFRLKNE  420
AMLP1a      291 qlpfpstmqqhspmssqtssasgplhsvslplplpmalgapqpppaaspsqqlgpdafai 350
MHC A      1427 LAIDVERSSAHANNLEKKQRNFDKVVSEWQHKCNDLQAELENAQKEARSYSAELFRVRAQ 1486
Myosin_HC  1414 LMVDVERANGLASQLERKQNNFNRTLAEWQKKYADSQAELENAQRDARGQSTEIFRLKAQ 1473
MHC B      1440 AQVDVERANGVASALEKKQKGFDKIIDEWRKKTDDLAAELDGAQRDLRNTSTDLFKAKNA 1499

                    430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|
consensus   421 LEELKDQVEALRRENKNLQDEIHDLTDQLGEGGRNVHELEKARRRLEAEKDELQAALEEA  480
AMLP1a      351 VERAQQMVEILTEENRVLHQELQGYYDNAD----KLHKFEKELQRISEAYESLVKSTTKR 406
MHC A      1487 CEEVGDTVASLRRENKNLADEIHDLTDQLGEGGRNTHELEKARKHLALEKEELQAALEEA 1546
Myosin_HC  1474 LEEVHEQMEGLRRENKNLSDEIHDLTEQLGEGGRSVHEIDKNRRRLEMEKEELQAALEEA 1533
MHC B      1500 QEELAEVVEGLRRENKSLSQEIKDLTDQLGEGGRSVHEMQKIIRRLEIEKEELQHALDEA 1559
```

FIG. 1

B

Myosin-tail motif

(Continued)

```
                    490       500       510       520       530       540
                ....*....|....*....|....*....|....*....|....*....|....*....|
consensus   481 EAALELEESKVLRAQVELSQIRSEIERRLAEKEEEFENTRKNHQRAIESLQATLEAETKG  540
AMLP1a       407 ESLDKAMRNK---LEGEIRRL-HDFNRDLRDRLETANRQLSSREYEGHGDKAAEGHYASQ 462
MHC A       1547 EGALEQEEAKVMRATLEISQIRQEIDRRLQEKEEEFDNTRRNHQRAIESMQASLEAEAKG 1606
Myosin_HC   1534 ESALEQEEAKVQRAQLEMSQIRQEIDRRLAEKEEEFEATRKNHQRAMESQQASLEAEGKG 1593
MHC B       1560 EAALEAEESKVLRAQVEVSQIRSEIEKRIQEKEEEFENTRKNHARALESMQASLETEAKG 1619

                    550       560       570       580       590       600
                ....*....|....*....|....*....|....*....|....*....|....*....|
consensus   541 KAEASRLKKKLEGDINELEIALDHANKANAEAQKNVKKYQQQVKELQTQVEEEQRAREDA  600
AMLP1a       463 NKEFLKEKEKLEMELAAVRTASEDHRRHIEILDQALSNAQARVIKLEEELREKQAYVEKV 522
MHC A       1607 KAEALRIKKKLEGDINELEIALDATNRGKAELEKNVKKYQGQIRELQSQVEEEQAQRDEA 1666
Myosin_HC   1594 KAEAMRVKKKLEQDINELEVSLDGANRARAEQEENVKKFQQQVRELQSQLEDDQRQRDDL 1653
MHC B       1620 KAELLRIKKKLEGDINELEIALDHANKANADAQKNLKRYQEQVRELQLQVEEEQRNGADT 1679

                    610       620       630       640       650       660
                ....*....|....*....|....*....|....*....|....*....|....*....|
consensus   601 REQLAVAERRATALEAELEELRSALEQAERARKQAETELAEASERVNELTAQNS-SLIAQ  659
AMLP1a       523 EKLQQALTQLQSACEKREQMERRLRTWLERELDALRTQQKHGNGQPANMPEYNApALLEL 582
MHC A       1667 KEHYQMAERRCAAINGELEELRTILEQAERARKAAENELADASDRVNELQAQVS-TVGSQ 1725
Myosin_HC   1654 REQFQAAERRATVLAGELDELRIALDQAERSRKIAEAERAEASDRATEMSTQTA-SLAAQ 1712
MHC B       1680 REQFFNAEKRATLLQSEKEELLVANEAAERARKQAEYEAADARDQANEANAQVS-SLTSA 1738
```

FIG. 1

B

Myosin-tail motif

(Continued)

```
                      670       680       690       700       710       720
                 ....*....|....*....|....*....|....*....|....*....|....*....|
consensus    660 KRKLEGELAALQSDLD-------EAVNELKAAEERAKKAQADA---------------AR  697
AMLP1a       583 VREKEERILALEADMTkweqkylEESTIRHFAMNAAATAAAERdttiinhsrngsygeSS 642
MHC A       1726 KRKLEGDVTAMQSDLD-------ELNNELKDADERAKHAMADA---------------TR 1763
Myosin_HC   1713 KRKLEADLAAMQADLE-------EAANEAKQADERAKKAMADS---------------AR 1750
MHC B       1739 KRKLEGEIQAIHADLD-------ETLNEYKAAEERSKKAIADA---------------TR 1776

                      730       740       750       760       770       780
                 ....*....|....*....|....*....|....*....|....*....|....*....|
consensus    698 LAEELRQEQEHSQHLERLRKQLESQVKELQVRLDEAEAAALKGGKKMIQKLEARVRELEA  757
AMLP1a       643 LEAHIWQEEEEVVQANRRCQDMEYTIKNLHAKIIEKDA--------MIKVLQQRSRKDAG 694
MHC A       1764 LADELRQEQDHGLSVEKMRKSLESQVKELQVRLDESEAAALKGGKKMIQKLESRVRELEA 1823
Myosin_HC   1751 VFEEIRQEQEHTQHVEKARKQLEIQVKELMARLEDSESGAMKNGRKAMGKLEQRVRELET 1810
MHC B       1777 LAEELRQEQEHSQHVDRLRKGLEQQLKEIQVRLDEAEAAALKGGKKVIAKLEQRVRELES 1836

                      790       800       810       820       830       840
                 ....*....|....*....|....*....|....*....|....*....|....*....|
consensus    758 ELDGEQRRHAETQ----KNLRKMERRVKELQFQVEEDKKNLERLQDLVDKLQAKIKTYKR  813
AMLP1a       695 KTDSSSLRPARSVpsiaAATGTHSRQTSLTSSQLAEEKKeektwkgsiglllgkehheha 754
MHC A       1824 ELDSEQRRHAETQ----KSMRKVDRRVKELSFQQEEDRKNYERMQELVDKLQNKIKTYKR 1879
Myosin_HC   1811 ELAAEQRRHGETQ----KNLRKVDRRMKEISLQAEEDKKSHDRMQELVEKLQGKIKTYKR 1866
MHC B       1837 ELDGEQRRFQDAN----KNLGRADRRVRELQFQVDEDKKNFERLQDLIDKLQQKLKTQKK 1892
```

FIG. 1

B

Myosin-tail motif

(Continued)

```
                        850       860       870       880
                   ....*....|....*....|....*....|....*....|....*..
consensus     814 QLEEAEEVAQINLSKYRKAQRELEDAEERADTAERSLNKLRAKSRRT  860
AMLP1a         755 sapllpppptsalssiasttaassahaktgskdsstqtdksaelfwp 801
MHC A         1880 QVEEAEEIAAINLAKFRKVQQELEDAEERADQSEGALQKLRAKNRSS 1926
Myosin_HC     1867 QVQEAEEIAAINLAKYRKIQHEIEDAEERADQAEQALQKLRAKNRSS 1913
MHC B         1893 QVEEAEELANLNLQKYKQLTHQLEDAEERADQAENSLSKMRSKSRAS 1939
```

SEQ ID NO: 866
SEQ ID NO: 867
SEQ ID NO: 868
SEQ ID NO: 869
SEQ ID NO: 870

FIG. 1



FIG. 2

AMLP1a

nt: SEQ ID NO: 1
aa: SEQ ID NO: 3

```
AGCCCCAGTAGTCCTGTCCAGGTTCTAGAAGACTCCACCTACTTTTCCCCAG      52

ACTTTCAGCTCTATTCTGGGAGGCATGAAACATCTGCTTTGACGGTGGAGGC     104

AACCAGTAGCATCAGGGAAAAAGTTGTTGAAGATCCTCTTTGTAACTTCCAC     156

                                        M   R   G   S        4
TCCCCAAACTTCCTGAGGATCTCAGAGGTGGAA ATG AGA GGT TCC        201

 E   D   A   A   A   G   T   V   L   Q   R   L   I        17
GAG GAT GCG GCA GCT GGA ACG GTA TTG CAG CGG CTG ATC      240

 Q   E   Q   L   R   Y   G   T   P   T   E   N   M        30
CAG GAA CAA CTG CGG TAT GGC ACC CCA ACC GAG AAC ATG      279

 N   L   L   A   I   Q   H   Q   A   T   G   S   A        43
AAC TTG CTG GCC ATT CAG CAC CAG GCC ACA GGG AGT GCA      318

 G   P   A   H   P   T   N   N   F   S   S   T   E        56
GGA CCA GCC CAT CCT ACA AAT AAC TTT TCT TCC ACG GAA      357

 N   L   T   Q   E   D   P   Q   M   V   Y   Q   S        69
AAC CTC ACT CAA GAA GAC CCA CAA ATG GTC TAC CAG TCA      396

 A   R   Q   E   P   Q   G   Q   E   H   Q   V   D        82
GCA CGC CAA GAA CCG CAG GGT CAA GAA CAC CAG GTG GAC      435

 N   T   V   M   E   K   Q   V   R   S   T   Q   P        95
AAT ACG GTG ATG GAG AAA CAG GTC CGG TCC ACG CAG CCT      474

 Q   Q   N   N   E   E   L   P   T   Y   E   E   A       108
CAG CAG AAC AAC GAG GAA CTG CCC ACT TAC GAG GAG GCC      513
```

FIG. 3

```
 K   A   Q   S   Q   F   F   R   G   Q   Q   Q   Q      121
AAA GCA CAG TCG CAG TTC TTC AGG GGG CAG CAG CAG CAA     552

 Q   Q   Q   G   A   V   G   H   G   Y   Y   M   A      134
CAG CAG CAG GGG GCG GTG GGC CAT GGT TAC TAC ATG GCA     591

 G   G   T   S   Q   K   S   R   T   E   G   R   P      147
GGG GGC ACC AGT CAG AAG TCC CGA ACT GAG GGG AGG CCC     630

 T   V   N   R   A   N   S   G   Q   A   H   K   D      160
ACT GTG AAC CGT GCC AAC AGT GGA CAG GCG CAT AAG GAC     669

 E   A   L   K   E   L   K   Q   G   H   I   R   S      173
GAG GCG CTG AAG GAA CTG AAG CAG GGC CAC ATC CGC TCG     708

 L   S   E   R   I   M   Q   L   S   L   E   R   N      186
CTC AGC GAG AGA ATC ATG CAG CTG TCC CTG GAG AGG AAT     747

 G   A   K   Q   H   L   P   G   S   G   N   G   K      199
GGG GCC AAG CAA CAC CTT CCC GGC TCG GGG AAT GGA AAG     786

 D   F   K   V   G   G   G   P   P   P   A   Q   P      212
GAC TTC AAA GTA GGA GGG GGG CCC CCC CCT GCC CAG CCT     825

 A   G   K   V   L   D   P   R   G   P   P   P   E      225
GCA GGT AAA GTG CTG GAC CCT CGG GGT CCT CCA CCT GAG     864

 Y   P   F   K   T   K   Q   M   M   S   P   V   S      238
TAC CCC TTC AAG ACC AAG CAA ATG ATG TCC CCA GTC AGC     903

 K   T   Q   E   H   G   L   F   Y   G   D   Q   H      251
AAG ACC CAG GAG CAC GGA CTT TTT TAT GGT GAC CAG CAC     942

 P   G   M   L   H   E   M   V   K   P   Y   P   A      264
CCC GGG ATG CTC CAC GAG ATG GTC AAG CCC TAC CCT GCT     981

 P   Q   P   V   R   T   D   V   A   V   L   R   Y      277
CCT CAG CCT GTG AGA ACA GAT GTG GCC GTC CTG CGG TAC    1020
```

FIG. 3

```
 Q   P   P   P   E   Y   G   V   T   S   R   P   C     290
CAG CCA CCC CCT GAG TAT GGG GTA ACG AGC CGC CCA TGC   1059

 Q   L   P   F   P   S   T   M   Q   Q   H   S   P     303
CAA CTT CCG TTC CCA TCA ACC ATG CAG CAG CAC AGC CCC   1098

 M   S   S   Q   T   S   S   A   S   G   P   L   H     316
ATG TCC TCC CAG ACC TCT TCC GCC AGC GGG CCA CTG CAC   1137

 S   V   S   L   P   L   P   L   P   M   A   L   G     329
TCT GTC TCC CTG CCG CTT CCA CTC CCG ATG GCC CTG GGT   1176

 A   P   Q   P   P   P   A   A   S   P   S   Q   Q     342
GCT CCA CAG CCC CCG CCT GCC GCC TCC CCC AGC CAG CAG   1215

 L   G   P   D   A   F   A   I   V   E   R   A   Q     355
CTT GGT CCA GAT GCC TTT GCG ATT GTG GAG CGA GCC CAG   1254

 Q   M   V   E   I   L   T   E   E   N   R   V   L     368
CAA ATG GTG GAG ATA TTA ACA GAG GAG AAC CGG GTG CTT   1293

 H   Q   E   L   Q   G   Y   Y   D   N   A   D   K     381
CAC CAG GAA CTT CAG GGT TAC TAC GAC AAT GCC GAC AAG   1332

 L   H   K   F   E   K   E   L   Q   R   I   S   E     394
CTC CAC AAG TTT GAA AAA GAA CTT CAG AGA ATT TCG GAA   1371

 A   Y   E   S   L   V   K   S   T   T   K   R   E     407
GCC TAT GAA AGT CTG GTC AAG TCT ACC ACC AAG CGA GAA   1410

 S   L   D   K   A   M   R   N   K   L   E   G   E     420
TCG CTG GAC AAG GCC ATG AGA AAC AAA TTG GAA GGC GAG   1449

 I   R   R   L   H   D   F   N   R   D   L   R   D     433
ATT AGA AGA CTT CAT GAT TTC AAC AGA GAC CTC CGA GAT   1488

 R   L   E   T   A   N   R   Q   L   S   S   R   E     446
CGA CTA GAG ACT GCT AAC AGG CAA CTA TCC AGC AGG GAA   1527
```

FIG. 3

```
 Y   E   G   H   G   D   K   A   A   E   G   H   Y      459
TAC GAA GGG CAT GGA GAC AAA GCT GCA GAG GGG CAT TAT    1566

 A   S   Q   N   K   E   F   L   K   E   K   E   K      472
GCT TCC CAG AAC AAA GAA TTC TTG AAG GAA AAG GAG AAA    1605

 L   E   M   E   L   A   A   V   R   T   A   S   E      485
TTA GAA ATG GAG TTA GCA GCA GTG CGG ACT GCA AGT GAG    1644

 D   H   R   R   H   I   E   I   L   D   Q   A   L      498
GAC CAT CGG AGA CAC ATC GAG ATC CTG GAC CAG GCT TTG    1683

 S   N   A   Q   A   R   V   I   K   L   E   E   E      511
 AGC AAC GCC CAG GCC AGG GTC ATC AAG CTG GAA GAG GAG    1722

 L   R   E   K   Q   A   Y   V   E   K   V   E   K      524
TTA CGA GAG AAG CAA GCA TAT GTT GAG AAA GTT GAG AAG    1761

 L   Q   Q   A   L   T   Q   L   Q   S   A   C   E      537
CTG CAG CAG GCC CTG ACC CAG CTG CAG TCT GCA TGT GAG    1800

 K   R   E   Q   M   E   R   R   L   R   T   W   L      550
AAG CGA GAA CAG ATG GAG CGG AGA CTG CGG ACT TGG CTG    1839

 E   R   E   L   D   A   L   R   T   Q   Q   K   H      563
GAG AGA GAG CTG GAT GCA CTG AGA ACC CAG CAG AAA CAT    1878

 G   N   G   Q   P   A   N   M   P   E   Y   N   A      576
GGA AAT GGC CAG CCA GCC AAC ATG CCG GAA TAC AAT GCC    1917

 P   A   L   L   E   L   V   R   E   K   E   E   R      589
CCA GCC CTC CTG GAA CTT GTG CGG GAG AAG GAG GAG CGG    1956

 I   L   A   L   E   A   D   M   T   K   W   E   Q      602
ATC CTG GCC CTG GAG GCC GAC ATG ACA AAG TGG GAG CAG    1995

 K   Y   L   E   E   S   T   I   R   H   F   A   M      615
AAG TAC CTG GAG GAG AGC ACC ATC CGA CAC TTT GCC ATG    2034

 N   A   A   A   T   A   A   A   E   R   D   T   T      628
AAT GCC GCA GCC ACT GCA GCA GCT GAG AGG GAC ACC ACG    2073
```

FIG. 3

```
 I   I   N   H   S   R   N   G   S   Y   G   E   S      641
ATC ATC AAC CAC TCA CGG AAT GGC AGC TAC GGA GAG AGC    2112

 S   L   E   A   H   I   W   Q   E   E   E   E   V      654
TCG CTG GAG GCC CAC ATC TGG CAA GAG GAG GAG GAG GTG    2151

 V   Q   A   N   R   R   C   Q   D   M   E   Y   T      667
GTG CAG GCC AAC AGA AGG TGT CAG GAC ATG GAA TAC ACT    2190

 I   K   N   L   H   A   K   I   I   E   K   D   A      680
ATT AAA AAT CTC CAT GCC AAA ATC ATA GAG AAA GAT GCT    2229

 M   I   K   V   L   Q   Q   R   S   R   K   D   A      693
ATG ATT AAG GTC CTG CAG CAG CGA TCT CGT AAA GAT GCC    2268

 G   K   T   D   S   S   S   L   R   P   A   R   S      706
GGG AAG ACA GAC TCC TCC AGC CTA CGT CCT GCC CGC TCC    2307

 V   P   S   I   A   A   A   T   G   T   H   S   R      719
GTT CCA TCC ATA GCA GCA GCT ACT GGG ACA CAC TCT CGC    2346

 Q   T   S   L   T   S   S   Q   L   A   E   E   K      732
CAG ACC TCT CTT ACC AGC AGC CAG CTG GCT GAG GAA AAG    2385

 K   E   E   K   T   W   K   G   S   I   G   L   L      745
AAG GAA GAG AAG ACC TGG AAG GGG AGC ATA GGA TTG CTG    2424

 L   G   K   E   H   H   E   H   A   S   A   P   L      758
CTG GGG AAG GAG CAC CAT GAG CAT GCC TCT GCC CCA CTG    2463

 L   P   P   P   P   T   S   A   L   S   S   I   A      771
CTG CCA CCC CCA CCC ACC TCA GCA CTG TCC TCC ATA GCC    2502

 S   T   T   A   A   S   S   A   H   A   K   T   G      784
TCC ACT ACG GCA GCC AGC AGT GCC CAC GCC AAG ACA GGC    2541

 S   K   D   S   S   T   Q   T   D   K   S   A   E      797
AGC AAG GAC AGC AGC ACA CAG ACT GAC AAG AGT GCC GAG    2580

 L   F   W   P   S   M   A   S   L   P   S   R   G      810
CTC TTC TGG CCC AGC ATG GCC TCC CTT CCC AGC CGC GGC    2619
```

FIG. 3

```
 R   L   S   T   T   P   A   H   S   P   V   L   K      823
CGG CTG AGC ACG ACC CCT GCT CAC AGC CCC GTC CTG AAA    2658

 H   P   A   A   K   G   T   A   E   K   L   E   N      836
CAC CCA GCG GCC AAA GGG ACC GCA GAG AAA CTG GAG AAC    2697

 S   P   G   H   G   K   S   P   D   H   R   G   R      849
TCT CCT GGC CAT GGG AAG TCG CCT GAC CAC AGA GGC CGG    2736

 V   S   S   L   L   H   K   P   E   F   P   D   G      862
GTC AGC AGC TTG CTG CAC AAG CCC GAG TTC CCT GAT GGA    2775

 E   M   M   E   V   L   I   *                         870
GAG ATG ATG GAA GTC CTC ATC TAA  CTGCCATCCCTGTGGAATT   2818

TCAGTACAGAACACTGACAAACAAGGAAAGCGGCAGAGAAGGAAGAAAGACC   2870

TAGAAGGTTGTAGATGGGAAATCAGGAATGATTTGAACTGATAAAGATTTCA   2922

GACTCATAAGAACACATTTTATAAATGTTAAACACAAAAACTACATGACTGA   2974

AGATAGAAGAGAATGCGATGGATTTTATTACACATGGTGGAAGAGAGAAGAG   3026

GCGTGTAGGTTTGCAAACAAAGTTAAGAAATAGGAAACTGAATTTTTCATTG   3078

TACAGAAAATGTATCTCTTGGGGAGGGCCTGTGTACCCCCATTCTCTGATTA   3130

TAAACAGATAACCCAAAAAAAAAAAAAAAAAAAAAAAAAAAG             3173
```

FIG. 3

nt: SEQ ID NO: 4
aa: SEQ ID NO: 6

```
AGCCCCAGTAGTCCTGTCCAGGTTCTAGAAGACTCCACCTACTTTTCCCCAG      52

ACTTTCAGCTCTATTCTGGGAGGCATGAAACATCTGCTTTGACGGTGGAGGC     104

AACCAGTAGCATCAGGGAAAAAGTTGTTGAAGATCCTCTTTGTAACTTCCAC     156

                                          M   R   G   S        4
TCCCCAAACTTCCTGAGGATCTCAGAGGTGGAA ATG AGA GGT TCC         201

 E   D   A   A   A   G   T   V   L   Q   R   L   I        17
GAG GAT GCG GCA GCT GGA ACA GTA TTG CAG CGG CTG ATC       240

 Q   E   Q   L   R   Y   G   T   P   T   E   N   M        30
CAG GAA CAA CTG CGG TAT GGC ACC CCA ACC GAG AAC ATG       279

 N   L   L   A   I   Q   H   Q   A   T   G   S   A        43
AAC TTG CTG GCC ATT CAG CAC CAG GCC ACA GGG AGT GCA       318

 G   P   A   H   P   T   N   N   F   S   S   T   E        56
GGA CCA GCC CAT CCT ACA AAC AAC TTT TCT TCC ACG GAA       357

 N   L   T   Q   E   D   P   Q   M   V   Y   Q   S        69
AAC CTC ACT CAA GAA GAC CCA CAA ATG GTC TAC CAG TCA       396

 A   R   Q   E   P   Q   G   Q   E   H   Q   V   D        82
GCA CGC CAA GAA CCG CAG GGT CAA GAA CAC CAG GTG GAC       435

 N   T   V   M   E   K   Q   V   R   S   T   Q   P        95
AAT ACG GTG ATG GAG AAA CAG GTC CGG TCC ACG CAG CCT       474

 Q   Q   N   N   E   E   L   P   T   Y   E   E   A       108
CAG CAG AAC AAC GAG GAA CTG CCC ACT TAC GAG GAG GCC       513
```

FIG. 4

```
 K   A   Q   S   Q   F   F   R   G   Q   Q   Q   Q      121
AAA GCA CAG TCG CAG TTC TTC AGG GGG CAG CAG CAG CAG      552

 Q   Q   Q   Q   G   A   V   G   H   G   Y   Y   M      134
CAA CAG CAG CAG GGG GCG GTG GGC CAT GGT TAC TAC ATG      591

 A   G   G   T   S   Q   K   S   R   T   E   G   R      147
GCA GGG GGC ACC AGT CAG AAG TCC CGA ACT GAG GGG AGG      630

 P   T   V   N   R   A   N   S   G   Q   A   H   K      160
CCC ACT GTG AAC CGT GCC AAC AGT GGA CAG GCG CAT AAG      669

 D   E   A   L   K   D   L   K   Q   G   H   V   R      173
GAC GAG GCG CTG AAG GAT CTG AAG CAG GGC CAC GTC CGC      708

 S   L   T   E   R   I   M   Q   L   S   L   E   R      186
TCG CTC ACC GAG AGA ATC ATG CAG CTG TCC CTG GAG AGG      747

 N   G   A   K   Q   H   L   P   G   S   G   N   G      199
AAT GGG GCC AAG CAA CAC CTT CCC GGC TCG GGG AAT GGA      786

 K   G   F   K   V   G   G   G   P   S   P   A   Q      212
AAG GGC TTC AAA GTA GGA GGG GGG CCC TCC CCT GCC CAG      825

 P   A   G   K   V   L   D   P   R   G   P   P   P      225
CCT GCA GGT AAA GTG CTG GAC CCT CGG GGT CCT CCA CCT      864

 E   Y   P   F   K   T   K   Q   M   M   S   P   V      238
GAG TAC CCC TTC AAG ACC AAG CAA ATG ATG TCC CCA GTC      903

 S   K   T   Q   E   H   G   L   F   Y   G   D   Q      251
AGC AAG ACC CAG GAG CAC GGA CTT TTT TAT GGT GAC CAG      942

 H   P   G   M   L   H   E   M   V   K   P   Y   P      264
CAC CCC GGG ATG CTC CAC GAG ATG GTC AAG CCC TAC CCT      981

 A   P   Q   P   V   R   T   D   V   A   V   L   R      277
GCT CCT CAG CCT GTG AGA ACA GAT GTG GCC GTC CTG CGG     1020
```

FIG. 4

```
 Y   Q   P   P   P   E   Y   G   V   T   S   R   P     290
TAC CAG CCA CCC CCT GAG TAT GGG GTA ACG AGC CGC CCA   1059

 C   Q   L   P   F   P   S   T   M   Q   Q   H   S     303
TGC CAA CTT CCG TTC CCA TCA ACC ATG CAG CAG CAC AGC   1098

 P   M   S   S   Q   T   S   S   A   S   G   P   L     316
CCC ATG TCC TCC CAG ACC TCT TCC GCC AGC GGG CCA CTG   1137

 H   S   V   S   L   P   L   P   L   P   M   A   L     329
CAC TCT GTC TCC CTG CCG CTT CCA CTC CCG ATG GCC CTG   1176

 G   A   P   Q   P   P   P   A   A   S   P   S   Q     342
GGT GCT CCA CAG CCC CCG CCT GCC GCC TCC CCC AGC CAG   1215

 Q   L   G   P   D   A   F   A   I   V   E   R   A     355
CAG CTT GGT CCA GAT GCC TTT GCG ATT GTG GAG CGA GCC   1254

 Q   Q   M   V   E   I   L   T   E   E   N   R   V     368
CAG CAA ATG GTG GAG ATA TTA ACA GAG GAG AAC CGG GTG   1293

 L   H   Q   E   L   Q   G   Y   Y   D   N   A   D     381
CTT CAC CAG GAA CTT CAG GGT TAC TAC GAC AAT GCC GAC   1332

 K   L   H   K   F   E   K   E   L   Q   R   I   S     394
AAG CTC CAC AAG TTT GAA AAA GAA CTT CAG AGA ATT TCG   1371

 E   A   Y   E   S   L   V   K   S   T   T   K   R     407
GAA GCC TAT GAA AGT CTG GTC AAG TCT ACC ACC AAG CGA   1410

 E   S   L   D   K   A   M   R   N   K   L   E   G     420
GAA TCG CTG GAC AAG GCC ATG AGA AAC AAA TTG GAA GGC   1449

 E   I   R   R   L   H   D   F   N   R   D   L   R     433
GAG ATT AGA AGA CTT CAT GAT TTC AAC AGA GAC CTC CGA   1488

 D   R   L   E   T   A   N   R   Q   L   S   S   R     446
GAT CGA CTA GAG ACT GCT AAC AGG CAA CTA TCC AGC AGG   1527

 E   Y   E   G   H   E   D   K   A   A   E   G   H     459
GAA TAC GAA GGG CAT GAA GAC AAA GCT GCA GAG GGG CAT   1566
```

FIG. 4

```
 Y   A   S   Q   N   K   E   F   L   K   E   K   E      472
TAT GCT TCC CAG AAC AAA GAA TTC TTG AAG GAA AAG GAG    1605

 E   L   E   M   E   L   A   A   V   R   T   A   S      485
GAA TTA GAA ATG GAG TTA GCA GCA GTG CGG ACT GCA AGT    1644

 E   D   H   R   R   H   I   E   I   L   D   Q   A      498
GAG GAC CAT CGG AGA CAC ATC GAG ATC CTG GAC CAG GCT    1683

 L   S   N   A   Q   A   R   V   I   K   L   E   E      511
TTG AGC AAC GCC CAG GCC AGG GTC ATC AAG CTG GAA GAG    1722

 E   L   R   E   K   Q   A   Y   V   E   K   V   E      524
GAG TTA CGA GAG AAG CAA GCA TAT GTT GAG AAA GTT GAG    1761

 K   L   Q   Q   A   L   T   Q   L   Q   S   A   C      537
AAG CTG CAG CAG GCC CTG ACC CAG CTG CAG TCT GCA TGT    1800

 E   K   R   E   Q   M   E   R   R   L   R   T   W      550
GAG AAG CGA GAA CAG ATG GAG CGG AGA CTG CGG ACT TGG    1839

 L   E   R   E   L   D   A   L   R   T   Q   Q   *      563
CTG GAG AGA GAG CTG GAT GCA CTG AGA ACC CAG CAG TAG    1878

TCCTATGAGAAAGAAGAGAGAAGGTTCTTGAAGAATGTTCTTTGAAAGGAAA  1930

ATGAGGCACAGAAACATGGAAATGGCCAGCCAGCCAACATGCCGGAATACAA  1982

TGCCCCAGCCCTCCTGGAACTTGTGCGGGAGAAGGAGGAGCGGATCCTGGCC  2034

CTGGAGGCCGACATGACAAAGTGGGAGCAGAAGTACCTGGAGGAGAGCACCA  2086

TCCGACACTTTGCCATGAATGCCGCAGCCACTGCAGCAGCTGAGAGGGACAC  2138

CACGATCATCAACCACTCACGGAATGGCAGCTACGGAGAGAGCTCGCTGGAG  2190

GCCCGCATCTGGCAAGAGGAGGAGGAGGTGGTGCAGGCCAACAGAAGGTGTC  2242

AGGACATGGAATACACTATTAAAAATCTCCATGCCAAAATCATAGAGAAAGA  2294

TGCTATGATTAAGGTCCTGCAGCAGCGATCTCGTAAAGATGCCGGGAAGACA  2346
```

FIG. 4

GACTCCTCCAGCCTACGTCCTGCCCGCTCCGTTCCATCCATAGCAGCAGCTA 2398

CTGGGACACACTCTCGCCAGACCTCTCTTACCAGCAGCCAGCTGGCTGAGGA 2450

AAAGAAGGAAGAGAAGACCTGGAAGGGGAGCATAGGATTGCTGCTGGGGAAG 2502

GAGCACCATGAGCATGCCTCTGCCCCACTGCTGCCACCCCCACCCACCTCAG 2554

CACTGTCCTCCATAGCCTCCACTACGGCAGCCAGCAGTGCCCACGCCAAGAC 2606

AGGCAGCAAGGACAGCAGCACACAGACTGACAAGAGTGCCGAGCTCTTCTGG 2658

CCCAGCATGGCCTCCCTTCCCAGCCGCGGCCGGCTGAGCACGACCCCTGCTC 2710

ACAGCCCCGTCCTGAAACACCCAGCGGCCAAAGGGACCGCAGAGAAACTGGA 2762

GAACTCTCCTGGCCATGGGAAGTCGCCTGACCACAGAGGCCGGGTCAGCAGC 2814

TTGCTGCACAAGCCCGAGTTCCCTGATGGAGAGATGATGGAAGTCCTCATCT 2866

AACTGCCATCCCTGTGGAATTTCAGTACAGAACACTGACAAACAAGGAAAGC 2918

GGCAGAGAAAGAAGAAAGACCTAGAAGGTTGTAGATGGGAAATCAGGAATGA 2970

TTTGAACTGATAAAGATTTCAGACTCATAAGAACACATTTTATAAATGTTAA 3022

ACACAAAAACTACATGACTGAAGATAGAAGAGAATGCGATGGATTTTATTAC 3074

ACATGGTGGAAGAGAGAAGAGGCGTGTAGGTTTGCAAACAAAGTTAAGAAAT 3126

AGGAAACTGAATTTTTCATTGTACAGAAAATGTATCTCTTGGGGAGGGCCTG 3178

TGTACCCCCATTCTCTGGTTATAAACAGATAAACCCAAAAAAAAAAAAAAAA 3230

AAAAAAAAAAAAAAAAA 3248

FIG. 4



FIG. 5